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ABSTRACT 
 
Ankunda Therese Kariisa: Nucleotide Second Messengers Signal Through 
Transcriptional and Posttranscriptional Regulators to Control the Production of a 
Colonization Factor in Vibrio cholerae 
(Under the direction of Rita Tamayo) 
 
 
The diarrheal human pathogen Vibrio cholerae causes millions of cases of 
severe cholera disease every year, resulting in substantial morbidity and mortality. 
Although V. cholerae is primarily an aquatic organism, it is also adept at colonizing and 
flourishing in the human small intestine. To persist and transition between the aquatic 
environment and the host, V. cholerae controls the production of colonization factors 
and virulence determinants. V. cholerae alters this through the production of intracellular 
second messengers, such as cyclic diguanylate (c-di-GMP) and cyclic adenosine 
monophosphate (cAMP), that relay information about the extracellular environment to 
intracellular effectors. Within the cell, c-di-GMP interacts with a variety of effector 
molecules, such as RNA riboswitches and proteins, to achieve transcriptional, post-
transcriptional and post-translational control of regulated processes. cAMP signals 
primarily through its receptor, the cAMP Receptor Protein (CRP), and regulates 
processes at the level of transcription. In this study, we examine the regulation of gbpA 
by c-di-GMP and cAMP; GbpA is a colonization factor that contributes to attachment of 
V. cholerae to the host small intestine and to chitinous surfaces. A c-di-GMP riboswitch, 
Vc1, was recently identified in the 5’ untranslated region of gbpA. Our results show that 
 iv 
Vc1 can bind c-di-GMP in vitro and that mutations that reduce binding abrogate GbpA 
production. Thus, c-di-GMP positively regulates gbpA expression via Vc1. In addition, 
we defined an additional mechanism of regulation of gbpA in which c-di-GMP negatively 
impacts activation gbpA transcription initiation by acting through cAMP-CRP. These 
studies identify two distinct signals, c-di-GMP and cAMP, that contribute to the 
regulation of gbpA. Our findings highlight the complex contribution of nucleotide second 
messengers in the adaptation of V. cholerae to host and aquatic environments. 
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CHAPTER 1: INTRODUCTION 
 
CHOLERA DISEASE 
  Cholera is a gastrointestinal disease characterized by profuse watery “rice water” 
diarrhea (1-3). The voluminous stool can reach volumes of up to 1 L per hour, and if left 
untreated, cholera can result in death due to dehydration within hours of onset of 
symptoms (4). The World Health Organization (WHO) estimates that approximately 1.4 
billion people worldwide are at risk of contracting cholera, predominantly people living in 
developing countries (5). The highest burden of cholera is observed in areas where it is 
endemic, about 2.8 million cases and 91,000 deaths occur annually (5). Within these at-
risk populations in cholera-endemic areas, roughly 50% of disease and death occurs in 
children under the age of 5 (5), likely because young children are more susceptible to 
cholera due to a naïve immune system and poor protective immunity (5). In contrast, in 
areas where cholera is not endemic, the number of cholera cases and deaths annually 
is 87,000 and 2,500, respectively (5). Furthermore, in non-endemic areas, children and 
adults are equally susceptible to cholera due to lack of previous exposure (5,6). 
Currently, over 99% of the reported incidence and burden of cholera occurs in 
Bangladesh, India and Sub-Saharan Africa (5,7). In the developed world, cholera has 
been completely eradicated, and isolated outbreaks are rapidly contained and resolved.  
 As mentioned above, the incidence and burden of cholera is predominantly 
restricted to the developing world. Reasons for this include poor water sanitation, poor 
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health care infrastructure, high population density and environmental factors. 
Environmental factors can include increasing rainfall, rising water temperatures and 
natural disasters, such as earthquakes and floods. The contribution of these factors to 
cholera transmission was most recently observed in Haiti during the outbreak that 
started in October 2010. Following the earthquake on January 12th 2010, Haiti’s already 
frail infrastructure incurred significant damages that had detrimental effects on the 
health care and sanitation sectors. To aid with relief efforts, seemingly healthy UN 
Nepalese health care workers, among others, were recruited to Haiti. One or more of 
the workers were asymptomatically infected with pathogenic Vibrio cholerae, a 
bacterium indigenous to marine and brackish waters and the causative agent of cholera. 
Using genomic approaches, it was determined from independent stool samples that the 
outbreak was caused by a single pathogenic strain of V. cholerae (8). Furthermore, 
comparative genomics revealed that the Haitian strain was nearly identical to 
contemporary Nepalese V. cholerae strains.  Thus, it was concluded that the first strain 
of pathogenic V. cholerae in Haiti was introduced into water sources by Nepalese UN 
workers (9). The aquatic environment, ambient temperature and stagnant fresh water 
promoted V. cholerae outgrowth and further contamination of water sources. Due to the 
large number of people displaced from their homes, many were obliged to live in very 
dense and often overcrowded camps. Favorable V. cholerae growth conditions and high 
population densities, coupled with the lack of access to clean water, led to the rapid 
transmission of cholera within a week of the arrival of the UN Nepalese health care 
workers. The resulting outbreak devastated the lives of many in Haiti. As of January 7th 
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2014, the Haitian officials reported 697,256 cases and 8,534 deaths due to cholera (10). 
Notably, this occurred in a region in which cholera had not previously been reported. 
 
CHOLERA HISTORY 
Cholera has been endemic in the Ganges delta region of the Indian subcontinent 
for many centuries. However, the first reports of cholera were not until 1817, when it 
crossed into Russia. The transmission event was likely due to the rise in trade and 
travel. In addition to spreading to Russia, the outbreak extended to parts of China and 
the Middle East. This outbreak resulted in the first cholera pandemic, the Asiatic cholera 
pandemic, which lasted until 1824. In the second pandemic, from 1829-1851, cholera 
reached the Americas and Europe for the first time. The third and fourth pandemics, 
which spanned 1852-1875, introduced cholera into parts of South America and North 
Africa and Sub-Saharan Africa, where it remains a significant health concern. During the 
fifth and sixth pandemics, from 1881-1923, cholera outbreaks were the most 
widespread in history affecting parts of Africa, the Middle East, South East Asia and 
Europe. However, the deaths from cholera were lower during the later pandemics due 
to greater understanding of cholera transmission and increased surveillance. 
Collectively, over the last 200 years, there have been seven cholera pandemics. The 
current and ongoing seventh pandemic, which includes the outbreak in Haiti, began in 
1961 in Indonesia. In the last 50 years, the seventh has spread rapidly to other 
countries in Asia, Europe, Africa and Latin America (3). 
  Before transmission of cholera was understood, the miasma theory, which 
suggested that cholera was transmitted through bad air, was widely perpetrated. It was 
not until 1854, when physician John Snow investigated the pattern of disease 
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transmission during a cholera outbreak in London, that the oral-fecal route of 
transmission gained support. Snow traced the source of the outbreak to the broad street 
pump in London and urged authorities to remove the handle of the pump to curb the 
outbreak. As a result of Snow’s investigation, monitoring of cholera transmission 
founded the field of epidemiology and cholera became the first reportable disease (11).  
 
Vibrio cholerae AND PATHOGENESIS 
  The causative agent of the disease cholera is the Gram-negative, curved rod, 
facultative bacterium called Vibrio cholerae (12). V. cholerae has two circular 
chromosomes composed of four million base pairs that encode roughly 4000 genes. V. 
cholerae was first isolated in 1854 by an Italian anatomist named Filippo Pacini (13). 
Pacini went on to publish extensively on V. cholerae, describing its pathogenesis and 
proposing methods for cholera treatment. In 1883, Robert Koch independently identified 
V. cholerae as the causative agent of cholera disease, following research in Egypt and 
Calcutta (12). 
  V. cholerae is primarily an aquatic bacterium, commonly found in the fresh water 
reservoirs, where it can grow planktonically or associate in a biofilm with various 
organisms such as zooplankton and phytoplankton (14,15). In the environment, V. 
cholerae is often associated with crustaceans, such as copepods, where it survives by 
feeding on their chitinous exoskeleton, which provides a carbon and nitrogen source 
(16-18). V. cholerae species can also survive on larger crustaceans such as arthropods, 
on chironomid egg masses and within amoebae (19-21). Environmental factors that 
affect water levels and water temperatures, such as floods and climate change, can 
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promote the bloom and distribution of zooplankton and increase the spread of cholera in 
susceptible areas (22). As a species, V. cholerae exhibits genetic diversity, and in 
aquatic reservoirs over 200 serogroups have been identified (1). Serogroups are 
differentiated by O antigen variations in the lipopolysaccharide (LPS). Serogroups can 
be subdivided into biotypes, and biotypes can be subdivided into serotypes. Only 
serogroups O1 and O139 have been associated with cholera disease, suggesting that 
V. cholerae has primarily evolved to survive in the aquatic environment (3,23). 
Pathogenic O1 and O139 serogroups are distinguished from non-pathogenic strains by 
the presence of the Vibrio pathogenicity island (VPI) genomic island and the lysogenic 
bacteriophage CTXΦ. CTXΦ and VPI encode two key players in V. cholerae 
pathogenesis, cholera toxin (CT) and toxin co-regulated pili (TCP), respectively (24, 25). 
The O1 serogroup is composed of two biotypes, El Tor and classical, and each biotype 
contains the Inaba and Ogawa serotypes (23). The classical and El Tor biotypes differ 
in the type of CTXΦ and their number of VPIs; the classical biotypes encode one (VPI-
1) and the El Tor biotypes encode two (VPI-1 and VPI-2) (26). The classical biotype was 
responsible for the first six pandemics but it has been largely replaced by the El Tor 
biotype, which was responsible for the seventh pandemic and most of the ongoing 
outbreaks (23). The O139 serogroup was first identified in 1992 and has since caused 
severe epidemics in South Asia (23, 27, 28). In addition to its role in pathogenesis, TCP 
acts as the receptor for CTXΦ (29). Therefore, evolution of pathogenic V. cholerae 
relies on the lateral transfer of VPI, which contains the gene encoding TCP, followed by 
CTXΦ. This suggests that V. cholerae strains in the environment became accidental 
human pathogens after acquiring the ability to colonize the mammalian host and cause 
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disease through horizontal gene transfer. This finding, along with the recent emergence 
of the serogroup O139, draws concerns that new strains of pathogenic V. cholerae may 
continue arise (30). In addition, many O1 and O139 variants isolated in the last few 
decades possess the SXT genetic element, which confers resistance streptomycin and 
co-trimoxazole (31). 
  V. cholerae is normally transmitted to a human host through contaminated food 
or water. Upon ingestion, pathogenic V. cholerae can colonize the small intestine (2, 3). 
Colonization can be asymptomatic and result in shedding for only a few days, or 
symptomatic and result in diarrhea and shedding for up to 2 weeks (32, 33). 
Symptomatic patients can experience either mild or severe diarrhea, and if left 
untreated, severe diarrhea is fatal in over 50% of cases due to rapid dehydration (34). 
Human infections may play an important role in the V. cholerae life cycle as bacterial 
shedding can lead to the introduction or reintroduction of large numbers of V. cholerae 
into aquatic reservoirs. For instance, human carriers coming from regions where cholera 
is endemic can seed new outbreaks of cholera in naïve areas (see Haiti outbreak 
above). In addition, pathogenic strains shed by a host are hyperinfectious for up to 5 
hours post-infection. Hyperinfectious bacteria, which have an infectious dose 1/10th of 
environmentally derived strains, may accelerate the transmission of cholera during 
outbreaks (35). Indeed, mathematical models that incorporate hyperinfectivity into their 
calculations can reproduce the explosive rates of transmission often observed during 
outbreaks (36).  
  The main driver of cholera symptoms is the enterotoxin cholera toxin (CT). CT is 
a multimeric protein composed of five B subunits (B5) and one A subunit (A1) (37). 
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Production and secretion of A1B5 by V. cholerae during infection leads to the 
engagement of B5 with the GM1 ganglioside receptor on intestinal epithelial cells and 
the translocation of A1 into the host cell cytosol (38). Once cytoplasmic, A1 becomes 
enzymatically active and ADP-ribosylates the Gsα subunit of host adenylate cyclase, 
locking it into a constitutively active GDP bound conformation. This irreversibly activates 
the adenylate cyclase leading to uncontrolled synthesis of cAMP and activation of the 
Cystic Fibrosis transmembrane receptor (CFTR) (39, 40). The consequence of 
activating this signaling cascade is the massive efflux of ions and water into the 
intestinal lumen and the hallmark profuse and watery diarrhea. Massive fluid losses can 
reach volumes of 1 L per hour and result in death due to dehydration within hours of 
onset of disease (4). 
 In response to severe diarrheal symptoms from cholera disease, aggressive 
rehydration therapy can reduce mortality from over 50% to 0.2% (3). The composition of 
this therapy is critical to restoring normal electrolyte homeostasis, and depending on the 
severity of the patient’s condition it is administered via oral or intravenous routes (41, 
42). Additionally, in response to diarrhea, antibiotic treatment can be administered to 
help reduce symptoms (in about 50% of cases) and shorten the duration of disease (34, 
43). In rare incidences, tetracycline, erythromycin and ciprofloxacin resistant strains 
have been isolated (44, 45). Therefore, the emergence of antibiotic resistant strains 
may make the treatment of cholera more challenging and costly. Nevertheless, 
antibiotics are secondary treatments to rehydration therapy since dehydration is the 
primary cause of morbidity and mortality. In an effort to prevent cholera outbreaks 
several vaccines have been developed, although none have led to the implementation 
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of a major vaccine program. One major obstacle that remain is limited long-term 
efficacy; only 50% of patients retain protective immunity when challenged 2-3 years 
following vaccination (46, 47). Although long-term protection is poor, vaccinating a 
proportion of a population at-risk can reduce the overall incidence of cholera 
transmission even in unprotected individuals (48). This phenomenon, termed “herd 
immunity”, may be an important consideration when implementing future vaccine 
programs to combat cholera.  
 
COLONIZATION FACTORS IN V. cholerae 
To cause disease in a mammalian host and persist in the aquatic environment, 
V. cholerae must produce colonization factors that mediate attachment to the various 
surfaces it encounters (49). One of the best-studied colonization factors is TCP, which 
is encoded within VPI in epidemic and pandemic strains (25, 29). Along with CT, the 
second essential virulence factor is TCP, which plays an important role in V. cholerae 
colonization of the small intestine and is coregulated with CT (50, 51). Infections models 
using mice and humans have confirmed that TCP is absolutely required for colonization 
and subsequent disease (50, 51). TCP is a type IV pilus composed of TcpA subunits 
that make up length of the pilus structure, and help mediate microcolony formation 
through pilus-pilus interactions (52). Modifications to the pili that abrogate these 
interactions, but preserve pilus structure, reveal that microcolony formation is required 
for colonization of the mammalian intestine and infection by CTXΦ (52). Furthermore, 
imaging of V. cholerae TCP in vivo shows that they play a protective role against the 
antimicrobial effects of bile by forming bundles around the bacteria and serving as a 
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physical barrier (53). In recent studies, TCP was shown to directly play a role in 
attachment to Caco-2 human intestinal epithelial cells (53). 
V. cholerae in the aquatic environment, including those recently shed from an 
infected human, must establish interactions with biotic and abiotic surfaces in the water 
(14, 15). In the environment, V. cholerae will typically engage these surfaces as a 
biofilm, to resist environmental stresses (54). When biofilm formation on the chitin shell 
of the squid pen was measured, TCP was identified as an important factor in late stage 
maturation biofilm, but not initial attachment to chitin (55). Interestingly, using a test-tube 
to measure biofilm production, TCP was shown to be dispensable during all stages of 
biofilm formation (56). Therefore, although TCP does not function as an adhesin for 
chitin, it is important for biofilm maturation and potentially bacterial fitness. Overall, TCP 
appears to play a role in colonization in both the mammalian host and in the 
environment.  
Two other pili have been implicated in colonization of chitin and biofilm 
production: mannose-sensitive hemagglutinin-like pili (MSHA) and chitin regulated pili 
(ChiRP). MSHA was shown to participate in biofilm formation on abiotic surfaces, but 
not on chitin (56). However, despite the negligible contribution of MSHA to biofilm 
production on chitin, MSHA appears to be important for the initial attachment to the 
chitinous exoskeletons of zooplankton such as copepods (57, 58). ChiRP is another 
chitin binding pilus that is produced during growth with chitin and/or chitin 
oligosaccharides. Studies to identify factors required for chitin utilization, found that a 
strain deficient in pilA, which encodes a predicted ChiRP subunit, exhibited a fitness 
defect during surface growth on chitin (17).  
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Two nonpilus adhesins have been found to play a dual role in colonizing the host 
and environment: FrhA and GbpA. In a transcriptome analysis of flagellar regulatory 
mutants, frhA was identified as a positively regulated target of the flagellar regulatory 
hierarchy (59). FrhA is a hemagglutinin involved in binding to and agglutination of 
erythrocytes and attachment to human epithelial cells (59). Consistent with these roles, 
frhA mutants showed a colonization defect in the infant mouse model of infection. 
Interestingly, FrhA was also shown to be important for the early stages of biofilm 
production on abiotic surfaces and chitin beads (59). Collectively, these studies suggest 
that FrhA plays a role in the host and environmental phases of the life cycle of 
pathogenic V. cholerae.  
The second nonpilus adhesin, GbpA, is a N-acetylglucosamine (GlcNAc)-binding 
protein that is encoded by locus VCA0811 (60). GbpA is secreted by the type two 
secretion system onto the bacterial cell surface, where it recognizes GlcNAc 
modifications found on some proteins, and GlcNAc derived carbohydrates such as chitin 
(60). GbpA is composed of four domains (1-4), and it exists as a monomer in solution. 
Domains 1 and 4 bind chitin oligosaccharides and GlcNAc modified glycans, whereas 
domains 3 and 4 are dispensable for chtin binding but are important for GbpA binding to 
the bacterial cell surface (61). GbpA production is positively regulated by its substrate, 
GlcNAc (17). When grown on chitin, V. cholerae secretes chitinases that release chitin 
oligosaccharides and GlcNAc monomers. GlcNAc is transported into V. cholerae and 
phosphorylated by specific phosphoenolpyruvate transport system (PTS) components, 
and serves as a carbon and nitrogen source (62). In addition, phospho-GlcNAc can bind 
the transcriptional repressor NagC, leading to the derepression of genes important for 
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GlcNAc sensing and metabolism, including gbpA (62). Interactions of V. cholerae with 
mucin, which also contains GlcNAc moieties, can also result in increased gbpA 
expression through NagC depression, suggesting that during V. cholerae colonization of 
the small intestine GbpA production might be elevated (63). GbpA levels also are 
affected post-translationally through the activities of the quorum-sensing regulated 
proteases, HapA and PrtV (64). HapA and PrtV are produced at high cell density and 
are believed to aid in detachment of V. cholerae from surfaces so that the bacterium 
can transition to a new surface, e.g., from the host back into the aquatic environment or 
between surfaces in the environment (64).  
V. cholerae strains deficient in gbpA are significantly attenuated in binding mucin 
and intestinal epithelial cells, due to failed interactions with GlcNAc containing 
glycoprotein modifications (60, 63). Consistent with these results, GbpA is important for 
colonization and disease in the infant mouse (60). In addition, GbpA is important for 
colonizing the chitinous exoskeleton of the crustacean Daphna magna, suggesting that 
it also plays a role in V. cholerae attachment to similar environmental organisms (58, 
60). Therefore, along with TCP and FrhA, GbpA adds to the repertoire of V. cholerae 
colonization factors that possess dual functions in host pathogenesis and environmental 
persistence (49). 
 
NUCLEOTIDE SECOND MESSENGERS  
The production of a particular colonization factor under the right environmental 
condition can be critical to bacterial survival. As bacteria transition between different 
environments, various stimuli influence bacterial behaviors in a myriad of ways. For 
example, signals sensed at the cell surface can regulate intracellular levels of small 
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molecule second messengers, which relay information about the extracellular milieu to 
intracellular effectors. In this section we will focus on nucleotide second messengers 
implicated in bacterial signaling. Production of these intracellular nucleotides, which 
include c-di-GMP, c-di-AMP, c-GMP-AMP, cGMP, cAMP, and (p)ppGpp, has been 
shown to regulate biofilm formation, motility, virulence, nutrient acquisition, stress 
responses and sporulation (reviewed in 65-68) (Figure 1.1). Accordingly, dysregulation 
of these signals likely impairs the ability of bacteria to transition between disparate 
environments.  
Cyclic adenosine 3’,5’-monophosphate (cAMP) was first identified as a second 
messenger in liver cells in 1957 by Earl Sutherland, and as a signaling molecule 
regulating carbon metabolism in Escherichia coli in 1969 (69, 70). In bacteria, 
intracellular cAMP levels are heavily influenced by the availability of extracellular 
nutrient sources, and cAMP along with cAMP Receptor Protein (CRP) govern the 
utilization of nutrient sources. Cyclic guanosine 3’,5’-monophosphate (cGMP) was first 
identified in 1963 in rat urine and levels correlated with the hormonal state in the animal 
(71). A role for cGMP is largely restricted to eukaryotic cells, where it is associated with 
transmembrane signal transduction, protein kinase activity and many other important 
processes (72). In bacteria, production of cGMP was observed as early as 1974, but 
only recently has a function for cGMP in intracellular signaling been ascribed (73). In 
studies using Rhodospirillum centenum, a cGMP specific synthase was indentified and 
cGMP production was linked to cyst formation (74). The linear nucleotides guanosine 
3’,5’-bispyrophosphate (ppGpp) and guanosine 3’-diphosphate, 5’-triphosphate 
(pppGpp) are also intracellular bacterial second messengers. (p)ppGpp production in E. 
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coli was first indentified in 1970 and later classified as an “alarmone” produced in 
response to nutrient starvation and other stresses (75, 76).  
It was not until several decades following the discovery of cAMP, cGMP and 
(p)ppGpp that cyclic dinucleotides were identified. Perhaps the most broadly studied is 
cyclic dimeric guanosine 3’,5’-monophosphate (c-di-GMP), identified in 1989 as an 
allosteric regulator of bacterial cellulose synthase in Gluconacetobacter xylinum (77). 
The increased interest in c-di-GMP as a ubiquitous bacterial second messenger in the 
last decade, led to the identification of its role in virulence, motility, and biofilm formation 
in a vast number of organisms. About 20 years later, in 2008, cyclic dimeric adenosine 
3’,5’- monophosphate (c-di-AMP) was identified as second messenger in Gram-positive 
bacteria (78). Since the discovery of c-di-AMP, studies have shown that it regulates 
bacterial cell growth, sporulation, stress responses, antimicrobial resistance and 
virulence (79). Lastly, cyclic guanosine monophosphate adenosine monophospate (c-
GMP-AMP) was identified in 2012. A function for c-GMP-AMP has been ascribed to few 
organisms; in V. cholerae c-GMP-AMP production during infection promotes chemotaxis 
and in numerous Deltaproteobacteria, including Geobacter species, it is predicted to 
function in extracellular electron transfer (80-82). 
 
c-di-GMP SIGNALING 
 The second messenger c-di-GMP is widely recognized to play an important role in 
bacterial adaptation to changing environmental conditions (66, 83). Numerous studies 
have demonstrated that c-di-GMP modulates biological processes including motility, 
virulence, production of adhesins and exopolysaccharide matrix, cell cycle progression, 
and responses to environmental stresses (Figure 1.2). Genetic studies suggest that V. 
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cholerae modulates intracellular c-di-GMP levels as it transitions from its native aquatic 
environment into the host intestine. Reduction of c-di-GMP is required to promote 
bacterial motility and increase expression of virulence factors, and there is evidence 
suggesting that V. cholerae may downregulate c-di-GMP production during early stages 
of infection (84-88). Specifically, the production of VieSA, a two-component system 
composed of the response regulator c-di-GMP phophodiesterase VieA, is required for 
virulence in the mouse and CT production in vitro. Conversely, production of c-di-GMP 
promotes biofilm formation, which may enhance V. cholerae survival on chitin and other 
aquatic surfaces (89-91). Accordingly, inactivation vieA results in increased biofilm 
production, and similarly overexpression of a diguanylate cyclase, VC0956, increases 
biofilm production (91, 92). The molecular basis of c-di-GMP-dependent regulation in V. 
cholerae involves impacts on transcriptional, posttranscriptional and posttranslational 
mechanisms.  
 In response to extracellular cues, which are largely unknown, bacterial cells adjust 
the intracellular level of c-di-GMP through the opposing activities of diguanylate 
cyclases (DGCs) and phosphodiesterases (PDEs), which synthesize and hydrolyze c-
di-GMP, respectively. The enzymatic activity of DGCs is supplied by a GGDEF domain, 
named for conserved residues in the catalytic site (93-96) Two distinct domains, EAL 
and HD-GYP, also named for conserved residues, confer c-di-GMP hydrolytic activity to 
PDEs (97-99). The PDE and DGC enzymatic domains are often present in proteins in 
conjunction with sensory and regulatory domains such as PAS, HAMP, blue light 
sensing (BLUF), haemerythrin, GAF, CHASE, MASE and/or receiver domains linked to 
two-component signal transduction systems (83). The linkage of DGC and PDE 
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enzymatic domains with these additional modules provides a post-translational means 
for a variety of stimuli to impact DGC and PDE activity and thus the level of c-di-GMP in 
the cell. Transcriptional and post-transcriptional regulation of DGC and PDE gene 
expression also influences intracellular c-di-GMP levels. 
 
c-di-GMP SIGNALING VIA PROTEIN AND RNA BASED RECEPTORS 
To date there are several known intracellular c-di-GMP receptors, which include 
protein and riboswitch sensors. Protein sensors include transcription factors that directly 
sense c-di-GMP to modulate gene expression, or proteins that contain PilZ domains, 
degenerate EAL domains, I-site domains or GIL domains (GGDEF I-site like domains) 
(100). The specific interactions of these receptors with c-di-GMP mediate the 
physiological changes observed in response to changes in the level of the second 
messenger. In the following section, we discuss the various types of c-di-GMP effectors, 
how the effectors recognize c-di-GMP, and how c-di-GMP sensing contributes to the 
regulation of biological processes. For comprehensive reviews of c-di-GMP signaling 
and effectors, we direct readers to other excellent reviews, details to follow will focus on 
receptors found in V. cholerae (101, 102).  
 
PILZ DOMAIN EFFECTORS 
In an early study of the regulation of the cellulose synthase in G. xylinus, 
Benziman and co-workers observed that c-di-GMP stimulates the activity of the 
cellulose synthase BcsAB (77). The PilZ domain present in the α-subunit of BcsAB was 
later shown to directly bind c-di-GMP (111). Sequence analysis of the PilZ protein led to 
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the discovery of this domain in a variety of bacteria and suggested that the PilZ domain 
may play an important regulatory role. Genes encoding a PilZ domain are broadly 
distributed in bacterial genomes (103). As with GGDEF, EAL and HD-GYP domains, 
bacterial genomes often encode multiple proteins containing PilZ domains in 
combination with other domains, suggesting broad regulatory roles for PilZ proteins. 
Numerous PilZ domain c-di-GMP receptors with diverse signaling functions and precise 
modes of action have been identified.  
As in many bacterial species, in V. cholerae c-di-GMP inhibits swimming motility 
and favors biofilm formation; in addition, c-di-GMP negatively regulates virulence gene 
expression (87, 91, 92, 104, 105). V. cholerae encodes 5 proteins containing PilZ 
domains, PlzA, PlzB, PlzC, PlzD, and PlzE. In vitro, PlzC and PlzD bind c-di-GMP via 
their PilZ domains (106); it is unclear whether PlzA, PlzB and PlzE bind c-di-GMP under 
conditions not tested. In vivo, mutation of plzB or plzC results in decreased motility, 
mutation of plzB or plzD results in decreased biofilm formation, and mutation of plzB or 
both plzC and plzD results in reduced colonization of the infant mouse small intestine 
through unknown mechanisms (106). PlzD contains the RxxxR motif that is conserved 
among PilZ domains (and among all 5 PilZ domain proteins of V. cholerae). The 
arginines in this motif are essential for binding of c-di-GMP in PlzD and PilZ domains in 
other species (106, 111). Structural studies show that PlzD (VCA0042) exists as a 
dimer in both apo- and ligand-bound forms (107) (PBD ID 1YLN; R Zhang, M Zhou, S 
Moy, F Collart, and A Joachimiak, 2005). The PilZ and the other domain in the protein, 
the YcgR-N domain, are connected by a short seven-residue loop that contains the 
RxxxR motif. This loop is referred to as the “c-di-GMP switch”, as it directly contacts the 
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c-di-GMP ligand and functions in the conformational change induced by c-di-GMP 
binding (107). In the apo structure, the C-terminal PilZ domain is located far from the 
two-fold axis and it makes no contact with the YcgR-N domain in the same monomer or 
in another monomer. In contrast, in the c-di-GMP bound structure of PlzD, the PilZ and 
YcgR-N domains in a single monomer are found in close proximity, with one c-di-GMP 
molecule packed tightly in their mutual interface (107). Thus, c-di-GMP binding changes 
the extended apo-PlzD structure into a more compact ligand-bound structure in which 
the PilZ domains make new contacts across the dimer interface.  
To date, PilZ domain proteins have been identified in a variety of organisms and 
associated with functions that include flagellar motor activity, type IV pilus assembly, 
alginate and cellulose production and virulence (106, 108-111). The mechanisms of 
action of PilZ domain containing proteins are not always apparent from sequence and 
structural information; even PilZ domain proteins with very similar domain architectures 
can display distinct binding stoichiometries and mechanistic properties. It is likely that 
there are additional modes of action employed by this class of proteins, and that this 
diversity contributes to generating the broad regulatory effects observed. 
 
c-di-GMP SENSING TRANSCRIPTION FACTORS  
 Transcription factors that sense c-di-GMP have been reported in several 
bacterial species. These regulators interact with c-di-GMP via various motifs, and the 
DNA binding region of the transcription factor lends specificity, allowing targeted 
regulation of gene expression. Thus, c-di-GMP can be broadly employed to control a 
wide variety of pathways. In V. cholerae, three transcription factors that sense c-di-GMP 
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have been identified to date, each of which was previously characterized for their roles 
in motility and/or biofilm development.  
The master regulator of flagellar biosynthesis in V. cholerae is FlrA. FlrA is a 
σ54-dependent enhancer binding protein containing AAA+ ATPase and DNA-binding 
domains. FlrA binds c-di-GMP, which prevents FlrA from interacting with the flrBC 
promoter and activating flagellar gene expression (112). Regulation of FlrA activity by c-
di-GMP defines the mechanism for the previously observed phenomenon that flagellar 
motility is inhibited by c-di-GMP in V. cholerae. In addition, transcriptome analysis 
revealed that over 300 genes are predicted to be regulated by FlrA, only 50 of which fall 
within the flagellar/chemotaxis operon (59).  
The LuxR family transcription factor VpsT promotes V. cholerae biofilm formation 
by activating the expression of vps genes required for exopolysaccharide production 
(113). VpsT consists of an N-terminal REC domain and a C-terminal HTH domain 
involved in DNA binding. VpsT does not appear to be a response regulator, as no 
cognate sensor kinase has been identified and residues for phosphor-transfer in the 
REC domain are poorly conserved. Instead, VpsT binds c-di-GMP (KD ~ 3.2 µM), an 
interaction that promotes VpsT binding to target promoters (89). Structural analysis of 
VpsT with c-di-GMP revealed that two intercalated c-di-GMP molecules interact with 
VpsT and stabilize the REC dimerization interface. c-di-GMP interacts with VpsT via a 
four residue W[F/L/M][T/S]R sequence within the REC domain (89). Importantly, 
mutation of residues in this motif abolish binding of c-di-GMP and target promoters in 
vitro, which abolishes regulation of vps genes and biofilm production in vivo (89).  
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The transcriptional regulator VpsR is an NtrC-family σ54-dependent enhancer 
binding protein that activates biofilm genes in V. cholerae (114, 115). VpsR contains an 
AAA+ ATP binding domain and a HTH DNA binding domain, and VpsR binds c-di-GMP 
in vitro (KD ~ 1.6 µM), possibly via its Walker A box (116). However, binding of c-di-GMP 
does not affect the ability of VpsR to interact with the target promoters tested in vitro 
(116). It is possible that binding of c-di-GMP does not affect the structure of VpsR and 
thus does not impact VpsR promoter-binding function. Alternatively, c-di-GMP binding to 
VpsR may affect transcription of only a subset of VpsR-regulated genes, or may affect 
the subcellular localization or stability of VpsR. 
 
CLASS I AND CLASS II c-di-GMP SENSING RIBOSWITCHES 
In addition to the many types of protein sensors of c-di-GMP, RNA sensors of c-
di-GMP have also been identified and are widely distributed in bacterial genomes. 
Riboswitches, cis-acting regulatory elements found in the 5’ untranslated region (UTR) 
of some mRNA, consist of an aptamer that binds a specific ligand and an expression 
platform that regulates downstream gene expression. Regulation typically occurs as a 
result of conformational changes in the RNA structure in response to ligand binding. 
The two most common modes of gene regulation by riboswitches involve control of 
transcription read-through or translation initiation. The aptamer and expression 
platforms are modular in that a given aptamer can work in conjunction with different 
expression platforms depending on the specific riboswitch (117-120).  
Two classes of c-di-GMP sensing riboswitches have been identified, class I and 
class II (121-123). To date, there are approximately 500 class I c-di-GMP riboswitches 
predicted in a wide range of pathogenic and non-pathogenic bacteria. The class I c-di-
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GMP riboswitches contain a GEMM motif, so named because they often reside in the 5’ 
UTR of genes with functions predicted to relate to the environment, membrane or 
motility (124). Several studies indicate that the GEMM motif represents the aptamer of 
the c-di-GMP riboswitch, however the regions anticipated to correspond to the 
expression platform appear to be highly divergent among putative class I riboswitches. 
The class II c-di-GMP riboswitch shares no structure or sequence homology with the 
class I riboswitch. class II riboswitches are less abundant than class I riboswitches, with 
45 putative class II riboswitches identified to date (125).  
Due to the lack of sequence and structural similarity, the two riboswitch classes 
interact with c-di-GMP via distinct mechanisms. In the class I riboswitch Vc2 from V. 
cholerae, c-di-GMP binds at the junction of three helices, P1, P2, and P3 (123, 126). 
Vc2 makes contacts with c-di-GMP via three nucleotides, G20, C92, and A47. One 
guanine base from c-di-GMP forms a Hoogsteen pair with G20, while the other forms a 
Watson–Crick pair with C92. A47 bridges the P2 and P3 helices of Vc2 and also 
contacts c-di-GMP by stacking between the guanine bases, producing extensive base 
stacking interactions between the RNA and ligand. P2 and P3, as well as c-di-GMP 
contact residues, are highly conserved among the class I riboswitches, suggesting that 
these features are critical for c-di-GMP recognition by these riboswitches (123, 126). In 
the class II riboswitch, no canonical base pairings are made with c-di-GMP, but stacking 
interactions are observed. Three conserved adenosines, A13, A70, and A61, intercalate 
below, between, and above the two guanine bases of c-di-GMP, respectively. In 
addition, one guanine base of c-di-GMP is recognized as part of a base triple with A69 
and U37 (base triples are clusters of three RNA nucleobases that interact edge-to-edge 
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by hydrogen bonding). The other guanine base of c-di-GMP forms a single hydrogen 
bond with G73 and contacts the 2′-OH of A70 and a fully hydrated magnesium ion (122, 
125). Furthermore, several of the nucleotides directly involved in recognizing c-di-GMP, 
A69, A70 and G73, are conserved in at least 90% of class II sequences identified to 
date (122).  
While predictions can be made as to how sensing of c-di-GMP by a riboswitch 
impacts the biology of an organism based on the identity of the downstream gene, little 
has been demonstrated experimentally. The class I riboswitch Vc2 in V. cholerae, for 
instance, has been well characterized in vitro and has been shown to regulate a 
reporter gene in response to c-di-GMP in vivo using the heterologous bacterial host E. 
coli (124). The exact mechanism of action for Vc2 remains unknown; however, c-di-
GMP has no effect on transcript length, therefore the mechanism of action is likely post-
transcriptional. Vc2 lies upstream of VC1722, which is predicted to encode a protein 
with homology to TfoX, a factor involved in uptake of exogenous DNA (17, 124, 127). 
However, the consequence of c-di-GMP binding to Vc2 and consequent regulation of 
VC1722 in V. cholerae is unknown. The second class I riboswitch in V. cholerae is 
called Vc1 and lies upstream of gbpA, which encodes the GlcNAc binding protein 
involved in the interaction of V. cholerae with environmental chitin and with the host 
intestine. No studies of the Vc1 riboswitch or its relevance to V. cholerae biology have 
been reported. The in vivo role of Vc1 will be discussed in Chapter 2. 
 
cAMP AND THE PHOSPHOENOLPYRUVATE TRANSPORT SYSTEM  
cAMP signaling is widespread and highly conserved among eukaryotic and 
prokaryotic organisms. In bacteria, intracellular cAMP levels are heavily influenced by 
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the availability of extracellular nutrient sources (128). In brief, for Gram-negative 
bacteria, uptake of a preferred carbon source by the phosphoenolpyruvate (PEP)-
carbohydrate phosphotransferase transport system (PTS) is dependent on key 
components of the pathway and the intracellular ratio of PEP to pyruvate. When PEP to 
pyruvate levels are high, a phosphoryl group from PEP is transferred to the PTS 
component enzyme I (EI), which initiates a phosphorylation cascade important for 
utilization of PTS dependent sugars. EI transfers the phosphoryl group to histidine 
protein (HPr), HPr transfers the phosphoryl group to EIIA, EIIA transfers the phosphoryl 
group to EIIBC and EIIBC transfers the phosphoryl group to the incoming sugar. PTS 
dependent sugars are transported into the cell by their cognate EIIC specific 
transporter. The EII components of PTS are usually membrane bound and form a 
complex to facilitate uptake and phosphorylation of the incoming sugar. Once 
phosphorylated, the sugar is metabolized through glycolysis, which in turn influences 
the intracellular pool of PEP and the rate of EI phosphorylation. Whereas some PTS 
components are specific for a particular sugar, for instance EIIBC, some PTS 
components can act on multiple different incoming sugars, for instance EIIA, HPr and 
EI. Accordingly, V. cholerae deficient in EIIA is unable to grow on the PTS sugars 
glucose, GlcNAc, sucrose or tetrahalose (129). During growth on non-PTS carbon 
sources, the phosphoryl group on EIIA is not transferred to the incoming nutrients. 
Phosphorylated EIIA can interact with the enzyme adenylate cyclase (AC) to stimulate 
its activity, leading to increased intracellular cAMP production. Therefore, the 
phosphorylation state of PTS components, namely EIIA, and the levels of intracellular 
cAMP can serve as a measure of PTS and non-PTS nutrient availability. In addition, the 
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rate of glycolysis and PEP to pyruvate ratios, which are heavily influenced by the type of 
carbon source available, will also influence the PTS pathway and cAMP production.  
V. cholerae has 25 genes that encode proteins with known or predicted roles as 
PTS components; these include two EI homologs, three HPr homologs and nine EIIA 
homologs (130). In V. cholerae, sugars dependent on PTS for uptake include sucrose, 
mannitol and fructose (129). Interestingly, unlike in E. coli in which glucose uptake is 
strictly PTS-dependent, V. cholerae can also utilize glucose in a PTS independent 
manner; genetic deletion of several PTS components still allows for glucose utilization. 
Similarly, a V. cholerae strain deficient for the EIIBGlcNAc transporter, can still grow in 
media with GlcNAc as the sole carbon source, suggesting non-PTS utilization of 
GlcNAc may occur (62).  
The role of PTS systems in V. cholerae has proven to be very complicated and 
extends beyond utilization of carbon sources. For instance, several components of PTS, 
such as EI, HPr, EIIA and EIIBC have been shown to influence biofilm production and 
colonization of the mammalian small intestine (129-134). 
 
cAMP SIGNALING VIA THE cAMP RECEPTOR PROTEIN 
The phosphorylation state of PTS components heavily influences intracellular 
cAMP production. To date, the only known sensor of cAMP is the cAMP receptor 
protein (CRP) (128). cAMP-CRP act as a regulatory complex that promotes the 
expression of genes required for growth on non-PTS carbon sources. In numerous 
organisms, including V. cholerae, the cAMP-CRP complex can also regulate the 
expression of genes associated with quorum sensing, motility, biofilm production, 
competence and virulence (Figure 1.3) (16, 135-140). As such, the bacterium 
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incorporates information about extracellular nutrient availability to accordingly regulate 
factors involved in these processes.  
Early studies looking at the role of cAMP-CRP in V. cholerae showed that strains 
deficient in cya, the gene encoding AC, have increased biofilm production, and 
increased vps expression (136). The same was observed for a crp mutant, implicating 
the cAMP-CRP complex in inhibiting biofilm production. cAMP-CRP was also shown to 
repress the expression of vpsT, one of the master regulators of biofilm production in V. 
cholerae (137). Interestingly, cAMP-CRP controls the expression of ten genes predicted 
to encoded enzymes with DGC and PDE activity, suggesting that cAMP-CRP signaling 
can influence intracellular c-di-GMP turnover (136). Deletion of one of the predicted 
DGCs, cdgA, eliminated the elevated biofilm production observed in a crp mutant, 
suggesting cAMP-CRP controls biofilm production by influencing c-di-GMP production 
(136).  
A role for cAMP-CRP in inducing competence was also observed. V. cholerae 
can become competent for natural transformation in the presence of chitin (127). 
Interestingly, cAMP-CRP can enhance the chitin induced competence pathway at 
several junctures (16). cAMP-CRP promotes attachment to chitin, promotes utilization of 
chitin as a carbon source, and enhances the expression of competence genes pilA, pilM 
and comEA (16, 141). These data suggest that cAMP-CRP promotes DNA uptake by 
activating important genes in the competence pathway. 
Colonization and virulence factors are also regulated by cAMP-CRP. V. cholerae 
deficient in cya and/or crp produces elevated levels of CT and TCP, suggesting that 
cAMP-CRP negatively regulates their production (140). Interestingly, these strains are 
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attenuated for colonization in a mouse model despite elevated levels of CT and TCP, 
suggesting the cAMP-CRP pathway promotes the expression of other genes required 
for colonization and growth in a host (137, 140). Indeed, cAMP-CRP is a positive 
regulator of the outer membrane proteins OmpT, OmpU and OmpW, as well as genes 
involved in chemotaxis and metabolism (136, 137). cAMP-CRP also positively regulates 
motility, however, the importance of motility in V. cholerae pathogenesis remains 
unclear (137). Quorum sensing is another process controlled by the cAMP-CRP 
pathway in V. cholerae. HapR, the master regulator of quorum sensing is produced at 
high-cell density when levels of the autoinducer, CAI-1, are high. Strains deficient in 
csqA, the gene that encodes the CAI-1 synthase, have reduced hapR expression and 
increased production of CT and TCP (142). cAMP-CRP acts as a positive regulator of 
cqsA expression, therefore, the effect of cAMP-CRP on CT and TCP may be linked to 
its regulation of csqA (138).  
Although phenotypic assays have established an important role for cAMP-CRP in 
numerous processes, the cAMP-CRP regulon is likely much broader. In a screen to 
identify the transcriptome profile of cya and crp mutants, up to 20% of the V. cholerae 
genome were differentially regulated compared to wild type (136). Regulation by cAMP-
CRP can occur by direct interactions with a target promoter, or indirectly through its 
effect on other regulators. cAMP-CRP can also act as a transcriptional regulator in a co-
regulatory or antagonistic fashion. For instance, cAMP-CRP can inhibit TcpH, an 
activator of virulence gene expression, by competing with AphAB for binding at the 
tcpPH promoter (143). In an analogous but opposite fashion, ToxR can inhibit cAMP-
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CRP-dependent activation of the ompT , encoding an outer membrane protein, by 
competing with the cAMP-CRP for binding at the ompT promoter (144).  
 
REGULATION OF gbpA BY c-di-GMP AND cAMP 
  c-di-GMP has pleiotropic effects on bacterial physiology and broadly impacts 
gene expression. With the exception of a handful of transcription factors that have been 
shown to regulate gene expression in response to c-di-GMP, the molecular basis of 
gene regulation by c-di-GMP is poorly understood. The identification of c-di-GMP 
specific riboswitches distributed widely among bacterial genomes positions these 
regulatory RNA domains to serve as important c-di-GMP effectors modulating 
downstream gene expression. Elegant studies have biochemically characterized a 
representative GEMM riboswitch, Vc2 from V. cholerae, but the functionality of c-di-
GMP riboswitches in their native genetic contexts has been largely unexplored (123, 
126, 145). In this thesis, we examine Vc1, a putative c-di-GMP riboswitch in V. 
cholerae. Vc1 is located in the 5’ untranslated region of gbpA, which encodes a 
colonization factor. We hypothesize that c-di-GMP positively regulates gbpA through 
Vc1. 
 Another major signaling network common to many bacteria is the nutrient-
responsive transcriptional regulator CRP. In V. cholerae, a recent transcriptome 
analysis revealed that CRP represses the production c-di-GMP by repressing the 
expression of a DGC, cdgA (136). These findings suggest that the c-di-GMP and CRP 
regulatory pathways interact, and that CRP signaling can inhibit c-di-GMP signaling. 
Herein, we describe the transcriptional regulation of gbpA, by CRP and c-di-GMP. We 
show that c-di-GMP inhibits transcriptional activation of gbpA by CRP, which directly 
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binds the gbpA promoter in a cAMP-dependent manner. These findings suggest that c-
di-GMP directly interferes with the interaction of cAMP-CRP and the gbpA promoter via 
an unidentified regulator. The use of two distinct second messenger signaling 
mechanisms to regulate gbpA transcription may allow V. cholerae finely modulate GbpA 
production, and therefore colonization of aquatic and host surfaces, in response to 
discrete environmental stimuli. 
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Figure 1.1. Structures of nucleotide second messengers. Adapted from (67)
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Figure 1.2. c-di-GMP regulated processes in bacteria. In response to extracellular cues, 
intracellular levels of c-di-GMP (red circles) are modulated by the activity of DGC and 
PDE enzymes. Intracellular c-di-GMP receptors include protein effectors, transcription 
factors and riboswitches. Modulation of c-di-GMP levels controls the transition between 
sessile to motile lifestyles. 
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Figure 1.3. cAMP regulated processes in bacteria. In response to nutrient availability, 
intracellular levels of cAMP (green diamonds) are modulated by the activity of AC and 
CpdA enzymes. CRP is the receptor for cAMP and together they regulate the 
expression of genes required for nutrient utilization and other important bacterial 
processes. 
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CHAPTER 2: THE RNA DOMAIN VC1 REGULATES DOWNSTREAM GENE 
EXPRESSION IN RESPONSE TO CYCLIC DIGUANYLATE IN VIBRIO CHOLERAE 
 
Summary 
In many bacterial species, including the aquatic bacterium and human pathogen 
Vibrio cholerae, the second messenger cyclic diguanylate (c-di-GMP) modulates 
processes such as biofilm formation, motility and virulence factor production. By 
interacting with various effectors, c-di-GMP regulates gene expression or protein 
activity. One class of c-di-GMP receptors is the GEMM riboswitch, representatives of 
which have been shown to bind c-di-GMP in vitro. Herein, we examined the in vitro and 
in vivo function of a putative GEMM riboswitch in Vibrio cholerae called Vc1, which lies 
upstream of the gene encoding GbpA, a colonization factor that contributes to 
attachment of V. cholerae to environmental and host surfaces containing N-
acetylglucosamine moieties. We provide evidence that Vc1 RNA interacts directly with 
c-di-GMP in vitro, but with possibly via residues different from those in a canonical 
GEMM riboswitch. By isolating the regulatory function of Vc1, we show that the Vc1 
element positively regulates downstream gene expression in response to c-di-GMP and 
that the mutation of a conserved residue in Vc1 reduces the interaction in vitro and in 
vivo. The same mutation on the V. cholerae chromosome significantly reduced the 
expression of gbpA and production of the GbpA protein. Together these data suggest 
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that the Vc1 element responds to c-di-GMP in vivo, but may not function as a high 
affinity riboswitch. Positive regulation of gbpA expression by c-di-GMP via Vc1 may 
influence the ability of V. cholerae to associate with chitin in the aquatic environment 
and the host intestinal environment. 
Importance 
Cyclic diguanylate (c-di-GMP) has pleiotropic effects on bacterial physiology and 
broadly impacts gene expression. With the exception of a handful of transcription 
factors that have been shown to regulate gene expression in response to c-di-GMP, the 
molecular basis of gene regulation by c-di-GMP is poorly understood. The identification 
of c-di-GMP specific riboswitches distributed widely among bacterial genomes positions 
these regulatory RNA domains to serve as important c-di-GMP effectors modulating 
downstream gene expression. Elegant studies have biochemically characterized a 
representative GEMM riboswitch, Vc2 from Vibrio cholerae, but the functionality of c-di-
GMP riboswitches in their native genetic contexts has been largely unexplored. This 
study investigates whether the putative c-di-GMP riboswitch Vc1 from V. cholerae is 
functional in vitro and in vivo, and reveals important differences from the canonical 
riboswitch Vc2.  
Introduction 
 Cyclic diguanylate (c-di-GMP) is a ubiquitous second messenger important for 
bacterial adaptation to environmental conditions. In response to largely undefined 
signals at the cell surface, changes in intracellular c-di-GMP concentration can relay 
information to target effectors, regulating processes such as biofilm formation, motility 
and virulence gene expression (reviewed in (1-3). The intracellular level of c-di-GMP is 
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controlled by the activities of diguanylate cyclases (DGCs) and phosphodiesterases 
(PDEs), enzymes responsible for the synthesis and degradation of c-di-GMP, 
respectively (4-10). Bacterial genomes often contain multiple genes encoding putative 
DGC and PDE enzymes, potentially reflecting a requirement for tight regulation of c-di-
GMP levels and the need to modulate c-di-GMP in response to diverse extracellular 
cues. 
 Various classes of intracellular c-di-GMP receptors have been identified and can 
control c-di-GMP regulated processes via transcriptional, post-transcriptional or post-
translational mechanisms. The best characterized are protein-based sensors of c-di-
GMP, such as transcriptional regulators and proteins containing the PilZ domain. In the 
human diarrheal pathogen, Vibrio cholerae, transcriptional regulation can occur through 
the transcription factors VpsT and VpsR, which directly sense c-di-GMP and modulate 
the expression of target genes involved in biofilm development (11-14). Recently, the 
master regulator of motility genes FlrA was found to sense c-di-GMP (15). Binding of c-
di-GMP to FlrA reduced the interaction between the transcription factor and a target 
flagellar gene promoter, thus decreasing flagellar gene expression and, in turn, bacterial 
motility. Analysis of the five PilZ domain proteins encoded by V. cholerae indicate that at 
least two of the PilZ proteins can bind c-di-GMP, and that the PilZ proteins regulate 
motility, biofilm formation and virulence of V. cholerae, likely through post-transcriptional 
mechanisms (16). 
In addition to protein sensors of c-di-GMP, post-transcriptional regulation by c-di-
GMP can occur through riboswitches, cis acting regulatory elements found in the 5’ 
untranslated region (UTR) of some mRNA (17-19). Riboswitches consist of an aptamer 
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domain that binds a specific ligand and an adjacent expression platform that regulates 
downstream gene expression in response to ligand binding. Regulation typically occurs 
as a result of ligand-induced conformational changes in the RNA structure (20, 21). 
Most commonly, riboswitches regulate gene expression through control of either 
premature transcriptional termination or translational initiation. Two types of c-di-GMP 
sensing riboswitches have been identified, class I and class II (17, 22). The two classes 
share no structure or sequence homology. The class I c-di-GMP riboswitches contain a 
GEMM motif, which is widespread in bacteria and so named because it often resides in 
the 5’ UTR of genes with functions predicted to relate to the environment, membrane or 
motility (17, 23). Based on the co-crystal structure of c-di-GMP with the V. cholerae 
aptamer Vc2, GEMM motifs are predicted to contain two adjacent stem-loops, termed 
P2 and P3, a tetraloop-tetraloop receptor motif that stabilizes the interaction between 
P2 and P3, and a P1 stem that forms through base pairing between the flanking 5’ 
nucleotides of P2 and the flanking 3’ nucleotides of P3 (17, 19, 23). The nucleotides of 
Vc2 that contact c-di-GMP lie at the junction of P1, P2, and P3. 
Although the aptamer of the GEMM riboswitch has been defined and some specific 
nucleotides required for efficient gene expression identified (17), few studies have 
directly addressed the functionality of a c-di-GMP riboswitch in vivo, in its native genetic 
context, and the impact of c-di-GMP sensing on the physiology of a bacterium. 
Clostridium difficile encodes numerous putative c-di-GMP riboswitches (both class I and 
class II), some of which lie upstream of genes encoding surface proteins and organelles 
such as flagella and Type IV pili (17, 22). Artificial elevation of c-di-GMP in C. difficile 
represses flagellar gene expression and swimming motility (24-26). These findings are 
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consistent with prior work showing that the GEMM riboswitch Cd1 upstream of a 
flagellar operon functions as an “off switch” in response to c-di-GMP; mutations in Cd1 
that impair its interaction with c-di-GMP result in increased reporter gene expression in 
a heterologous bacterial host (17). Conversely, the class II riboswitch upstream of a pilin 
gene functions as an “on switch” in response to c-di-GMP in C. difficile (27). C-di-GMP 
positively regulates type IV pilin gene expression through direct interaction with the 
riboswitch, promoting cell aggregation.  
The biochemistry and function of the second predicted GEMM riboswitch in V. 
cholerae, called Vc1, has not been examined. The predicted GEMM motif of Vc1 has 
75% overall identity with the well-characterized Vc2 GEMM motif, with 85% identity in 
the region that encodes the first stem-loop, P2 (See Figure 1A). The residues that 
contact the c-di-GMP ligand in Vc2 (G20, A47 and C92) are conserved in Vc1 (G12, 
A39, and C104, respectively). The nucleotides that form the interhelical Watson-Crick 
base pair, universally conserved among GEMM riboswitches, are also present in Vc1 
(C36 and G90 in P2 and P3 of Vc1, respectively). While critical features of the GEMM 
riboswitch are conserved in Vc1, the differences between Vc2 and Vc1 may help define 
broadly the mechanisms by which c-di-GMP acts through GEMM riboswitches.  
Vc1 lies upstream of gbpA, which encodes a well-characterized V. cholerae 
colonization factor. GbpA is a secreted protein that aids in colonization of surfaces in 
aquatic environments (the natural habitat of V. cholerae) and the small intestine (the 
tissue colonized by pathogenic V. cholerae) (28). GbpA recognizes chitin, a polymer of 
N-acetylglucosamine (GlcNAc) found in the exoskeletons of zooplankton and 
crustaceans colonized by V. cholerae in aquatic reservoirs (28). GbpA also plays a role 
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in colonization of the small intestine by interacting with GlcNAc present in mucin and on 
the surface of intestinal epithelial cells (28, 29). Accordingly, V. cholerae mutants 
lacking gbpA are attenuated both in an animal model of infection and attachment to 
chitinous surfaces. Studying Vc1 may thus provide insight about the role of c-di-GMP 
and Vc1 in modulating attachment of V. cholerae to environmental and host surfaces. 
 In this study, we combine biochemical and genetic approaches to test the 
hypothesis that the Vc1 sequence upstream of the gbpA open reading frame functions 
as a riboswitch to control gbpA expression in response to c-di-GMP. We provide 
evidence that Vc1 directly interacts with c-di-GMP in vitro, and interfering with Vc1 
sensing of c-di-GMP impairs downstream gene expression in vivo. Vc1 has properties 
that distinguish it from the GEMM c-di-GMP riboswitch characterized to date, but is 
nonetheless a c-di-GMP responsive RNA element. These data suggest that c-di-GMP 
signaling through Vc1 promotes gbpA expression and GbpA-dependent adherence to 
host and environmental surfaces. 
 
Materials and Methods 
Growth conditions and media. V. cholerae C6706 and isogenic mutant strains 
(Table S1) were cultured at 37°C in Luria-Bertani (LB) broth containing 100 µg/ml 
streptomycin (Sm), 10µg/ml chloramphenicol (Cm), and/or 50 µg/ml ampicillin (Amp), as 
appropriate.  
 
Artificial manipulation of intracellular c-di-GMP. The reduction of the 
intracellular level of c-di-GMP in V. cholerae was achieved as described previously (30, 
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31). Briefly, overnight cultures of V. cholerae harboring pBAD33 (“vector”), 
pBAD33::vieA (“pPDE”), pBAD33::vieA-E170A (“pPDEmut”) or pBAD33::VCA0956 
(“pDGC”) were back-diluted 1:100 in LB-Cm broth and grown at 37oC with shaking. 
Induced cultures contained 0.2% L-arabinose unless otherwise specified. Samples were 
collected for western blotting, β-galactosidase assays and/or qRT-PCR analysis as 
described below. 
 
5’ Rapid Amplification of cDNA Ends (RACE). RNA was collected using 
TRIsure (Bioline) and the RNeasy kit (Qiagen) as described previously (32). A gbpA 
specific primer, gbpAsp1, was used to make cDNA from RNA in a reverse transcription 
reaction with the Tetro cDNA Synthesis Kit (Bioline), using the manufacturer’s protocol. 
Next, Terminal transferase, TdT (NEB), was added to the reaction to introduce a 
homopolymeric A sequence to the 5’ end of the cDNA molecules, using the 
manufacturer’s protocol. PCR using nested primers specific to the 5’ homopolymeric tail 
(Race1g, Race1c, Race1a) and gbpA (gbpAsp2) were used to amplify the cDNA 
products. Sequencing of amplified cDNA products identified the +1 site of transcription. 
 
 Genetic manipulations. Strains and plasmids used in this study are listed in 
Table S1. All oligonucleotide primers used for cloning are listed in Table S2. Details 
regarding the generation of strains used in this study are described in the Supplemental 
Methods.  
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GbpA antibody production. Anti-GbpA antiserum was produced by Yenzym 
192 Antibodies, LLC, South San Francisco, CA. Antiserum was raised in rabbits to a 
synthetic peptide (CSNATQYQPGTGSHWEMAWDKR) that corresponds to GbpA from 
V. cholerae. The animal facilities were NIH/OLAW/PHS assured, USDA certified, and 
IACUC regulated. 
 
 Western blot analysis. Overnight cultures were diluted 1:100 and grown in 
LB broth at 37°C with aeration until mid-exponential phase (OD600 ~ 0.6-0.8). Equal 
volumes of supernatant, normalized to OD600, were collected, and proteins were 
precipitated using 10% trichloroacetic acid (TCA). TCA-precipitated samples were 
separated by electrophoresis, transferred onto nitrocellulose membranes, and probed 
with rabbit anti-GbpA antibodies. Goat α-rabbit IgG conjugated with IR800 dye (Thermo 
Scientific) was used as the secondary antibody. Membranes were imaged using an 
Odyssey imaging system (LI-COR). At least three independent experiments were 
performed, and a representative image is presented. Densitometry analyses were 
carried out using Odyssey software by normalizing the intensities of the bands 
corresponding to GbpA to those of a cross reactive band that did not change intensity in 
any of the strains or conditions tested (indicated by asterisks in relevant images). 
 
In vitro transcription. For SHAPE analysis, V. cholerae C6706 genomic DNA 
was used as the template in PCR with primers T7linkF + T7R, yielding a product 
consisting of the T7 promoter and the -15 to +665 portion of the gbpA transcript. The 
PCR product was used as template for in vitro transcription of the RNA using the 
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Ambion MEGAscript® T7 Kit, according to the manufacturer’s instructions. The RNA 
was precipitated with ethanol and suspended in water. RNAs were resolved on a 
denaturing 6% polyacrylamide gel (1X TB, 7M urea, 6% acrylamide). The desired RNA 
bands were excised from the gel and placed in RNase-free water overnight at 4oC to 
elute the RNA. The eluted material was ethanol precipitated to recover RNA, and the 
RNA was suspended in TE buffer. 
For equilibrium dialysis, Vc1WT and Vc1G12T templates used for the transcription 
reactions were amplified from C6706 and C6706 Vc1G12T genomic DNA, respectively, 
using T7Vc1F + Vc1R3. Vc2WT and Vc2G20T were amplified from C6706 genomic DNA 
and pCVD442::Vc2G20T, respectively, using T7Vc2F + T7Vc2R. RNA was transcribed 
from the resulting DNA as described above, yielding products with the T7 promoter and 
the -15 to +140 region of the gbpA 5’ UTR (Vc1 and Vc1G12U; numbering according to 5’ 
RACE results) or the -2 to +209 region of the VC1722 transcript (Vc2 and Vc2G20U; 
numbering according to 3IRW entry in PDB). 
 
SHAPE analysis of the gbpA mRNA. Vc1 RNA (10 µl, 7 µM) was denatured by 
heating at 95 oC for 2 minutes and snap-cooled on ice for 2 minutes. RNA (2 µl) was 
combined with 6 µl of 3.3× folding buffer (33 mM HEPES, 333 mM MgCl2, 333 mM 
NaCl, pH 8), 2 µl of water and either 10 µl of water or 10 µl of 1 mM c-di-GMP(33). The 
RNA was folded at 37 oC for 30 min. Folded RNA (9 µl) was added to 1 µl of 30 mM 
1M7 (in DMSO) or to 1 µl DMSO only, immediately mixed thoroughly, and incubated at 
37oC for 3 min. RNA was precipitated with ethanol and suspended in TE buffer. SHAPE 
adducts were detected by primer extension as described (33). 1M7 and DMSO treated 
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RNA, as well as untreated RNA (later used for sequencing), were mixed with 
fluorescently labeled DNA oligonucleotides that anneal to gbpA (Vc1SHAPE_R). Primer 
extension was initiated by addition of Superscript III reverse transcriptase (Invitrogen). 
Sequence information was generated using unmodified RNA by performing primer 
extension in the presence of dideoxynucleotide triphosphates (ddNTPs). Primer 
extension products were ethanol precipitated and suspended in formamide. Products 
were resolved on an ABI 3500 capillary electrophoresis instrument and analyzed using 
QuShape (34). Each experiment was performed at least three times, and statistical 
significance was determined using Student’s t-test. 
 
Equilibrium dialysis. In vitro transcribed Vc1, Vc1G12U, Vc2 and Vc2G20U RNA 
were denatured by heating at 95oC for 2 minutes and snap-cooled on ice for 2 minutes. 
RNA was then combined with 6 µl of 5X folding buffer (50 mM HEPES, 500 mM MgCl2, 
500 mM NaCl, pH 8) and added in a 30 µl total volume to chamber A of an equilibrium 
dialysis device, Dispo Equilibrium Dialyzer (Harvard Apparatus). c-di-GMP32 was diluted 
1:50, combined with 6 µl of 5× folding buffer, and added in a 30 µl total volume to 
chamber B of the equilibrium dialysis device. The final concentrations of RNA and 
ligand in the binding reactions were: 15 nM c-di-GMP32, 20 mM Vc1 and Vc1G12U, and 
10 mM Vc2 and Vc2G20U. Samples were allowed to equilibrate for 10 hours, and then 2 
µl were removed for scintillation counting. For competition experiments, following 10 
hours equilibration, the contents of chamber B were removed and replaced with 100 µM 
GTP or 100 µM c-di-GMP diluted in 5X folding buffer. Samples were allowed to 
equilibrate for an additional 10 hours, then 2 µl were removed for scintillation counting. 
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Binding was calculated as the percentage of the total radioactivity present in the 
chamber (A) containing RNA. Each experiment was repeated independently at least 
three times. 
 
RNA isolation and quantitative real-time PCR. Transcriptional analyses by 
quantitative reverse transcriptase PCR (qRT-PCR) were done essentially as previously 
described, using mid-exponential phase (OD600 ~ 0.5-0.7) cultures (32). For cDNA 
synthesis, 200 ng of RNA was reverse transcribed using the Tetro cDNA Synthesis Kit 
with random hexamers as primers (Bioline). As negative controls, reactions were run 
without reverse transcriptase. cDNA samples were combined with 2× SYBR/fluorescein 
mix (SensiMix; Bioline), 7.5 µM of each primer (RPB2F + RPB2R for rpoB, gbpAqF2 + 
gbpAqR2 for the gbpA ORF) (Table S2). The reactions were run using a MyiQ 
thermocycler (Bio-Rad) and the following program: 95°C for 10 min, followed by 40 
cycles of 95°C for 30 s, 55°C for 1 min, and 72°C for 30 s. Melt curves were performed 
to verify the amplification of single products, and all values were adjusted for primer 
binding efficiency, as calculated from a standard curve of C6706 genomic DNA. Data 
were analyzed using the ∆∆Ct method, with values normalized to the specified 
reference strain/condition, and transcript levels normalized to those of the housekeeping 
gene rpoB in each sample (32, 35). For each strain a minimum of three biological 
samples was tested. Statistical significance was determined by unpaired t-test. 
 
Beta-galactosidase assays. Dilutions of overnight cultures were assayed for β-
galactosidase activity using ortho-nitrophenyl-β-D-galactoside as a substrate as 
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described previously (36). At least three independent experiments were done and the 
data were combined. Statistical analyses were done using unpaired t-tests. 
 
Supplemental Methods 
 Genetic manipulations and strain construction. To make deletions by allelic 
exchange, using genomic DNA from V. cholerae C6706, ~800 bp fragments upstream 
and downstream of the sequences to be deleted were amplified by PCR using primers 
named according to the pattern geneF1 + geneR1 for the upstream region of homology 
and geneF2 + geneR2 for the downstream region of homology. The primers introduced 
restriction sites (underlined sequences in Table S2) that allowed ligation of the two PCR 
products to each other and into the suicide vector pCVD442. The ligations were 
transformed into DH5αλpir by electroporation and transformed colonies were identified 
on LB-Amp agar. The desired clones that contain the upstream and downstream 
fragments were identified by PCR using primers geneF1 + geneR2 and/or pCVDseqF + 
pCVDseqR, which flank the multiple cloning site of pCVD442. For deletion of gbpA, the 
resulting pCVD442::∆gbpA plasmid was transformed into Sm10λpir by electroporation 
and grown on LB-Amp agar. The resulting strain was mated with V. cholerae C6706 on 
LB agar for ~8hrs, then transconjugants were selected on LB-Sm-Amp agar. Sm-Amp-
resistant transconjugants were grown in LB broth in the absence of selection for 8 
hours, then dilutions of the cultures were plated on LB-Sm agar containing 10% 
sucrose. Sucrose-resistant, Amp-sensitive colonies were screened for the relevant 
deletion by PCR using the corresponding geneF0 + geneR2 primers. To create a V. 
cholerae strain with a deletion of Vc1 (∆Vc1), fragments upstream and downstream to 
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Vc1 were amplified using Vc1F + placP2R and placP2F + Vc1R primers, respectively, 
using genomic DNA from V. cholerae C6706 as the template. The upstream and 
downstream fragments were digested with the relevant enzymes and ligated into 
pCVD442. The ligation was transformed into DH5αλpir by electroporation and 
transformed colonies were identified on LB-Amp agar. The desired clone was identified 
by PCR using primers pCVDseqF + pCVDseqR. The resulting pCVD442::∆Vc1 plasmid 
was transformed into Sm10λpir by electroporation, then mated with V. cholerae C6706 
on LB agar. Mutants containing the Vc1 deletion were made and identified as described 
above. 
 Point mutations in Vc1 and Vc2 were generated by incorporating the desired 
nucleotide changes into self-complementary primers. These primers were used in 
separate PCRs to amplify two, overlapping fragments which were then cloned into the 
allelic exchange vector pCVD442. Genomic DNA from V. cholerae C6706 was used in 
all cases. Specifically, to generate the “P1” mutation consisting of CACAC to GTGTG 
mutations in the putative P1 stem of Vc1, the upstream fragment was amplified using 
Vc1F + VC1BR and the downstream fragment with primers Vc1BF + Vc1R. A similar 
technique was used to create point mutations in Vc1. For the Vc1G12T mutant, primer 
combinations Vc1F + Vc1gTR and Vc1gTF + Vc1R were used to amplify the two 
overlapping fragments; for the Vc1A39T mutant, Vc1F + Vc1aTR and Vc1aTF + Vc1R 
were used; for the Vc1C104G mutant, Vc1F + Vc1cGR and Vc1cGF + Vc1R were used; 
and for Vc2G20T, Vc2G20TF1 + Vc2G20TR1 and Vc2G20TF2 + Vc2G20TR2 were used. 
For all four Vc1 mutants, the resulting pairs of fragments were combined and used as 
the template in PCR reactions with Vc1F and Vc1R as primers, to yield a spliced 
 57 
product containing the desired nucleotide changes. For the Vc2 mutation, Vc2G20TF1 + 
Vc2G20TR2 were used to obtain the spliced product. The spliced PCR products were 
digested with the appropriate restriction enzymes, for which restriction sites were 
introduced with the outer primers, then cloned into similarly digested pCVD442. 
Plasmids containing insert were identified by PCR, and point mutations were confirmed 
by sequencing. The confirmed plasmids were introduced into V. cholerae C6706 via 
SM10λpir, and the desired V. cholerae mutants were identified, as described above. All 
mutations to the V. cholerae chromosome were confirmed by sequencing.  
 The plasmid-borne lacZ reporter constructs were made by amplifying the 5’ UTR of 
gbpA from genomic DNA of V. cholerae C6706 “Vc1WT”, Vc1P1, Vc1G12T, Vc1A39T, or 
Vc1C104G using primers gbpArbF and gbpAPrR and digested with EcoRI and SalI. The 
Vc1 fragments were ligated into similarly-digested pPlacthiM#2-lacZ, then ligations were 
transformed into DH5α. Amp-resistant clones were screened by PCR using primers 
pLacSeq + gbpAPrR. The resulting plasmids have Vc1 (wild type or mutant) as a 
translational fusion to lacZ, with the lac promoter driving transcription. Likewise, the 
pPgbpA-Vc1-lacZ and pPgbpA-∆Vc1-lacZ plasmids were constructed by amplifying 
PgbpA-∆Vc1-Vc1 from V. cholerae C6706 and DVc1, respectively, by PCR using 
gbpAP2F + gbpAR2. The PCR products were digested with EcoRI and SalI and ligated 
into pPlacthiM#2-lacZ digested with the same enzymes. The ligation reaction was 
transformed into DH5α cells by electroporation, and resulting Amp-resistant colonies 
were screened with primers pLacSeq + gbpAR2.  
To make the chromosomal Vc1 reporter strains, the pPlac-Vc1-lacZ and pPlac-
Vc1G12T-lacZ vector backbones were amplified to exclude the Plac promoter gbpArbF + 
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PlacZR3, which introduced EcoRI and SphI sites, respectively. The PlacUV5 promoter 
was amplified from p2UY35A using PlacUV5F + PlacUV5R, which also introduced SphI 
and EcoRI sites, respectively (37). The PlacUV5 promoter and Vc1-lacZ vector (now 
lacking Plac) were digested with SphI and EcoRI, ligated together, and cloned in E. coli 
DH5α, yielding plasmid pPlacUV5-Vc1UTR-lacZ and pPlacUV5-Vc1UTRG12T-lacZ.  
To make the chromosomal Vc2 reporter strain, the pPlac-Vc1-lacZ vector 
backbone was amplified to exclude the Plac promoter and the Vc1 riboswitch using 
placZF + PlacZR3, which introduced SalI and SphI sites, respectively. The Vc2 
riboswitch, found in the 5’ UTR of VC1722, was amplified from genomic DNA of V. 
cholerae C6706 using Vc2rsF and Vc2Rrs2, which introduce EcoRI and SalI sites, 
respectively. The PlacUV5 promoter was amplified from p2UY35A using PlacUV5F + 
PlacUV5R, which also introduced SphI and EcoRI sites, respectively (37). The PlacUV5 
promoter, Vc2 riboswitch and the lacZ vector (now lacking Plac and Vc1) were digested 
with SphI and EcoRI, SalI and EcoRI, and SphI and SalI, respectively. The three 
products were ligated together, and cloned in E. coli DH5α, yielding plasmid pPlacUV5-
Vc2UTR-lacZ.  
The resulting plasmids, pPlacUV5-UTR-lacZ, pPlacUV5-UTRVc1G12T-lacZ, and 
pPlacUV5-Vc2UTR-lacZ, were used as the template for amplification of the fusions with 
primers PlacF5 + PlacR5, which introduced StuI and NotI sites, respectively. The PCR 
products were digested with StuI and NotI and cloned into similarly digested pJL1, a 
suicide vector which allows targeting of DNA into the lacZ gene of V. cholerae (38). The 
pJL1 constructs were introduced into V. cholerae C6706 by conjugation via SM10λpir E. 
coli. Incorporation of the fusions in the V. cholerae lacZ gene was achieved by standard 
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allelic exchange methods and confirmed by PCR with lacZsF +lacZsR and by 
sequencing. The resulting chromosomal reporter strains were transformed with vector, 
pPDE and pPDEmut plasmids by electroporation to allow manipulation of c-di-GMP (9, 
31). 
 
Results 
 The predicted structure and c-di-GMP binding sites of Vc1. We first defined 
the 5’ UTR of gbpA by identifying the transcriptional start site using 5’ Rapid 
Amplification of cDNA Ends (5’ RACE). To rule out potential differences in the length of 
the gbpA 5’ UTR in response to c-di-GMP, 5’ RACE was performed with RNA collected 
from strains with both wild type and low c-di-GMP levels. The intracellular level of c-di-
GMP in V. cholerae was reduced by ectopic expression of a c-di-GMP PDE. Briefly, V. 
cholerae harboring a plasmid that allows inducible expression of the well-characterized 
c-di-GMP PDE, VieA, was used to test the effect of depleting intracellular c-di-GMP (9, 
31). V. cholerae containing vector only, treated identically to V. cholerae with pPDE, 
serves as an unperturbed “wild-type” c-di-GMP control. 5’ RACE showed that the 
transcriptional start site (+1) remains unchanged between V. cholerae with native and 
low c-di-GMP levels and is 225 nucleotides upstream of the annotated translational start 
site of gbpA (Figure 2.1A). The predicted GEMM motif of Vc1 is thus encoded within the 
first 111 nucleotides of the gbpA 5’ UTR. Using this information and the GEMM 
consensus sequence and structure, the RNA structure of the first 120 bases of the gbpA 
5’UTR, which encompass the GEMM motif of Vc1, was modeled and is consistent with 
the accepted secondary structure of Vc2 (Figure 2.1A and 2.1B).  
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 Mutations in predicted c-di-GMP contact residues of Vc1 affect downstream 
gene expression. To examine the role of Vc1 in regulating gene expression in 
response to c-di-GMP, we constructed a translational reporter consisting of the gbpA 5’ 
UTR fused to lacZ from Escherichia coli (Figure 2.7). The heterologous promoter Plac 
drove expression, allowing constitutive, PgbpA independent transcription initiation during 
growth in rich medium. We generated four derivatives of the reporter plasmid, each with 
a mutation in Vc1 predicted to interfere with sensing c-di-GMP. The “Vc1P1” derivative 
contains a stretch of five nucleotide changes in Vc1: C4G, A5T, C6G, A7T, C8G. The 
other three mutant reporters each contain a single point mutation in a nucleotide 
predicted to interact directly with the c-di-GMP ligand: G12T, A39T and C104G (noted in 
Figures 2.1A and 2.1B) (19). The plasmids were introduced into V. cholerae, and 
reporter activity was measured using a β-galactosidase assay. Relative to the wild type 
reporter, the Vc1P1, G12T and A39T mutations significantly reduced, but did not 
eliminate, β-galactosidase activity (Figure 2.2A). These results suggest that G12 and 
A39 may be important for sensing c-di-GMP and for full expression of the downstream 
gene. Conversely, the C104G mutation caused a modest increase in β-galactosidase 
activity, suggesting it is not required for sensing c-di-GMP. To confirm this result, an 
alternate mutation, C104A, was made, but this mutation also did not have an effect on 
β-galactosidase activity (data not shown).  
We next assessed the functionality of Vc1 in its native genetic context. The four 
mutations described above, P1, G12T, A39T and C104G, were individually introduced 
into the chromosomal Vc1 in V. cholerae C6706 via allelic exchange, and GbpA 
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production was measured by western blot. A strain with an in-frame deletion of gbpA 
served as a control. Consistent with the β-galactosidase reporter assays, the level of 
GbpA decreased significantly in the P1 and G12T mutants (Figure 2.2B and 2.2C). 
GbpA protein abundance was not significantly altered in the A39T and C014G mutants. 
Thus, unlike in Vc2, in which each of the equivalent nucleotides plays critical roles in c-
di-GMP sensing, the G12 mutation in Vc1 is the only one to significantly impact 
downstream gene expression.  
 
Evidence that Vc1 interacts directly with c-di-GMP in vitro. To test whether 
Vc1 interacts with c-di-GMP, we used several approaches. First, we used selective 2’-
hydroxyl acylation analyzed by primer extension (SHAPE) chemistry to probe the 
potential interaction between Vc1 and c-di-GMP (39). SHAPE uses acylating agents, 
such as 1-methyl-7-nitroisatoic anhydride (1M7), which selectively form adducts at the 
2’-hydroxyl group of an RNA nucleotide. The ability of 1M7 to react with a nucleotide 
depends on the local flexibility of that nucleotide within an RNA structure, and flexibility 
correlates with the constraint of the nucleotide within the structure (40). SHAPE has 
been used successfully to assess the interactions between several riboswitches and 
their target ligands, including the Vc2 aptamer and c-di-GMP (33, 41). A comparison of 
structures for a GEMM riboswitch in the presence and absence of c-di-GMP has not 
been reported to date, and we used SHAPE chemistry to assess the differences 
between apo-Vc1 and Vc1 with c-di-GMP. 
An in vitro transcript of the gbpA mRNA, encompassing the entire 5’ UTR of 
gbpA and 440 bases of the open reading frame (ORF), was folded in the presence or 
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absence of c-di-GMP, subjected to 1M7 modification and analyzed by SHAPE. An RNA 
sequence that extends downstream of the Vc1 aptamer was used because of the 
possibility that neighboring RNA sequence impacts the structure of the riboswitch. 
Statistically significant differences in reactivity were observed in three distinct regions of 
the GEMM motif in the presence and absence of c-di-GMP (Figure 2.3, asterisks). 
Nucleotides U9, U10, and U11, located adjacent to the first predicted c-di-GMP contact 
residue G12, showed a significant increase in reactivity in the presence of c-di-GMP. 
A40 showed a decrease in reactivity in the presence of c-di-GMP and is adjacent to the 
second predicted contact residue for c-di-GMP, A39. An increase in reactivity in the 
presence of c-di-GMP was also observed in the “P1” region immediately 5’ of Vc1. No 
changes were observed near or around C104. As a control, we performed SHAPE with 
Vc1 with and without another guanosine nucleotide, GTP. No statistically significant 
differences in Vc1 reactivity were observed in the presence of GTP relative to apo-Vc1, 
indicating that GTP and Vc1 do not interact (Figure 2.8). Together these results suggest 
that c-di-GMP specifically interacts with Vc1 via the G12 and A39 regions, but not the 
C104 region, though indirect effects of c-di-GMP on the reactivity of the G12 and A39 
regions are also possible. 
We next used equilibrium dialysis to assess the interaction between Vc1 RNA 
and c-di-GMP. These experiments were conducted using a two-chamber device 
(separated by a 5000 Da MWCO membrane) in which RNA was added to one chamber 
and 32P-labeled c-di-GMP (c-di-GMP32) was added to the second. After 10 hours 
incubation to allow equilibration of c-di-GMP32 between chambers, samples from each 
chamber were analyzed by scintillation counting. Binding is calculated as the 
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percentage of the total radioactivity present in the chamber containing RNA. If no 
binding of c-di-GMP32 occurs, c-di-GMP32 will distribute equally between the two 
chambers; if RNA capable of binding c-di-GMP32 is present, c-di-GMP32 will accumulate 
in that chamber. As expected, when no RNA was added, c-di-GMP32 was detected 
equally in both chambers (Figure 2.4A). Vc2 RNA, which served as a positive control, 
sequestered c-di-GMP32, indicating that Vc2 binds c-di-GMP as expected (17-19, 42). 
Vc1 RNA also sequestered c-di-GMP32, but less so than Vc2 RNA (77% versus 66% of 
c-di-GMP in the RNA chamber, respectively), suggesting that Vc1 RNA binds c-di-GMP 
but perhaps with a lower affinity than Vc2 (Figure 2.4A). Analysis of the denatured and 
refolded RNAs by native gel electrophoresis revealed multiple folded species for Vc1 
and Vc2, both in the presence and absence of c-di-GMP (data not shown), which may 
also have contributed to differences in c-di-GMP sequestration.  
We showed above that the G12T mutation in Vc1, but not the A39T or C104G 
mutations, reduces downstream gene expression, as measured both in reporter assays 
and in chromosomal mutants (Figure 2.2). The binding of the mutant Vc1 RNAs to c-di-
GMP was assessed using equilibrium dialysis to determine whether the mutants have 
similar profiles in vitro. The G12U mutation in the Vc1 RNA significantly diminished 
sequestration of c-di-GMP, but did not fully eliminate it, unlike the equivalent mutation in 
Vc2 (Figure 2.3B). That the Vc1G12U mutant RNA retained some ability to sequester c-di-
GMP32 indicates that this residue is not absolutely required for c-di-GMP binding.  
We examined the specificity of Vc1 for c-di-GMP using a two-step equilibrium 
dialysis binding experiment. Vc1, as well as the Vc2 positive control, were allowed to 
interact with radiolabeled c-di-GMP for 10 hours as described above, and the proportion 
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of c-di-GMP sequestered in the RNA-containing chamber was measured (Figure 2.4B, 
black bars). For the second step, the non-sequestered radiolabeled c-di-GMP was 
removed, and excess non-radiolabeled (“cold”) c-di-GMP or GTP was added. After an 
additional 10 hours to allow binding, the remaining radioactivity associated with the RNA 
was assessed (Figure 2.4B, grey bars). The interaction between c-di-GMP32 and Vc1 is 
specific, because addition of unlabeled c-di-GMP, but not unlabeled GTP, shifted the 
distribution of c-di-GMP32; cold c-di-GMP, but not GTP, competed with radiolabeled c-di-
GMP for binding with Vc1 (Figure 2.4B). Interestingly, addition of unlabeled c-di-GMP 
did not compete with c-di-GMP32 for Vc2 binding over the timescale of the dialysis 
assay, consistent with previous work showing that c-di-GMP dissociates very slowly 
from the Vc2 RNA (42). Conversely, Vc1 may have a faster off rate than Vc2, as c-di-
GMP32 could be displaced by the added unlabeled c-di-GMP over the 10 hour time 
course of the assay. 
 
Decreasing intracellular c-di-GMP reduces Vc1-dependent gene 
expression. The data presented above suggest that c-di-GMP signaling through Vc1 
promotes downstream gene expression. We therefore determined the effect of altering 
the intracellular c-di-GMP concentration on GbpA production, using plasmid-borne, 
inducible diguanylate cyclase (pDGC) and phosphodiesterase (pPDE) enzymes to 
artificially increase or decrease intracellular c-di-GMP levels in V. cholerae, respectively 
(9, 43). For this study, the gbpA 5’UTR containing Vc1 was fused to a lacZ reporter 
gene and placed under the control of the constitutive PlacUV5 promoter (37). This 
translational reporter was integrated into the V. cholerae chromosome within the native 
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lacZ gene, generating the “PlacUV5-Vc1UTR-lacZ” strain. Thus, the response of the Vc1 
element to c-di-GMP could be assessed in isolation from the native promoter and 
downstream gene, in single copy. A promoterless gbpA 5’ Vc1UTR-lacZ fusion strain 
served as a control to ensure that sequences within the 5’ UTR do not initiate 
transcription. pDGC, pPDE, pPDEmut and control vector were introduced into the 
reporter strains to allow manipulation of c-di-GMP as described (9, 43). As expected, 
the strains with the promoterless fusion had baseline β-galactosidase activity, 
regardless of c-di-GMP level (Figure 2.9). The V. cholerae PlacUV5-Vc1UTR-lacZ strain 
with reduced intracellular c-di-GMP (pPDE, + L-arabinose) showed a greater than 50% 
decrease in β-galactosidase activity compared to V. cholerae with wild-type levels of c-
di-GMP (vector, + L-arabinose) (Figure 2.5). Conversely, increasing intracellular c-di-
GMP through the ectopic production of a diguanylate cyclase (VCA0956) significantly 
increased β-galactosidase activity (Figure 2.9). In addition, expression from pPDEmut, in 
which a glutamic acid residue essential for PDE activity has been mutated to an alanine 
(VieA-E170A) (9), resulted in no change in β-galactosidase activity, indicating that 
altered expression is specifically due to decreased c-di-GMP (Figure 2.9). 
To further examine the importance of the Vc1- c-di-GMP interaction in promoting 
downstream gene expression, we examined V. cholerae containing a derivative of 
PlacUV5-Vc1UTR-lacZ in which the Vc1 sequence contains the G12T mutation (PlacUV5-
Vc1UTRG12T-lacZ). In this strain, reporter activity is reduced compared to that of V. 
cholerae with the wild type PlacUV5-Vc1UTR-lacZ fusion, and when compared to wild 
type c-di-GMP levels, reducing c-di-GMP does not reduce reporter activity (Figure 2.5). 
These results suggest decreasing c-di-GMP availability in the cell has a similar effect as 
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the G12 mutation, supporting a role for Vc1 in gbpA expression in response to c-di-
GMP. 
 We further examined whether Vc1 can regulate gene expression in response to a 
range of c-di-GMP concentrations by growing the PlacUV5-Vc1UTR-lacZ strain with pPDE 
in medium with a range of arabinose concentrations, which induces a range of PDE 
production and c-di-GMP levels. The resulting β-galactosidase activity decreased in a 
dose-dependent fashion, with a gradual reduction in activity as PDE production 
increased and c-di-GMP level decreased (Figure 2.6). The PlacUV5-Vc1UTR-lacZ strain 
with vector served as a negative control, and the addition of arabinose did not affect β-
galactosidase activity in this strain.  
 
Discussion  
The second messenger c-di-GMP plays a central role in bacterial adaptation to 
extracellular conditions, often mediating the switch between motile and sessile lifestyles. 
Numerous studies have revealed that, while c-di-GMP impacts common biological 
processes, it does so through diverse regulatory mechanisms. Recent work in C. difficile 
has implicated riboswitches in sensing c-di-GMP to control the production of bacterial 
surface organelles, such as flagella and Type IV pili, through post-transcriptional 
mechanisms involving the control of premature transcription termination (17, 22, 24-27). 
In this study, we investigated the in vivo role of the putative c-di-GMP riboswitch Vc1 in 
regulating gene expression in cis in V. cholerae.  
Several lines of evidence support a role for Vc1 in sensing c-di-GMP in V. 
cholerae. Of key importance is the finding that the Vc1 sequence itself influences gene 
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expression in cis, in response to changes in c-di-GMP. Specifically, isolating the Vc1 
sequence by fusing it to a reporter gene (lacZ), placing under the transcriptional control 
of a heterologous, constitutive promoter, and integrating in the V. cholerae chromosome 
rendered reporter activity regulatable by c-di-GMP. Depletion of c-di-GMP through the 
ectopic expression of a c-di-GMP phosphodiesterase gene reduced downstream gene 
expression, while expression of a diguanylate cyclase gene augmented expression. 
These regulatory effects are attributable specifically to altered c-di-GMP, as expression 
of a mutant PDE gene incapable of c-di-GMP hydrolysis did not affect expression. 
Moreover, mutating a single residue in the Vc1 sequence, the G12 nucleotide predicted 
to be involved in c-di-GMP binding, eliminated regulation of downstream expression by 
c-di-GMP. These findings are bolstered by experiments showing that the same mutation 
at the native gbpA locus similarly inhibited downstream gene expression. SHAPE and 
equilibrium dialysis studies using Vc1 RNA corroborate a direct interaction between Vc1 
and c-di-GMP. SHAPE analysis indicated that the reactivity of Vc1 changed in the 
presence of c-di-GMP, specifically in regions predicted to be contact points between c-
di-GMP and GEMM aptamers. Moreover, the G12 mutation that reduced downstream 
gene expression similarly diminished the Vc1—c-di-GMP interaction. Together these 
results support a role for the Vc1 element in regulation of gbpA expression in response 
to c-di-GMP, and point to Vc1 functioning as an “on” switch in response to c-di-GMP. 
However, some of our results are in conflict with attribution of GEMM riboswitch 
function to Vc1. For example, despite conservation of key residues in Vc1, the 
interaction of c-di-GMP with Vc1 RNA appears to be less than that with Vc2 RNA. 
These results may reflect a lower binding affinity of Vc1 for c-di-GMP compared to the 
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affinity of Vc2, which is extremely high (10 pM) (42). The assay we used lacks the 
sensitivity necessary to determine the KD of Vc1 and c-di-GMP, though a future 
comparison of binding affinities of Vc1, Vc2 and other c-di-GMP riboswitches would be 
needed to know the range of sensitivities of GEMM riboswitches for c-di-GMP. In 
addition, the equilibrium dialysis data suggest that the rate of dissociation of c-di-GMP 
from Vc1 and Vc2 differs. The addition of excess, non-radiolabelled competitor c-di-
GMP to the equilibrium chambers led to displacement of labeled c-di-GMP from Vc1, 
but not from Vc2. These results suggest that binding of c-di-GMP by Vc1 is reversible, 
which may allow for more rapid adaptation and modulation of GbpA production. 
Furthermore, in Vc2, G20, A47 and C92 are contact points for c-di-GMP and are critical 
for c-di-GMP binding. Previous analyses of Vc2 showed that mutating G20 (equivalent 
to G12 in Vc1) reduced binding of c-di-GMP by 30,000-fold (42). SHAPE analysis of 
Vc1 showed that the regions adjacent to G12 and A39 had significantly altered reactivity 
in the presence of c-di-GMP, suggesting that those residues participate in c-di-GMP 
sensing. However, the equivalent residues in Vc1, G12, A39 and C104, are not 
essential for c-di-GMP binding. The Vc1 G12 mutation reduces, but does not eliminate, 
the interaction with c-di-GMP in vitro or downstream gene expression in vivo. Thus, 
while several lines of evidence indicate that c-di-GMP signals through Vc1, this element 
differs from the canonical GEMM riboswitch Vc2. Non-conserved sequences in Vc1 may 
alter its interaction with Vc1, or, despite high conservation between Vc1 and Vc2, it is 
possible that c-di-GMP makes alternate contacts with Vc1. Attempts to identify alternate 
binding residues using error prone PCR to generate mutant derivatives of the PlacUV5-
Vc1UTR-lacZ reporter failed to identify single point mutations that eliminate reporter 
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activity, so additional experimentation is necessary to determine how the interaction of 
c-di-GMP with Vc1 differs from that with Vc2. Thus, Vc1 may be a poor riboswitch, or 
not a riboswitch in the strictest definition. Nonetheless, the Vc1 sequence is capable of 
regulating downstream gene expression in response to c-di-GMP. Other putative c-di-
GMP riboswitches may also vary in their interactions with and responses to c-di-GMP.  
 Induction of a c-di-GMP phosphodiesterase using a broad range of inducer 
concentrations to achieve a spectrum of intracellular c-di-GMP levels showed that Vc1 
promotes downstream gene expression in a dose-dependent manner. The ability of Vc1 
to respond to a range of c-di-GMP levels is consistent with work done previously using a 
reporter controlled by an engineered c-di-GMP riboswitch, which also suggested that 
reporter activity varied depending on intracellular c-di-GMP levels (44).  
 Unlike the c-di-GMP riboswitches described to date, the sequence immediately 3’ 
of the predicted Vc1 aptamer does not indicate a likely mechanism of gene regulation. 
There are no obvious Rho-independent transcription terminator or anti-Shine Delgarno 
sequences. The same is true for the region 3’ of the Vc1 aptamer. Quantitative reverse 
transcriptase PCR analysis of the entire gbpA transcript, which involved probing for the 
aptamer as well as four additional regions along the length of the mRNA, showed that 
the G12 mutation in Vc1 results in significantly reduced transcript abundance uniformly 
across the gbpA mRNA (data not shown). Additional work is needed to determine 
whether this occurs as a result of Vc1 controlling transcriptional read-through or 
transcript stability, or as an indirect effect on transcript stability in the absence of 
translation elongation. The mechanism by which the canonical GEMM riboswitch Vc2 
regulates VC1722 expression is similarly unknown. 
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 Several lines of evidence suggest that c-di-GMP levels change in V. cholerae 
during transitions between its native aquatic environment and the host intestine. For 
example, V. cholerae forms biofilms on surfaces in the environment, such as the chitin, 
and numerous studies have shown that biofilm formation is positively regulated by c-di-
GMP (13, 31, 45). Furthermore, increased intracellular c-di-GMP enhances the binding 
of V. cholerae to chitin in vitro in a process dependent on the hemagglutinin FrhA (46). 
Conversely, reduction of c-di-GMP is required to promote bacterial motility and increase 
expression of virulence factors in the intestinal tract (13, 31, 45). Genetic evidence 
suggests that c-di-GMP levels again increase during later stages of infection (47). In the 
context of V. cholerae biology, the effect of Vc1 sensing of c-di-GMP to augment GbpA 
production may contribute to colonization of environmental (chitin) and host surfaces. 
Determining the role of c-di-GMP in controlling c-di-GMP—regulated processes of V. 
cholerae is complicated by the finding that the gbpA promoter is negatively regulated by 
c-di-GMP (Chapter 2). To determine the role of Vc1 in controlling chitin binding or host 
colonization would thus require testing Vc1 mutants for altered phenotypes. 
Unfortunately, despite using the same V. cholerae strain and numerous approaches, we 
were unable to reproduce the effects of an in-frame deletion of gbpA on V. cholerae 
binding to chitin or host colonization, so we could not assess the role of Vc1 specifically 
in these processes. Future work will define the roles of Vc1 and Vc2 in modulating c-di-
GMP-regulated processes in response to extracellular cues in V. cholerae. 
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Figures 
 
 
Figure 2.1. Vc1 secondary structure and putative contact residues for c-di-GMP. (A) 
Identification of the +1 site of transcription, which is 225 base pairs upstream of the 
annotated translational start site, using 5’ RACE. Vc2 and Vc1 were aligned using 
ClustalW2. Asterisks represent nucleotides that are conserved between Vc1 and Vc2. 
Nucleotides bolded and underlined are contact residues for c-di-GMP in Vc2 and are 
predicted contact residues for c-di-GMP in Vc1. The regions predicted to encode P2 
and P3 are labeled. (B) The predicted structure of Vc1 based on an alignment with Vc2 
and the consensus GEMM aptamer structure. The predicted tetraloop and tetraloop 
receptor are noted.  
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Figure 2.2. Vc1 influences downstream gene expression. (A) β-galactosidase activity of 
V. cholerae strains with plasmid-borne lacZ translational fusions to wild type Vc1 or 
mutant derivatives. Transcription initiation is controlled by the lac promoter. Three 
independent experiments were done, and the means and standard deviations are 
shown. *** P < 0.001, * P < 0.05 by unpaired t-test. (B) Western blot analysis of the 
GbpA levels in the supernatants of cultures of wild type V. cholerae, an isogenic ∆gbpA 
strain, or strains with mutations in Vc1 (P1, G12T, A39T, or C104G). The image shown 
is representative of three independent experiments. (C) Densitometry was done by 
comparing the intensity of the GbpA band to that of a cross-reactive band in the same 
lane (indicated by an asterisk), then normalizing to the wild type values. Shown are the 
means and standard deviations for three independent experiments. *** P < 0.001 by 
unpaired t-test. 
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Figure 2.3. c-di-GMP impacts the reactivity of specific regions in Vc1 RNA. In vitro 
transcribed Vc1 RNA was incubated with or without 500 µM c-di-GMP and analyzed by 
SHAPE. SHAPE reactivity values for each nucleotide position were obtained by 
averaging values from five independent experiments. The inset shows in red text the 
location of the nucleotides with significantly altered reactivity, mapped on the predicted 
structure of Vc1. The boxes denote the G12, A39 and C104 residues. * P < 0.05 by 
unpaired t-test comparing SHAPE reactivity values for each nucleotide position, with or 
without c-di-GMP, indicating significant changes in reactivity in response to c-di-GMP.  
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Figure 2.4. Vc1 directly and specifically interacts with c-di-GMP. (A) Binding of c-di-
GMP32 to in vitro transcribed Vc1 RNA and mutant derivatives was measured by 
equilibrium dialysis as described in the Materials and Methods. Vc2 and Vc2G20U RNA 
were included as controls, and no-RNA samples were used as a negative control. (B) 
The specificity of binding to c-di-GMP to Vc1 and Vc2 RNA was assessed by 
equilibrium dialysis, allowing c-di-GMP32 to bind and reach equilibrium as the first 
measurement (black bars), then competing with unlabeled, excess c-di-GMP or GTP 
and determining the percentage of c-di-GMP retained in the RNA chambers (grey bars). 
* P < 0.05 by unpaired t-test. 
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Figure 2.5. Lowering intracellular c-di-GMP reduces Vc1-dependent gene expression. β-
galactosidase activity of V. cholerae strains with chromosomal, translational fusions of 
E. coli lacZ to the gbpA 5’ UTR with wild type Vc1 or Vc1G12T, with transcription initiation 
under the control of the constitutive PlacUV5 promoter(37). Each reporter strain carried 
either vector (wild-type c-di-GMP level; grey bars) or pPDE (reduced c-di-GMP; black 
bars). Strains were grown in rich medium with 0.2% L-arabinose to induce VieA PDE 
production and c-di-GMP depletion. Three independent experiments were done, and the 
means and standard deviations are shown. **** P < 0.0001, n.s. = not significant by 
unpaired t-test. 
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Figure 2.6. Vc1 can respond to dose dependent changes in intracellular c-di-GMP 
levels. Dose response analysis using the PlacUV5-Vc1UTR-lacZ (A) and PlacUV5-Vc2UTR-
lacZ (B) reporter strains, each with vector or pPDE, grown in rich medium with a range 
of arabinose concentrations. Increasing PDE production corresponds with decreasing 
intracellular c-di-GMP. Measurements of β-galactosidase activity were done with three 
biological replicates, and the means and standard deviations are shown. * P < 0.05 by 
unpaired t-test. 
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Figure 2.7.  The translation start site of gbpA is at position +243. To create a 
translational fusion reporter plasmid, we first identified the methionine start codon in the 
gbpA ORF. The E. coli lacZ gene was substituted for the gbpA ORF beginning at either 
the methionine codon at position +225 (the annotated translational start site), or the 
methionine codon at position +243, in each case using the native translational initiation 
sequence. The β-galactosidase activity of V. cholerae strains with lacZ translational 
fusions to PgbpA-Vc1(225) or PgbpA-Vc1(243) that encompass the gbpA promoter and the 
225 bases or 243 bases of the 5’ UTR, respectively, was measured using a Miller 
assay. β-galactosidase activity was approximately 7-fold higher when the second 
methionine was included in the fusion, suggesting that the annotated translational start 
site is incorrect and the 5’UTR of gbpA is 243 bp long.  *** P < 0.001 by unpaired t-test. 
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Figure 2.8. GTP does not induce reactivity changes in Vc1 RNA. In vitro transcribed Vc1 
RNA was incubated with or without 500 µM GTP and analyzed by SHAPE. SHAPE 
reactivity values were obtained by averaging three independent experiments. The data 
were analyzed by unpaired t-test comparing SHAPE reactivity values for each 
nucleotide position; no significant differences were identified. 
 79 
 
 
Figure 2.9. The effect of PDE (VieA) and DGC (VCA0956) gene expression on PlacUV5-
UTR-lacZ reporter activity is specifically due to reduction of c-di-GMP. The β-
galactosidase activity was measured for V. cholerae strains with chromosomal 
translational fusions of E. coli lacZ to the wild type gbpA 5’ UTR, with either vector (wild-
type c-di-GMP level), pPDE (reduced c-di-GMP), pPDEmut (inactive PDE, c-di-GMP) or 
pDGC (DGC VCA0956, increased c-di-GMP). Transcription initiation was controlled by 
the constitutive PlacUV5 promoter. The β-galactosidase activity of control strains 
containing a promoterless UTR-lacZ fusion inserted in the chromosome, with either 
vector (wild type c-di-GMP) or pPDE (reduced c-di-GMP) confirm that no element in the 
UTR drive transcription. All strains were grown in rich medium with 0.2% L-arabinose to 
induce gene expression. Three independent experiments were done, and the means 
and standard deviations are shown. * P < 0.05, *** P < 0.001 by two-way ANOVA and 
Tukey’s multiple comparisons test. 
.  
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Table 2.1. Strains and plasmids used in this study.  
 
Strain Strain Description Reference 
Escherichia coli   
DH5α F– φ80lacZ ΔM15 Δ(lacZYA-argF)U169 recA1 
endA1 hsdR17 (rK-, mK+) phoA supE44 thi-1 
gvrA96 relA1 λ- tonA 
Invitrogen; 
(48) 
DH5αλpir F– Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 
supE44 thi-1 gvrA96 relA1 λpir 
48) 
SM10λpir thi thr leu tonA lacY supE recA::RPA-2-Te::Mu 
λpirR6K, Kmr 
(49) 
Vibrio cholerae   
 C6706 (O1 El Tor) (50) 
 C6706 pBAD33 This study 
 C6706 pBAD33::vieA (pPDE) This study 
 C6706 pBAD33::vieAE170A (pPDEmut) This study 
 C6706 ∆lacZ (51) 
 C6706 ∆lacZ pPlac-Vc1-lacZ This study 
 C6706 ∆lacZ pPlac-Vc1P1-lacZ This study 
 C6706 ∆lacZ pPlac-Vc1A39T-lacZ  This study 
 C6706 ∆lacZ pPlac-Vc1G12T -lacZ This study 
 C6706 ∆lacZ pPlac-Vc1C104G-lacZ This study 
 C6706 ∆gbpA (VCA0811) This study 
 C6706 Vc1P1 This study 
 C6706 Vc1G12T This study 
 C6706 Vc1A39T This study 
 C6706 Vc1C104G This study 
 C6706 Vc1G12T pBAD33 This study 
 C6706 Vc1G12T pBAD33::vieA (pPDE) This study 
 C6706 PlacUV5-Vc1UTR-lacZ This study 
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 C6706 PlacUV5-Vc1UTR-lacZ pBAD33 This study 
 
C6706 PlacUV5-Vc1UTR-lacZ pBAD33::vieA 
(pPDE) This study 
 
C6706 PlacUV5-Vc1UTR-lacZ pBAD33::vieAE170A 
(pPDEmut) This study 
 C6706 PlacUV5-Vc1UTRVc1G12T-lacZ This study 
 C6706 PlacUV5-Vc1UTRVc1G12T-lacZ pBAD33 This study 
 
C6706 PlacUV5-Vc1UTRVc1G12T-lacZ pBAD33::vieA 
(pPDE) This study 
 
C6706 PlacUV5-Vc1UTRVc1G12T-lacZ 
pBAD33::vieAE170A (pPDEmut) This study 
Plasmids    
pPlacthiM#2-lacZ 
The TPP riboswitch encoded in the 5‘ UTR of E. coli 
thiM was mutated to function as an ON switch and 
cloned into pPlac-lacZ. Origin of replication colEI.  
AmpR (52) 
pPlac-Vc1-lacZ 
Vc1 allele from C6706 cloned into  
plasmid pPlacthiM#2-lacZ 
This study 
pPlac-Vc1P1-lacZ Vc1P1 allele cloned into plasmid pPlacthiM#2-lacZ This study 
pPlac-Vc1A39T-lacZ  Vc1A39T allele cloned into plasmid pPlac-Vc1-lacZ This study 
pPlac-Vc1G12T-lacZ  Vc1G12T allele cloned into plasmid pPlac-Vc1-lacZ This study 
pPlac-Vc1 C104G-
lacZ  Vc1C104G allele cloned into plasmid pPlac-Vc1-lacZ 
This study 
pBAD33 Expression vector, Para promoter, CmR (53) 
pBAD33::vieA vieA in pBAD33 (“pPDE”) (31) 
pBAD33::vieAE17
0A 
vieAE170A (allele encoding enzymatically inactive 
VieA) (“pPDEmut”) 
(31) 
pCVD442 
oriR6K plasmid with a polylinker, mobRP4, bla, and 
sacB 
(54) 
pCVD442::∆gbpA Allelic exchange vector for in-frame deletion of gbpA This study 
pCVD442::Vc1P1 
Allelic exchange vector for mutation of P1 stem This study 
pCVD442::Vc1G12T 
Allelic exchange vector for mutation of nucleotide 
G12 in Vc1 
This study 
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pCVD442::Vc1A39T 
Allelic exchange vector for mutation of nucleotide 
A39 in Vc1 
This study 
pCVD442::Vc1C104
G 
Allelic exchange vector for mutation of nucleotide 
C104 in Vc1 
This study 
pCVD442::Vc2G20T 
Allelic exchange vector for mutation of nucleotide 
G20 in Vc2 
This study 
pJL1 
Allelic exchange vector for integration into V. 
cholerae lacZ gene 
(38) 
p2UY35A 
Template used for amplification of PlacUV5 
promoter 
(37) 
pJL1:: PlacUV5-
Vc1UTR-lacZ 
Allelic exchange vector for integration of PlacUV5-
Vc1UTR-lacZ translational fusion into V. cholerae 
lacZ gene (WT 5’ UTR of gbpA containing Vc1) 
This study 
pJL1:: PlacUV5-
Vc1UTRG12T-lacZ 
Allelic exchange vector for integration of PlacUV5-
Vc1UTRG12T-lacZ translational fusion into V. 
cholerae lacZ gene (mutant 5’ UTR of gbpA 
containing Vc1) 
This study 
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Table 2.2. Primers used in this study.  
 
Primer 
Name Oligonucleotide sequence (5’ to 3’) * Reference 
gbpAF1 TTGCATGCTACTCGTCAGGTCTTTGG This study 
gbpAR1 TTGGTACCCATCACAGACTCTTCTTTG This study 
gbpAF2 TTGGTACCTAAGTTATCCTCCCTCTTAC This study 
gbpAR2 TTGAGCTCTTTCTCTGGATGGGAGTC This study 
gbpAF0 GCAAACGGTAGCAAGAAG This study 
pCVDseqF CTGTTGCATGGGCATAAAGTTGCC This study 
pCVDseqR ACACAGGAACACTTAACGGCTGAC This study 
gbpAPrR CGATGTCGACCATCACAGACTCTTCTTTGTTAGC This study 
gbpAP2F CCGAATTCCCGAGTAAAGCATCAACCTTTCATATTG This study 
gbpArbF CCGAATTCAGTAAATTTGCTCTCGGTCACAC This study 
Race1a GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTTA This study 
Race1g GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTTG This study 
Race1c GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTTC This study 
Race2 GACTCGAGTCGACATCG This study 
gbpAsp1 GTGAATCTGAACTTCAGCACC This study 
gbpAsp2 GCACCTTCAGCAACGCATAAG This study 
gbpAsp3 TTGCCAAAGTGTGACCGAGAG This study 
gbpAsp4 ACCAAGAGAGAAAGCGAAGTC This study 
placP2R TTGCATGCTTGCCAAAGTGTGACCGAGAG This study 
placP2F TTGCATGCCAGCTAACAAAGAAGAGTCTGTG This study 
Vc1F1 CCTCTAGATACTCGTCAGGTCTTTGG This study 
Vc1R2 AAGAGCTCCGAGTGTACACGGTATCG This study 
Vc1R3 AGCAACGCATAAGACAAAACG This study 
Vc1gTF CACACTTTTGCAAACCCTTTGAAAAAATGG This study 
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Vc1gTR AGGGTTTGCAAAAGTGTGACCGAGAG This study 
Vc1aTF AATGGGACGCTAAGCTTCCGGTCTG This study 
Vc1aTR CGGAAGCATTGCGTCCCATTTTTTC This study 
Vc1cGF GGTTAGCAATTCGGTTTATACCG This study 
Vc1cGR ATTGCTAACCCCGCTATCC This study 
Vc2G20TF1 CCGAGCTCTCAGAGATGCCTTAATAGCTC This study 
Vc2G20TR1 CAGTGCAAACCATTCGAAAG This study 
Vc2G20TF2 GTTTGCACTGTGCGTGA This study 
Vc2G20TR2 GGCCCGGGGCGGCGGATAAAATCATTGC This study 
T7linkF TAATACGACTCACTATAGGGCCTTCGGGCCAACGGTCACACTTTGGCAAACCC This study 
T7R CATCACGCGACAATGGCTGGT This study 
gbpAR2 CGATGTCGACTTTAGGTTGTTTTTTCATCACAG This study 
T7Vc1F TAATACGACTCACTATAGGGAGAAGTAAATTTGCTCTCGGTCACAC This study 
T7Vc2F TAATACGACTCACTATAGGGAGAGGAAAAATGTCACGCACAGG This study 
T7Vc2R CATGCTGTTAGTCTCGGAGTATTG This study 
PlacZR3 GCGCATGCTCACATTAATTGCGTTGCGCTCTCG This study 
PlacUV5F GCGCATGCAAACCCTATGCTAC This study 
PlacUV5R GCGAATTCACACACTATACGAGCCG This study 
PlacF5 CCAGGCCTAATAGGCGTATCACGAGG This study 
PlacR5 CCGCGGCCGCGTCTTTCGACTGAGCCTTTC This study 
PlacZsF AGCACACTAACTACCAGC This study 
PlacZsR GTTTGTATGTGGTGGATGAG This study 
RPB2F CTGTCTCAAGCCGGTTACAA (35) 
RPB2R TTTCTACCAGTGCAGAGATGC (35) 
gbpAqF2 CTCTGGTATCAGTGGATTAGCG This study 
gbpAqR2 GTATTGAATCGCGCCACAGT This study 
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Vc1BF GTAAATTTGCTCTCGGTGTGTGTTTGGCAAACCCTTTG This study 
Vc1BR CAAAGGGTTTGCCAAACACACACCGAGAGCAAATTTAC This study 
pLacSeq ATTGTCTCATGAGCGGATAC This study 
placZF ATGCAAGTCGACCTGCTGGATC This study 
 
* The underlined sequences represent restriction enzyme recognition sites, and the bold 
and underline sequences represent point mutations. Italicized sequences encode a 6-
histidine tag. 
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CHAPTER 3: TWO NUCLEOTIDE SECOND MESSENGERS REGULATE THE 
PRODUCTION OF THE VIBRIO CHOLERAE COLONIZATION FACTOR GBPA 
 
Summary 
Background: The nucleotide second messengers cAMP and c-di-GMP allow 
many bacteria, including the human intestinal pathogen Vibrio cholerae, to respond to 
environmental stimuli with appropriate physiological adaptations. In response to 
limitation of specific carbohydrates, cAMP and its receptor CRP control the transcription 
of genes important for nutrient acquisition and utilization; c-di-GMP controls the 
transition between motile and sessile lifestyles often, but not exclusively, through 
transcriptional mechanisms. In this study, we investigated the convergence of cAMP 
and c-di-GMP signaling pathways in regulating the expression of gbpA. GbpA is a 
colonization factor that participates in the attachment of V. cholerae to N-
acetylglucosamine-containing surfaces in its native aquatic environment and the host 
intestinal tract.  
Results: We show that c-di-GMP inhibits gbpA activation in a fashion 
independent of the known transcription factors that directly sense c-di-GMP. 
Interestingly, inhibition of gbpA activation by c-di-GMP only occurs during growth on 
non-PTS dependent nutrient sources. Consistent with this result, we show that CRP 
binds to the gbpA promoter in a cAMP-dependent manner in vitro and drives 
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transcription of gbpA in vivo. The interplay between cAMP and c-di-GMP does not 
broadly impact the CRP-cAMP regulon, but occurs more specifically at the gbpA 
promoter.  
Conclusions: These findings suggest that c-di-GMP directly interferes with the 
interaction of CRP-cAMP and the gbpA promoter via an unidentified regulator. The use 
of two distinct second messenger signaling mechanisms to regulate gbpA transcription 
may allow V. cholerae to finely modulate GbpA production, and therefore colonization of 
aquatic and host surfaces, in response to discrete environmental stimuli. 
 
Introduction 
Nucleotide second messengers in bacteria play a key role in relaying information 
from the extracellular environment to intracellular effectors, resulting in an adaptive 
physiological response. Production of these intracellular nucleotides, which include c-di-
GMP, c-di-AMP, cGMP, cAMP, and (p)ppGpp, regulates fundamental processes 
including biofilm formation, motility, nutrient acquisition, stress responses, sporulation 
and, in some pathogens, virulence factor production (reviewed in [1-4]).  
c-di-GMP, utilized by many Gram-negative and Gram-positive bacteria, usually 
regulates transitions between motile and non-motile lifestyles. Specifically, c-di-GMP 
negatively regulates flagellar motility by inhibiting flagellum biosynthesis or function, and 
positively regulates adherence and biofilm development in many species [5]. The 
intracellular levels of c-di-GMP are regulated by the opposing activities of diguanylate 
cyclase (DGC) biosynthetic enzymes and phosphodiesterase (PDE) hydrolytic enzymes 
[6-12]. Many organisms contain numerous genes that encode proteins with known or 
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predicted functions as DGC and/or PDE enzymes. To date there are several known 
intracellular c-di-GMP receptors, including protein and RNA-based sensors. Proteins 
that directly sense c-di-GMP include transcription factors, proteins containing the well-
characterized PilZ domain, and others such as catalytically inactive PDEs that retain the 
capacity to bind c-di-GMP [13]. In addition, two distinct classes of c-di-GMP sensing 
riboswitch, broadly present in bacterial genomes, have been identified [14-17]. The 
presence of numerous c-di-GMP metabolic enzymes and an array of intracellular c-di-
GMP receptors points to complex c-di-GMP signaling networks that modulates a wide 
array of cellular functions. 
In the human diarrheal pathogen Vibrio cholerae, c-di-GMP promotes biofilm 
formation and inhibits flagellar motility [18-20]; in addition, c-di-GMP inhibits the 
expression of virulence genes including those encoding the major virulence factor, 
cholera toxin [21]. To date, three transcription factors that directly sense c-di-GMP have 
been identified in V. cholerae: VpsT, VpsR and FlrA [22-24]. Each of these was 
previously characterized as a regulator of biofilm formation and/or motility [20, 25-28]. 
Five proteins containing a PilZ domain have been described in V. cholerae, some of 
which have roles in biofilm, motility and/or virulence [29]. The V. cholerae genome also 
encodes two c-di-GMP riboswitches, Vc1 and Vc2, which lie upstream of gbpA and 
VC1722, respectively [14].  
cAMP signaling is widespread in bacteria, and intracellular cAMP levels are 
heavily influenced by the availability of extracellular nutrient sources [30]. In Gram-
negative bacteria, uptake of a preferred sugar by the phosphoenolpyruvate-
carbohydrate phosphotransferase transport system (PTS) relies on a sugar-specific 
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transporter, EIIA. Following uptake of a PTS sugar, EIIA and other PTS components 
participate in a phosphorylation cascade that culminates phospho-transfer from EIIA to 
the incoming sugar. The phosphorylation state of EIIA serves as a measure of PTS 
sugar availability. Under conditions of PTS sugar limitation (and absence of a PTS 
sugar substrate), EIIA remains phosphorylated and stimulates the adenylate cyclase 
(AC), triggering cAMP biosynthesis. To date, the only known sensor of cAMP in bacteria 
is the cAMP receptor protein (CRP) [30]. Together, the cAMP-CRP complex promotes 
the expression of genes involved in the uptake and utilization of non-PTS nutrient 
sources.  
V. cholerae uses the cAMP-CRP system to respond to the absence of PTS-
dependent sugars such as N-acetylglucosamine, sucrose, mannitol and fructose [31]. 
Unlike E. coli, in which glucose utilization is PTS-dependent, glucose can be utilized via 
PTS and non-PTS mechanisms in V. cholerae [31]. V. cholerae has also adapted the 
cAMP-CRP pathway to promote motility and inhibit biofilm formation [32, 33]. 
Transcriptome analyses have shown that cya and crp deletion mutants (which lack 
cAMP biosynthesis and sensing, respectively) have increased expression of genes 
involved in extracellular matrix production, reduced expression of genes involved in 
flagellum biosynthesis and chemotaxis [32, 33]. In addition, a crp deletion mutant has 
reduced expression of genes important for colonization and is attenuated in a mouse 
model of infection [32]. Interestingly, the cAMP-CRP signaling pathway impinges upon 
the c-di-GMP signaling network; a crp mutant has altered expression of numerous 
genes involved in c-di-GMP metabolism [33].  
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V. cholerae naturally inhabits aquatic reservoirs, where it associates with 
chitinous surfaces such the exoskeletons of zooplankton and crustaceans [34]. V. 
cholerae can be ingested through consumption of contaminated food or water and 
subsequently colonize the small intestine and cause diarrheal disease in humans. The 
colonization factor GbpA aids in the attachment of V. cholerae to surfaces in its native 
aquatic environment and in the host intestine [35, 36]. GbpA recognizes N-
acetylglucosamine (GlcNAc), a component of mucin and a modification of glycoprotein 
and lipids found on the surface of the intestinal epithelium, thus mediating interactions 
with the host intestinal epithelium [35, 36]. GlcNAc also comprises the polymer chitin, a 
major component of the exoskeletons of crustaceans and zooplankton, thus serving as 
a substratum for V. cholerae colonization in aquatic reservoirs [35]. In addition to 
serving as a ligand for GbpA, GlcNAc also regulates gbpA expression via the 
transcriptional regulator NagC [37, 38]. In V. cholerae and some other bacterial species, 
the transcription factor NagC regulates gene expression in response to GlcNAc and 
typically controls genes involved in GlcNAc uptake and metabolism [38-42]. 
Transcriptional profiling of a V. cholerae nagC mutant indicated that NagC represses 
gbpA transcription [38], suggesting that gbpA expression is down-regulated in the 
presence of mucin- and chitin-derived GlcNAc in the small intestine and in the aquatic 
environment, respectively [36-38].  
 In this study, we investigated the combined roles of the second messengers cAMP 
and c-di-GMP in regulating gbpA transcription. We report that c-di-GMP inhibits gbpA 
transcription independently of the previously described c-di-GMP riboswitch. Expression 
of gbpA is also influenced by the availability of PTS-dependent carbohydrates, and is 
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accordingly regulated by cAMP-CRP through direct binding of this complex to the gbpA 
promoter. Together, our results indicate that gbpA transcription is regulated by both c-
di-GMP and cAMP, in opposing fashion. The c-di-GMP and cAMP second messenger 
signaling pathways may thus function together to modulate the production of GbpA in 
response to discrete extracellular stimuli, likely impacting the ability of V. cholerae to 
colonize GlcNAc-containing surfaces in the aquatic and host environments. 
Materials and Methods 
Growth conditions and media. Escherichia coli, V. cholerae C6706 and mutant 
derivatives were cultured at 37 °C with aeration in Luria-Bertani (LB) broth containing 
100 µg/ml streptomycin (Sm), 10µg/ml chloramphenicol (Cm), and/or 50 µg/ml ampicillin 
(Amp), as appropriate. Where specified, V. cholerae was grown in M9 minimal medium 
(Fisher Scientific) supplemented with trace metals (1 ml l−1 of 5% MgSO4, 0.5% 
MnCl24H2O, 0.5% FeCl3, 0.4% nitrilotriacetic acid) [43] and 0.5% (w/v) of the indicated 
carbon source. 
 
Strain construction. Strains and plasmids included in this study are listed in 
Table S1. Primer information is contained in Table S2. The gbpA, nagC, crp, cpdA, cya, 
vpsT, vpsR and flrA genes were mutated by standard allelic exchange methods. A 
deletion in the Vc1 sequence upstream of gbpA was deleted in a similar manner. Using 
genomic DNA from V. cholerae C6706 as template, ~800 bp fragments upstream and 
downstream of the sequences to be deleted were amplified by PCR using primers 
named according to the pattern geneF1 + geneR1 for the upstream region of homology 
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and geneF2 + geneR2 for the downstream region of homology. The primers introduced 
restriction sites (underlined sequences in Table 2) allowing ligation of the resulting 
fragments to each other and into the pCVD442 suicide vector. The exception is the 
vpsR mutation, for which the two fragments were joined by splicing by overlap 
extension, and then ligated into pCVD442. The ligations were transformed into 
DH5αλpir by electroporation and transformed colonies were identified on LB-Amp agar. 
The desired clones containing the upstream and downstream fragments were identified 
by PCR using primers geneF1 + geneR2 and/or pCVDseqF + pCVDseqR, which flank 
the multiple cloning site of pCVD442. The allelic exchange steps were done as 
described previously [44]. Colonies were screened for the desired deletion by PCR 
using the corresponding geneF0 + geneR2 primers. 
 The pPgbpA-Vc1-lacZ and pPgbpA-∆Vc1-lacZ plasmids were constructed by 
amplifying the gbpA promoter and 5’ UTR from V. cholerae C6706 and DVc1 genomic 
DNA, respectively, by PCR using gbpAP2F + gbpAR2. The PCR products were 
digested with EcoRI and SalI and ligated into pPlacthiM#2-lacZ [45] digested with the 
same enzymes. The ligation reaction was transformed into DH5α cells by 
electroporation, and Amp-resistant colonies obtained were screened with primers 
pLacSeq + gbpAR2. The resulting plasmids have PgbpA-UTR (wild type or ∆Vc1) as a 
translational fusion to lacZ, with the lac promoter driving transcription. The plasmids 
were introduced by electroporation into V. cholerae C6706 in which the endogenous 
lacZ gene was inactivated [46]. The pBAD33 and pBAD33::vieA plasmids were 
introduced into the indicated strains by electroporation. 
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Manipulation of the intracellular c-di-GMP level in V. cholerae. The 
intracellular c-di-GMP level was depleted through the ectopic expression of a V. 
cholerae c-di-GMP phosphodiesterase gene, vieA, as described previously [47, 48]. 
Briefly, V. cholerae bearing pBAD33 (“vector”) or pBAD33::vieA (“pPDE”) were grown in 
LB-Cm broth at 37oC with aeration. At early exponential phase (OD600 ~ 0.2), 0.2% L-
arabinose was added to the cultures to induce vieA transcription from the PBAD 
promoter. Samples were collected at mid-exponential phase (OD600 ~ 0.5-0.7) for 
western blotting or qRT-PCR analysis as described below. 
 
Reporter activity assays. The β-galactosidase activity of stationary phase 
samples of strains containing lacZ reporter fusions was measured using a Miller assay 
[49]. Strains were grown in LB broth overnight (14-16h), diluted 1:10 in LB broth, and 
100 µl were assayed for hydrolysis of ortho-nitrophenyl-β-D-galactoside. At least three 
independent experiments were done, and the data were combined. Statistical analyses 
were done using unpaired t-tests. 
 
GbpA antibody production. Anti-GbpA antiserum was produced by Yenzym 
192 Antibodies, LLC, South San Francisco, CA. Antiserum was raised in rabbits to a 
synthetic peptide (CSNATQYQPGTGSHWEMAWDKR) that corresponds to GbpA from 
V. cholerae. The animal facilities were NIH/OLAW/PHS assured, USDA certified, and 
IACUC regulated. 
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 GbpA and CRP detection by western blot. Equal-volume samples of mid-
exponential phase cultures, normalized to OD600, were collected. For detection of GbpA, 
the samples were centrifuged to remove the bacteria. Supernatant proteins were TCA 
precipitated, separated by electrophoresis, and subjected to western blotting with rabbit 
anti-GbpA antibodies. For detection of CRP, cells grown as above were collected by 
centrifugation. Whole lysates were electrophoresed and transferred to nitrocellulose 
membranes. CRP (~23.6 kDa) was detected using anti-CRP monoclonal antibodies 
(Neoclone). For cell lysates, RNA Polymerase β subunit (~150 kDa) served as a loading 
control and was detected with monoclonal antibodies (AbCam). In all western blots, 
goat α-rabbit IgG conjugated with IR800 dye (Thermo Scientific) was used as the 
secondary antibody. The blots were imaged using an Odyssey imaging system (LI-
COR). At least three independent experiments were done, and a representative image 
is shown. Densitometry analyses were done using the Odyssey software. The 
intensities of the bands corresponding to GbpA in supernatants were normalized to 
those of a cross reactive band (indicated by asterisks in relevant images). For CRP 
quantification, the intensities of the bands of CRP in lysates were normalized to those of 
RNAP. 
 
RNA purification and analysis using quantitative real-time PCR. 
Transcriptional analyses using quantitative reverse-transcriptase PCR (qRT-PCR) were 
done as previously described [50]. Briefly, RNA was purified from mid-exponential 
phase (OD600 ~ 0.5-0.7) cultures. Genomic DNA was removed using the TURBO DNA-
free kit (Ambion). For cDNA synthesis, RNA (200 ng) was reverse transcribed using the 
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Tetro cDNA Synthesis Kit (Bioline). We included control reactions without reverse 
transcriptase for every cDNA sample. For the real time PCR reaction, cDNA and control 
samples were combined with 2× SYBR/fluorescein mix (SensiMix; Bioline) and 7.5 µM 
of each primer (named according to the scheme gene-qF and gene-qR for forward and 
reverse primers, respectively, Table S2). We used the following program to amplify 
target cDNA: 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 55°C for 1 min, 
and 72°C for 30 s. Melt curves were included to verify amplification of single products. 
The data were analyzed using the ∆∆Ct method, with Ct values normalized to the 
specified reference strain/condition, and to the Ct values of the reference gene rpoB 
and/or gyrA in each sample [50-52]. For each strain/condition, a minimum of three 
independent samples was tested. Statistical significance was determined by unpaired t-
test. 
 
 Cloning and expression of crp and purification of the recombinant protein. 
The CRP gene was amplified from V. cholerae 6706 genomic DNA using primers 
CRPeF + CRPeH6R, which incorporate EcoRI and SalI restriction sites into the product, 
respectively. The CRPeH6R primer introduces 6 histidine codons at the 3’ end of the 
gene. The PCR product was digested with EcoRI and SalI and ligated into similarly 
digested pMMB67EH, a low-copy vector allowing IPTG-inducible gene expression [53]. 
Ligations were transformed into E. coli DH5α cells. Ampicillin-resistant colonies 
containing pMMB67EH with crp-his6 insert were identified by PCR, yielding pMMB::crp-
his6. 
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 E. coli DH5α containing pMMB::crp-his6 was grown in LB broth at 37°C with 
aeration to early exponential phase (OD600 ~ 0.2), at which point IPTG was added for a 
0.5 mM final concentration. The culture was grown at 37°C with aeration to mid- 
exponential phase (OD 600 nm ~ 0.7), then cells were collected by centrifugation. Cells 
were suspended in His6 lysis buffer consisting of 10 mm Tris, pH 8, 300 mm NaCl, 50 
mm NaH2PO4, 10% glycerol, 1 mm phenylmethylsulfonyl fluoride, and 5 mM imidazole 
[10]. The cells were lysed by sonication, and CRP was purified by affinity 
chromatography with Ni-NTA resin (ThermoFisher) using the general methods 
described previously [10, 48]. The eluates were analyzed by SDS-PAGE and 
coomassie staining. CRP-containing fractions were dialyzed against 5 mM Tris 8.0, 10 
mM MgCl2, 5 mM KCl, 5 mM CaCl2, 10% glycerol using 10,000 MWCO Slide-A-Lyzer 
Dialysis Cassettes (Thermo Scientific). The CRP preparations were estimated to be > 
95% pure. Glycerol was added to a final concentration of 20%, and the protein 
concentration was determined using the BCA Protein Assay Kit (Pierce). Aliquots of the 
protein were stored at -20°C. 
 
Electrophoretic mobility shift assays (EMSAs). A 293 base pair gbpA 
promoter fragment was amplified from V. cholerae 6706 genomic DNA using primers 
gbpAP2F + Vc1R2. A 133 base pair non-specific control DNA fragment internal to the 
gbpA ORF was amplified with gbpAqF2 + gbpAqR2. EMSAs were done as previously 
described [54]. Binding reactions were done in 10 mM Tris pH 2.5, 1 mM EDTA, 100 
mM KCl, 0.1 mM DTT, 5% glycerol (v/v) and 0.01 mg/ml BSA (final concentrations). The 
gbpA promoter fragment, CRP, and cAMP (Sigma-Aldrich) were used at final 
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concentrations of 2.5 ng/ml, 11 ng/ml, and 33 mM, respectively. C-di-GMP (Biolog) was 
used at 33 mM, or 333 mM when in competition with cAMP. The non-specific DNA 
fragment (75 ng) was added to every mixture. After 1 hour incubation at room 
temperature (~25°C), the samples were electrophoresed on a 6% TAE polyacrylamide 
gel. The gel was stained with GelRed (Biotium, Inc.) in TAE for 10 minutes, and then 
visualized under UV light.  
 
Results 
Low c-di-GMP induces gbpA transcription in a Vc1-independent manner. 
A putative c-di-GMP riboswitch, named Vc1, was previously predicted upstream 
of the gbpA open reading frame. Using a heterologous reporter, we have found that 
depleting intracellular c-di-GMP or mutating a conserved residue in Vc1 impairs 
downstream gene expression (Chapter 2). Thus, c-di-GMP appears to promote gbpA 
expression via Vc1. Based on these data, we predicted that depleting intracellular c-di-
GMP and preventing its stimulation of Vc1 would result in decreased gbpA expression. 
To test this, we used a previously described strategy for ectopic expression of a c-di-
GMP phosphodiesterase (PDE), vieA, to manipulate intracellular c-di-GMP levels in V. 
cholerae. The abundance of the gbpA transcript and GbpA protein in V. cholerae 
bearing pPDE, which allows arabinose-induced expression of the PDE, was compared 
to those in V. cholerae with vector. Contrary to our expectation, western blot analysis of 
GbpA production showed that lowering c-di-GMP levels through PDE production 
resulted in a 2.8-fold increase in GbpA (Figure 3.1A). Regulation by c-di-GMP occurred 
at the level of gene expression, as quantitative real time PCR analysis indicated that 
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gbpA transcript levels were 11.1-fold higher in V. cholerae with depleted c-di-GMP 
(Figure 3.1B).  
We next tested whether c-di-GMP induction of GbpA production is dependent on 
the putative riboswitch Vc1. To do this, we assessed the effect of depleting c-di-GMP in 
V. cholerae lacking the Vc1 sequence. This strain, ∆Vc1, lacks nucleotides 17-202 of 
the transcript, which encompass most of the 5’UTR including the c-di-GMP riboswitch, 
but retains the native gbpA promoter and the native ribosomal binding site. The pPDE 
and control plasmids were introduced into the ∆Vc1 mutant, and the strains were 
assessed for changes in gbpA expression. In the ∆Vc1 strain with vector, gbpA 
transcript (Figure 3.1B) and GbpA protein (Figure 3.1A) were diminished by 75% and 
83%, respectively, compared to the wild type with vector, suggesting that removal of 
nucleotides 17-202 reduces expression. Yet depletion of c-di-GMP in the ∆Vc1 strain 
(pPDE) increased GbpA production 3.4-fold (Figure 3.1B) and gbpA transcription 15.4-
fold (Figure 3.1A), an effect equivalent to that seen in the wild type background.  
In addition, we used lacZ fusions to either the wild type gbpA promoter and 
5’UTR (PgbpA-Vc1-lacZ) or the promoter and 5’UTR lacking Vc1 (PgbpA-∆Vc1-lacZ) as 
reporters of gbpA expression. We measured β-galactosidase activity in V. cholerae with 
these plasmid-borne reporters, each with either vector or pPDE. In both the PgbpA-Vc1-
lacZ and PgbpA-∆Vc1-lacZ reporter strains, reduction of c-di-GMP (pPDE) resulted in a 
statistically significant ~2-fold increase in β-galactosidase activity (Figure 3.1C). Thus, c-
di-GMP inhibition of gbpA expression is independent of Vc1, indicating that low 
intracellular c-di-GMP concentrations promote gbpA transcription initiation via the gbpA 
promoter. 
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The c-di-GMP responsive regulators VpsT, VpsR and FlrA are not involved in the 
regulation of gbpA transcription by c-di-GMP. 
We next aimed to determine the mechanism by which c-di-GMP inhibits gbpA 
transcription. We hypothesized that a c-di-GMP sensing transcription factor interacts 
with the gbpA promoter, either inhibiting expression in response to c-di-GMP, or 
alleviating activation in response to c-di-GMP. We first focused on three previously 
identified c-di-GMP binding transcription factors, VpsT, FlrA and VpsR, as potential 
mediators of c-di-GMP regulation of gbpA expression [22-24]. Transcriptional profiling 
studies analyzing V. cholerae vpsT, vpsR and flrA mutants have implicated each of the 
regulators in controlling gbpA expression, with VpsT and VpsR suggested to act as 
activators and FlrA acting as a repressor [20, 55].  
We tested the effect of vpsT, vpsR or flrA mutation on gbpA expression in 
response to c-di-GMP. The pPDE and control plasmids were introduced into the ∆vpsT, 
∆vpsT and ∆flrA mutants, and gbpA expression was assessed by qRT-PCR and by 
western blot. Transcript analysis showed that the flrA mutant had somewhat (1.4-fold) 
higher gbpA transcript levels, and the vpsT and vpsR mutants had lower levels (55% 
and 46% decreased, respectively), than the parental strain (Figure 3.2B). These 
differences were not statistically significant, but the trends were supported by the results 
of the western blots comparing GbpA protein abundance in the mutants compared to 
the wild type with vector (Figure 3.2A). Furthermore, depletion of c-di-GMP (pPDE) in 
the ∆flrA, ∆vpsT and ∆vpsR mutants resulted in 4.8-, 9.6- and 11.0-fold increased gbpA 
transcript, respectively, compared to the mutants with unmodified c-di-GMP (Figure 
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3.2B). Inhibition of gbpA expression by c-di-GMP in the mutants and the wild type was 
apparent at the protein level as well (Figure 3.2A). The observed changes were 
equivalent to the increase seen in the wild type background. Thus, none of the known c-
di-GMP sensing transcription factors regulate gbpA expression in response to this 
second messenger. 
 
 
c-di-GMP inhibits gbpA transcription in a nutrient dependent manner. 
GlcNAc and GlcNAc-containing mucin have been shown to regulate gbpA 
expression, and to date the only known transcriptional regulator of gbpA is NagC, a 
repressor of genes involved in GlcNAc utilization and of gbpA transcription [36-38]. We 
sought to determine how c-di-GMP impacts regulation of the gbpA promoter in the 
presence of N-acetylglucosamine (GlcNAc). We reasoned that GlcNAc, and perhaps 
other carbohydrates, may affect c-di-GMP inhibition of gbpA expression, and that NagC 
may participate in this process. Specifically, we postulated that c-di-GMP promotes 
NagC inhibition of gbpA expression, such that depletion of c-di-GMP results in NagC 
de-repression.  
To test the effect of GlcNAc on regulation of gbpA expression by c-di-GMP, we 
generated V. cholerae strains with a translational fusion of lacZ to the gbpA promoter 
and 5’UTR, with either pPDE or the vector control. These strains were grown in a 
defined medium (M9 minimal medium, MM) supplemented with 0.5% (w/v) GlcNAc, 
glucose, maltose, sucrose, fructose or casamino acids. The additional carbohydrates 
were included to address whether the potential effect of GlcNAc is specific to this sugar, 
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and casamino acids were included as a non-carbohydrate carbon source control. The 
cultures were grown to mid-exponential phase (OD600 0.45-0.6), and expression of gbpA 
was measured by β-galactosidase assay, allowing normalization to the optical density of 
the culture to adjust for differences in growth due to the carbon source. Expression of 
gbpA was variable in the media tested (Figure 3.3, black bars), possibly due to 
differences in growth rate with the different carbon sources. Compared to V. cholerae 
with wild type c-di-GMP levels, reduction of c-di-GMP led to significantly increased 
reporter activity in V. cholerae grown in GlcNAc (1.35-fold), glucose (1.73-fold), maltose 
(1.59-fold) and casamino acids (1.67-fold), but not in bacteria grown in sucrose or 
fructose (Figure 3.3, grey bars). The results could not be attributed to growth rate, as 
depleting c-di-GMP (pPDE) did not affect overall growth (data not shown). These results 
indicate that growth on GlcNAc does not interfere with c-di-GMP regulation of gbpA 
expression.  
To test whether NagC is required for c-di-GMP inhibition of gbpA expression, 
pPDE and the control vector were introduced into V. cholerae with an in-frame deletion 
of nagC (∆nagC). Consistent with previous reports [37, 38], deletion of nagC resulted in 
2.2-fold higher GbpA protein (Figure 3.4A) and 1.8-fold higher gbpA transcript 
abundance (Figure 3.4B) than in the wild type. Upon lowering c-di-GMP levels through 
PDE gene expression, we observed 20-fold and 2.4-fold increases in gbpA transcript 
and GbpA protein, respectively, comparable to those seen in the wild type background 
(Figures 3.4B and 3.4A, respectively). Thus, NagC is not required for gbpA inhibition by 
c-di-GMP, corroborating the lack of an effect of growth with GlcNAc as the sole carbon 
source. 
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Low c-di-GMP induces gbpA transcription in a cAMP-CRP-dependent manner. 
In V. cholerae, GlcNAc, sucrose and fructose are solely imported via a 
phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS), and maltose is 
taken up via a PTS-independent mechanism [31]. Glucose is a PTS-substrate that can 
also be imported via a PTS-independent pathway, and GlcNAc has been reported to be 
a PTS dependent carbohydrate in V. cholerae [31]. However, a V. cholerae nagE 
mutant, which does not produce the GlcNAc PTS transporter component, is able to 
grow, albeit at a reduced rate, with GlcNAc as the sole carbon source, suggesting that 
an alternate GlcNAc uptake pathway(s) exists [38]. We observed that c-di-GMP 
inhibition of gbpA expression did not occur during growth relying on the strictly PTS-
dependent carbohydrates sucrose and fructose (Figure 3.3), suggesting a dependence 
of c-di-GMP regulation on carbon source availability and the mechanism of uptake. 
Limitation of PTS-carbohydrates results in increased cAMP biosynthesis and CRP 
activation, allowing the bacterium to activate alternate metabolic pathways [30]. Our 
results suggest that c-di-GMP inhibits gbpA transcription when cAMP-CRP levels are 
elevated. We thus considered the possibility that cAMP-CRP regulates gbpA 
transcription in a mechanism that is influenced by c-di-GMP levels. 
To test the role of CRP in regulating gbpA in response to c-di-GMP, we 
generated a V. cholerae ∆crp mutant and examined it for gbpA production. By western 
blot, the ∆crp mutant reproducibly produced ~40% less GbpA than the parent strain, 
supporting a role for CRP in upregulating GbpA production (Figure 3.4A). The gbpA 
transcript was also reduced by 53% in the ∆crp mutant (Figure 3.4B). We next 
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determined the role of CRP in mediating c-di-GMP regulation of gbpA by assessing 
expression in the ∆crp mutant bearing pPDE. Unlike in wild-type V. cholerae with the 
control plasmid, when intracellular c-di-GMP levels were lowered by PDE production in 
the ∆crp strain, there was no change in gbpA transcript or GbpA protein levels (Figures 
3.4B and 3.4A, respectively), indicating that CRP is required for activation of gbpA 
expression in response to decreased c-di-GMP concentrations.  
 We next evaluated the role of cAMP in the regulation of gbpA in V. cholerae. We 
generated a strain with an in-frame deletion of cya, which encodes the adenylate 
cyclase that synthesizes cAMP, yielding a strain that is incapable of CRP activation [56]. 
The cya mutant, like the CRP mutant, produced less GbpA, with an 80% decrease in 
protein compared to the wild type (Figure 3.5A). A significant 80% reduction in gbpA 
transcript abundance was also observed in the cya mutant using qRT-PCR (Figure 5B). 
V. cholerae ∆cya was then transformed with pPDE or the control vector, allowing us to 
determine the interplay between cAMP and c-di-GMP in controlling gbpA expression. 
When intracellular c-di-GMP was lowered by PDE production in the ∆cya background, 
there was no change in gbpA transcript or GbpA protein levels (Figures 3.5A and 3.5B), 
mirroring the effect seen with the crp mutation.  
Additionally, we tested the effect of CRP activation on GbpA production by 
mutating cpdA, which encodes the cAMP phosphodiesterase. In this mutant, cAMP 
cannot be degraded, and cAMP-CRP complex is constitutively active [52]. In the cpdA 
mutant the levels of gbpA transcript and GbpA production were comparable to the wild 
type parent (Figures 3.5B and 3.5A). Reducing c-di-GMP (pPDE) in the cpdA mutant 
increased gbpA transcript and GbpA protein levels by 10.5-fold and 3.2-fold, 
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respectively, compared to the same strain with unmodified c-di-GMP (Figures 3.5B and 
3.5A). These data further support that cAMP-CRP activates the expression of gbpA, 
and indicate that cAMP and CRP are required for c-di-GMP inhibition of gbpA 
expression. 
 
 
CRP production and activity are not directly affected by c-di-GMP. 
We next sought to understand how c-di-GMP influences CRP-dependent 
activation of gbpA expression; c-di-GMP could regulate crp transcription, CRP protein 
levels or CRP regulatory activity. To assess the effect of c-di-GMP on crp expression, 
crp transcript levels were measured in V. cholerae with wild type (vector) or reduced c-
di-GMP levels (pPDE). Transcript levels of crp were not affected by altering c-di-GMP 
(Figure 3.6A), suggesting that c-di-GMP directly or indirectly affects CRP protein levels 
or activity. The effect of c-di-GMP on CRP protein levels was determined by western 
blot. Lysates from wild type V. cholerae with vector or pPDE, as well as a crp-null 
control strain containing vector, were probed with anti-CRP antibodies. No differences in 
CRP abundance were apparent in V. cholerae with wild type or low c-di-GMP (Figure 
3.6B).  
The identification of a consensus CRP binding site 
(GTGAGAGCTTGATTCCACATAT) upstream of gbpA (and upstream of the Vc1 
sequence) using Virtual Footprint software [57] suggests that CRP interacts directly with 
the gbpA promoter. We postulated that c-di-GMP may interfere with the DNA-binding 
activity of CRP. To test this, we used electrophoretic mobility shift assays (EMSAs) to 
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evaluate the interactions between CRP, c-di-GMP and the gbpA promoter. A 293 bp 
DNA fragment encompassing the gbpA promoter and C-terminally tagged CRP were 
used, and a non-specific 133 bp DNA fragment was included as a negative control in 
each sample. As observed previously for other promoters [58, 59], CRP alone was 
unable to bind the gbpA promoter fragment, but upon addition of the CRP ligand cAMP, 
CRP bound and shifted the gbpA promoter fragment (Figure 3.6C). In contrast, the 
presence of c-di-GMP did not promote an interaction between CRP and the promoter 
fragment. Moreover, the addition of 10-fold excess c-d-GMP did not interfere with 
cAMP-CRP binding to the gbpA promoter. Therefore, in vitro, c-di-GMP does not 
influence the binding of cAMP–CRP to the gbpA promoter. 
 
The c-di-GMP and cAMP-CRP signaling pathways act together on the gbpA 
promoter, but not other cAMP-CRP regulatory targets. 
To determine if c-di-GMP impacts the regulatory function of CRP, we assessed 
the regulation of additional CRP regulatory targets by c-di-GMP. We predicted that if c-
di-GMP was having a global effect on CRP activity, additional CRP targets would be 
regulated in a fashion similar to gbpA. We tested three metabolic genes that are 
predicted targets of cAMP-CRP, VC1046, VC2013, and VC2544. All three genes were 
identified in a transcriptome analysis identifying CRP and cAMP regulated genes [33], 
and we additionally selected them because they each have a predicted CRP binding 
site in their promoter (Virtual Footprint) [57]. Our results showed that relative to the wild 
type parent strain, transcript levels of VC1046, VC2013, and VC2544 were reduced by 
65% or more in the ∆crp background, suggesting that these genes are positively 
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regulated by CRP (Figure 3.7A). Next, we compared the abundance of these transcripts 
in wild type V. cholerae with vector or pPDE to determine whether manipulation of c-di-
GMP affected expression of these genes. Whereas c-di-GMP depletion resulted in an 
18.5-fold increase in gbpA transcript abundance, we observed no difference in the 
abundance of these transcripts in the strain with low c-di-GMP, as compared to wild 
type c-di-GMP levels (Figure 3.7B). Together, these results suggest that the effect of 
low c-di-GMP on CRP activity at the gbpA promoter is not a global regulatory effect and 
that an additional factor mediates the impact of c-di-GMP on gbpA transcription 
initiation. 
 
Discussion   
 In response to extracellular stimuli, bacteria manipulate the levels of intracellular 
second messengers to drive behavioral changes that promote survival. Herein, we 
describe the combined effects of two nucleotide second messengers, c-di-GMP and 
cAMP, on transcriptional regulation of gbpA, a gene encoding a V. cholerae colonization 
factor produced in aquatic and host environmental conditions. Whereas cAMP promotes 
gbpA transcription via CRP binding to the gbpA promoter, c-di-GMP has a negative 
effect of gbpA promoter activity, and cAMP-CRP is epistatic to c-di-GMP regulation 
(Figure 8). As distinct extracellular cues trigger the c-di-GMP and cAMP signaling 
pathways, GbpA production may be modulated in response to multiple environmental 
parameters encountered by V. cholerae.  
 Having determined that c-di-GMP negatively affects gbpA promoter activity, we 
sought to identify the c-di-GMP effector that acts on the gbpA promoter. In the process, 
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we determined that CRP activates gbpA transcription. The CRP protein binds the gbpA 
promoter in a cAMP-dependent manner in vitro, and a crp mutant has somewhat 
decreased production of GbpA. Moreover, in the crp mutant, depletion of c-di-GMP did 
not result in increased gbpA expression. The same effect was apparent in a cya mutant, 
which lacks the adenylate cyclase responsible for cAMP synthesis (eliminating the CRP 
activating signal). The observation that a cAMP phosphodiesterase (cpdA) mutant, with 
constitutively activated CRP, showed the same increase in GbpA upon c-di-GMP 
depletion as the parental strain indicates that cAMP-CRP promotes gbpA transcription, 
and only under CRP-activating conditions is the inhibitory effect of c-di-GMP on gbpA 
transcription apparent. Consistent with this, c-di-GMP inhibition of gbpA expression was 
observed during growth on carbon sources that do not rely on a PTS for uptake 
(glucose, maltose and casamino acids)—conditions in which cAMP is produced and 
CRP is active [31]. In contrast, growth in media with the PTS-dependent sugars sucrose 
and fructose, whose uptake does not stimulate cAMP production and CRP activation 
[31], did not reveal an effect of c-di-GMP. Thus, c-di-GMP inhibition of gbpA 
transcription is observable when cAMP-CRP levels are high. That gbpA transcription 
was comparable in the presence of PTS-dependent and independent nutrient sources 
was a surprising result given that we anticipated that growth with PTS carbohydrates 
and the resulting low cAMP-CRP would decrease gbpA expression. However, it is 
possible that expression is affected by growth rate, which varies between growth media.  
 Given the role of CRP in c-di-GMP regulation of gbpA expression, we explored the 
possibility that c-di-GMP influences CRP at various levels. We excluded effects of c-di-
GMP on CRP gene transcription and protein abundance. In other bacterial species, c-di-
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GMP has a direct role in controlling the activity of CRP-like proteins [60, 61]. For 
example, c-di-GMP has been shown to bind CAP (catabolite activation protein)-like 
protein CLP from Xanthomonas campestris, which inhibits its ability to bind DNA and 
thus to regulate virulence gene expression [60]. Our data indicate that, while CRP does 
bind the gbpA promoter in a cAMP-dependent manner, c-di-GMP does not affect cAMP-
CRP binding. Finally, c-di-GMP did not affect CRP regulatory function, because c-di-
GMP did not broadly affect the expression of other CRP-regulated genes. Together 
these findings indicate that c-di-GMP does not regulate CRP, but regulates another 
effector that co-regulates with gbpA expression. 
 Several other potential mediators of c-di-GMP inhibition of gbpA transcription were 
considered. First, we examined the role of NagC. Not only was NagC the only known 
regulator of gbpA expression [38], the NagC and CRP regulons were previously linked 
in E. coli, in which the NagC and CRP orthologues co-regulate the expression of genes 
in the chitobiose operon [62]. While our results support previous reports indicating that 
NagC negatively regulates gbpA, this GlcNAc-responsive regulator had no impact on c-
di-GMP regulation of gbpA expression. GlcNAc was previously suggested to be a PTS-
dependent sugar in V. cholerae, in which case growth with GlcNAc as the sole carbon 
source would not be expected to activate the cAMP-CRP pathway [31]. However, 
upregulation of gbpA was observed upon c-di-GMP depletion during growth with 
GlcNAc, mirroring the results obtained during growth with PTS-independent nutrients. 
One possible explanation for these results is that gbpA is regulated via multiple 
mechanisms during growth in GlcNAc (cAMP-CRP, NagC, c-di-GMP, possibly others), 
making the net gbpA transcription level difficult to predict. Alternatively, GlcNAc, like 
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glucose, may not strictly rely on a PTS for uptake in V. cholerae. Indeed, although 
certain PTS components are essential for GlcNAc utilization in V. cholerae, a strain 
deficient in the EIIBGlcNAc transporter (NagE) retains the ability to grow with GlcNAc as 
the sole carbon source [38], suggesting that an additional GlcNAc transporter exists in 
this bacterium. Thus, an alternative pathway for GlcNAc transport would alleviate any 
impact on the cAMP-CRP pathway. 
 We directly evaluated three previously defined transcription factors known to bind 
c-di-GMP in V. cholerae, VpsT, VpsR and FlrA, as potential mediators of gbpA inhibition 
by c-di-GMP. These regulators are compelling candidates, because gbpA (VCA0811) 
appeared in transcriptional profiling studies of the respective mutants [20, 55]. The FlrA 
protein was recently shown to directly sense c-di-GMP, and c-di-GMP binding inhibits 
the interaction of FlrA with a target flagellar gene promoter (flrBC) [24]. Similarly, VpsT, 
a well-known activator of biofilm exopolysaccharide genes in V. cholerae [28], was 
recently shown to bind c-di-GMP, resulting in enhanced binding to the EPS gene 
promoters [22]. Finally, VpsR, another positive regulator of V. cholerae 
exopolysaccharide gene expression and biofilm production [26], appears to interact 
directly with c-di-GMP; unlike VpsT and FlrA, c-di-GMP binding did not influence VpsR 
binding to target promoters (vpsT and aphA)  [23]. However, none of these regulators 
were confirmed to regulate gbpA expression or affected c-di-GMP regulation of gbpA. 
The effector that senses c-di-GMP and impinges on gbpA expression remains 
unidentified. 
 It is possible that carbon source influences c-di-GMP levels in V. cholerae. Earlier 
studies showed cross-talk between cAMP and c-di-GMP signaling pathways in V. 
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cholerae. Fong et. al have demonstrated that cAMP-CRP signaling can impact c-di-
GMP production by repressing the expression of the DGC cdgA, and accordingly, a crp 
mutant behaves like a strain with elevated c-di-GMP levels [33]. To our knowledge, our 
findings are the first to link the regulatory effects of both cAMP and c-di-GMP at a single 
promoter. Increasing cAMP levels by inactivating the phosphodiesterase CpdA did not 
alter gbpA expression, suggesting that when CRP is maximally active, c-di-GMP can 
still inhibit CRP activation of gbpA. We speculate that direct interplay between cAMP-
CRP and a c-di-GMP regulated factor may impact gbpA transcription such that maximal 
CRP-dependent activation of gbpA is apparent under conditions in which cAMP is 
abundant and c-di-GMP is low. Alternatively, the two regulatory events may be 
independent, and the effect of c-di-GMP is only observable when cAMP-CRP is present. 
Additional studies are needed to determine how nutrient availability, cAMP-CRP and c-
di-GMP interact to control gbpA expression, and perhaps expression of other genes.  
 Previous studies have demonstrated a link between the available carbon source 
and surface colonization by V. cholerae. The ability to respond to PTS carbohydrates is 
important for binding to chitin, chitin degradation, and chitin-induced competence [52, 
63]. The presence of PTS sugars, mutation of the adenylate cyclase gene cyaA, and 
mutation of crp, each of which reduce or eliminate cAMP-CRP, diminish the ability of V. 
cholerae to interact with chitin [63]. As GbpA also plays a role in colonization of chitin 
and intestinal surfaces by V. cholerae [35, 36], it is tempting to speculate that cAMP-
CRP links gbpA expression with expression of genes encoding chitin utilization and 
chitin-induced competence components. In addition, in a germ-free mouse model, V. 
cholerae requires a functional PTS system to persist in the intestine, indicating that this 
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bacterium relies on PTS carbohydrates during infection [31]. cAMP-CRP also influences 
expression of numerous other virulence factors of V. cholerae [32, 56, 64, 65]. Thus 
GbpA is part of the larger cAMP-CRP regulated program central to surface colonization 
by V. cholerae.  
 Genetic evidence suggests that V. cholerae modulates intracellular c-di-GMP 
levels during transitions between its native aquatic environment and the host intestine. 
Biofilm formation is positively regulated by c-di-GMP, which may enhance V. cholerae 
survival on chitin and other aquatic surfaces [18, 22, 48]. Indeed, c-di-GMP regulates 
the production of at least one other chitin binding protein, the hemagglutinin FrhA, and 
has been demonstrated to promote attachment of V. cholerae to chitin beads [20]. 
Reduction of c-di-GMP is required to promote bacterial motility and increase expression 
of virulence factors [21, 47, 66-68] , and there is evidence suggesting that V. cholerae 
may increase c-di-GMP at later stages of infection [69]. Dysregulation of c-di-GMP 
signaling likely affects the ability of V. cholerae to persist in and transition between 
these environments. 
 The data presented here and in previous reports point to an exceedingly complex 
regulation of GbpA. We have determined that c-di-GMP augments GbpA production via 
a cis-acting element, Vc1, which lies in the gbpA 5’ untranslated region (Chapter 2). The 
action of c-di-GMP through Vc1 appears to oppose the inhibitory effect of c-di-GMP at 
the gbpA promoter. Based on these findings, we propose a model in which low c-di-
GMP levels promote gbpA expression by allowing activation of gbpA transcription by 
cAMP-CRP, but relatively few transcripts are stabilized by c-di-GMP. Conversely, high 
c-di-GMP interferes with CRP activation of gbpA transcription, but a higher proportion of 
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those transcripts are stabilized by c-di-GMP. Thus, the net level of GbpA produced 
would depend upon the levels of cAMP and the c-di-GMP regulated factor(s) that impact 
CRP-dependent activation of gbpA, and different threshold levels of c-di-GMP may 
mediate inhibition of gbpA transcription initiation versus message stabilization. 
 Another layer of GbpA regulation occurs through post-translational hydrolysis of 
GbpA by two quorum sensing regulated proteases, HapA and PrtV [70]. Cell density-
dependent hydrolysis of GbpA may also be linked to second messenger levels. The 
quorum sensing pathway of V. cholerae influences c-di-GMP levels at least in part 
through regulation of c-di-GMP metabolism genes [71, 72]. Quorum sensing is also 
linked to the cAMP-CRP signaling pathway in V. cholerae. CRP impacts the production 
of the quorum sensing regulator HapR, as well as synthesis of cholera autoinducer 1 
[32, 59, 73]. Thus, the c-di-GMP, cAMP and quorum sensing signaling networks are 
intricately intertwined, leading to complex regulation of GbpA production. 
 
Conclusions 
 In sum, the transcriptional, post-transcriptional and post-translational regulation of 
GbpA may allow V. cholerae to fine-tune GbpA production in response to a wide range 
of intracellular c-di-GMP concentrations. Importantly, numerous extracellular signals 
that impact intracellular c-di-GMP and cAMP levels could regulate GbpA production, 
influencing the ability of V. cholerae to colonize aquatic and host surfaces.   
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Figure 3.1. c-di-GMP inhibits gbpA expression independently of the Vc1 riboswitch. (A) 
GbpA production by V. cholerae wild type and ∆Vc1 strains, each with wild type c-di-
GMP (vector) or reduced c-di-GMP (pPDE), was determined by western blot. PDE gene 
expression was induced as described in the Materials and Methods. The image shown 
is a representative of three independent experiments. Densitometry analyses were done 
by normalizing the intensities of the bands corresponding to GbpA to the intensities of a 
cross-reactive band in the same lane (indicated by an asterisk), then comparing the 
normalized value to that of wild type V. cholerae with vector only. The fold change 
relative to wild type is indicated below each lane. (B) qRT-PCR was used to measure 
gbpA transcript levels in the strains described in (A), with black bars representing wild 
type c-di-GMP levels (vector) and grey bars representing decreased c-di-GMP (pPDE). 
The data were normalized relative to the wild-type containing vector only, using rpoB as 
the reference gene. Shown are the mean values and standard deviations. (C) PgbpA-
Vc1-lacZ or PgbpA-∆Vc1-lacZ fusions were each introduced into V. cholerae with wild 
type c-di-GMP (vector, black bars) or reduced c-di-GMP (pPDE, gray bars), and the β-
galactosidase activity in culture lysates of these strains was measured. Shown are the 
means and standard deviations of three independent experiments. (B and C) *** P < 
0.001 by unpaired t-test comparing the indicated sets of data. 
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Figure 3.2. Known c-di-GMP effectors FlrA, VpsT and VpsR do not regulate gbpA in 
response to c-di-GMP. (A) GbpA levels in the supernatants of wild type V. cholerae, 
∆flrA, ∆vpsT and ∆vpsR strains, each with wild type (vector) and reduced levels of c-di-
GMP (pPDE), were measured by western blot. PDE gene expression was induced as 
described in the Materials and Methods. The image shown is a representative of three 
separate experiments. Densitometry analyses were done by comparing the intensities 
of the GbpA bands to the intensities of a cross-reactive band in the same lane 
(indicated by an asterisk), then normalizing the value to that of wild type V. cholerae 
with vector. The fold change relative to the wild type is indicated below each lane. (B) 
qRT-PCR was used to measure the gbpA transcript abundance in wild type, ∆flrA, 
∆vpsT and ∆vpsR strains of V. cholerae, each with wild type (vector, black bars) and 
reduced levels of c-di-GMP (pPDE, grey bars). The data were normalized relative to the 
wild-type containing vector only, using rpoB as the reference gene. Shown are the 
means and standard deviations from at least three independent samples. For the 
indicated comparisons, *** P < 0.001 by unpaired t-test. 
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Figure 3.3. c-di-GMP inhibition of gbpA expression is influenced by carbon source 
availability. V. cholerae strains containing the PgbpA-Vc1-lacZ reporter fusion, with wild 
type c-di-GMP (vector, black bars) or reduced c-di-GMP (pPDE, grey bars), were grown 
in M9 minimal medium with 0.5% (w/v) N-acetylglucosamine (GlcNAc), glucose, 
maltose, sucrose, fructose or casamino acids to mid-logarithmic phase. PDE gene 
expression was induced as described in the Materials and Methods. Transcription was 
measured using β-galactosidase assays. Shown are the means and standard deviations 
from at least three independent experiments. For the indicated comparisons, *** P < 
0.001 by unpaired t-test. 
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Figure 3.4. Reduction of c-di-GMP induces gbpA expression in a CRP dependent 
manner. (A) GbpA levels in the supernatants of wild type V. cholerae, ∆nagC and ∆crp 
strains, each with wild type (vector) and reduced levels of c-di-GMP (pPDE), were 
measured by western blot. PDE gene expression was induced as described in the 
Materials and Methods. The image shown is a representative of three separate 
experiments. Densitometry analyses were done by comparing the intensities of the 
GbpA bands to the intensities of a cross-reactive band in the same lane (indicated by an 
asterisk), then normalizing the value to that of wild type V. cholerae with vector. The fold 
change relative to the wild type is indicated below each lane. (B) qRT-PCR was used to 
measure the gbpA transcript abundance in wild type, ∆nagC and ∆crp strains of V. 
cholerae, each with wild type (vector, black bars) and reduced levels of c-di-GMP 
(pPDE, grey bars). The data were normalized relative to the wild-type containing vector 
only, using rpoB as the reference gene. Shown are the means and standard deviations 
from at least three independent samples. For the indicated comparisons, * P < 0.05, *** 
P < 0.001 by unpaired t-test.  
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Figure 3.5. Inactivation of the cAMP-CRP signaling pathway prevents c-di-GMP 
inhibition of gbpA expression. (A) GbpA levels in the supernatants of wild type V. 
cholerae, ∆cpdA (constitutively active CRP) and ∆cya (constitutively inactive CRP) 
strains, each with wild type (vector) and reduced levels of c-di-GMP (pPDE), were 
measured by western blot. PDE gene expression was induced as described in the 
Materials and Methods. The image shown is a representative of three separate 
experiments. Densitometry analyses were done by comparing the intensities of the 
GbpA bands to the intensities of a cross-reactive band in the same lane (indicated by an 
asterisk), then normalizing the value to that of wild type V. cholerae with vector. The fold 
change relative to the wild type is indicated below each lane. (B) qRT-PCR was used to 
measure the gbpA transcript abundance in wild type, ∆cpdA and ∆cya strains of V. 
cholerae, each with wild type (vector, black bars) and reduced levels of c-di-GMP 
(pPDE, grey bars). The data were normalized relative to the wild-type containing vector 
only, using rpoB as the reference gene. Shown are the means and standard deviations 
from at least three independent samples. For the indicated comparisons, * P < 0.05, *** 
P < 0.001 by unpaired t-test.  
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Figure 3.6. c-di-GMP does not regulate CRP gene transcription, protein stability or DNA 
binding. (A) Transcript levels for crp in V. cholerae with wild type (vector) or reduced c-
di-GMP (pPDE) were measured by qRT-PCR. PDE gene expression was induced as 
described in the Materials and Methods. The data were normalized relative to the wild-
type containing vector only, using rpoB as the reference gene. Shown are the means 
and standard deviations from at three independent samples. (B) CRP protein (23.6 kDa) 
levels in lysates of V. cholerae with wild type (vector) or reduced c-di-GMP (pPDE) were 
measured by western blot. V. cholerae ∆crp containing vector was included as a 
negative control. RNA Polymerase was detected on the same blot as a loading control. 
The images shown are from a representative of three independent experiments. 
Densitometry analyses were done by comparing the intensities of the GbpA bands to 
the intensities of the RNAP band in the same lane, then normalizing the value to that of 
wild type V. cholerae with vector. The fold change relative to the wild type is shown 
below each lane. (C) Using electrophoretic mobility shift assays, purified recombinant 
CRP was tested for the ability to bind and shift a DNA fragment encompassing the gbpA 
promoter in the presence or absence of cAMP and/or c-di-GMP. As a control, a non-
specific DNA (indicated by “NS”) fragment was added to all binding reactions and was 
confirmed not to be shifted by CRP. *In the final lane, c-di-GMP was added in 10-fold 
excess of cAMP.
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Figure 3.7. cAMP-CRP specifically impacts gbpA expression in response to c-di-GMP. 
(A) Putative CRP-regulated genes were selected for analysis by qRT-PCR to assess 
transcript abundance in wild type (grey bars) and ∆crp (black bars) strains. The data 
were normalized relative to the wild-type, using rpoB and gyrA as the reference genes. 
(B) The transcript abundance for the genes analyzed in (A) was determined for V. 
cholerae with wild type (vector, grey bars) and reduced levels of c-di-GMP (pPDE, white 
bars). The data were normalized relative to the wild-type containing vector only, using 
rpoB and gyrA as the reference genes. (A and B) Shown are the means and standard 
deviations from at least three independent samples. For the indicated comparisons, *** 
P < 0.001 by unpaired t-test. 
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Figure 3.8. Model of c-di-GMP and cAMP regulation of GbpA production. During growth 
in conditions in which PTS carbohydrates are limiting, cAMP stimulates CRP to activate 
gbpA transcription. In response to an unknown stimulus (or stimuli), c-di-GMP inhibits 
gbpA transcription initiation via an unknown effector (factor “X”). c-di-GMP does not 
broadly impact the cAMP-CRP regulon, suggesting that the two signaling pathways 
converge on the gbpA promoter rather than act via cross-talk between the pathways. 
Because the effect of c-di-GMP depletion occurs only when CRP is present, cAMP-CRP 
is epistatic to c-di-GMP regulation. 
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Table 3.1. Strains used in this study. 
Strain Strain Description Reference 
Escherichia coli   
DH5α F– φ80lacZ ΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17 (rK-, mK+) phoA supE44 thi-1 gvrA96 relA1 λ- 
tonA 
Invitrogen; 
(77) 
DH5αλpir F– Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 supE44 thi-
1 gvrA96 relA1 λpir 
(77) 
SM10λpir thi thr leu tonA lacY supE recA::RPA-2-Te::Mu λpirR6K, 
Kmr 
(78) 
Vibrio cholerae   
 C6706 (O1 El Tor) (79) 
 C6706 ∆gbpA (VCA0811) This study 
 C6706 ∆lacZ (46) 
 C6706 ∆lacZ pPgbpA-Vc1-lacZ This study 
 C6706 ∆lacZ pPgbpA-DVc1-lacZ This study 
 C6706 pBAD33 This study 
 C6706 pBAD33::vieA (pPDE) This study 
 C6706 ∆Vc1 This study 
 C6706 ∆Vc1 pBAD33 This study 
 C6706 ∆Vc1 pBAD33::vieA (pPDE) This study 
 C6706 ∆nagC This study 
 C6706 ∆nagC pBAD33 This study 
 C6706 ∆nagC pBAD33::vieA (pPDE) This study 
 C6706 ∆crp   This study 
 C6706 ∆crp pBAD33 This study 
 C6706 ∆crp pBAD33::vieA (pPDE)  This study 
 C6706 ∆cpdA   This study 
 C6706 ∆cpdA pBAD33 This study 
 C6706 ∆cpdA pBAD33::vieA (pPDE)  This study 
 C6706 ∆cya   This study 
 C6706 ∆cya pBAD33 This study 
 C6706 ∆cya pBAD33::vieA (pPDE)  This study 
 C6706 ∆vpsT   This study 
 C6706 ∆vpsT pBAD33 This study 
 C6706 ∆vpsT pBAD33::vieA (pPDE)  This study 
 C6706 ∆vpsR   (47) 
 C6706 ∆vpsR pBAD33 This study 
 C6706 ∆vpsR pBAD33::vieA (pPDE)  This study 
 C6706 ∆flrA  This study 
 C6706 ∆flrA pBAD33 This study 
 C6706 ∆flrA pBAD33::vieA (pPDE)  This study 
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Table 3.2. Plasmids used in this study. 
Plasmid Name Plasmid Description Reference 
pPlacthiM#2-lacZ 
The TPP riboswitch encoded in the 5‘ UTR of E. coli 
thiM was mutated to function as an ON switch and 
cloned into pPlac-lacZ. Origin of replication colEI.  AmpR 
 (74) 
pPgbpA-Vc1-lacZ 
gbpA promoter and 5’UTR cloned into plasmid 
pPlacthiM#2-lacZ; translational fusion 
This study 
pPgbpA-∆Vc1-lacZ 
gbpA promoter and 5’UTR, minus the Vc1 sequence (∆ 
17-202 bp) cloned into plasmid pPlacthiM#2-lacZ; 
translational fusion 
This study 
pBAD33 Expression vector, Para promoter, CmR 
(75) 
pBAD33::vieA vieA in pBAD33 (“pPDE”) (48) 
pBAD33::crp-his6 Expression vector for purification of CRP  This study 
pCVD442 
oriR6K plasmid with a polylinker, mobRP4, bla, and 
sacB (76) 
pCVD442::∆gbpA Allelic exchange vector for in-frame deletion of gbpA This study 
pCVD442::∆Vc1 Allelic exchange vector for in-frame deletion of Vc1 This study 
pCVD442::∆nagC Allelic exchange vector for in-frame deletion of nagC This study 
pCVD442::∆crp 
Allelic exchange vector for in-frame deletion of crp 
(VC2614) 
This study 
pCVD442::∆cya 
Allelic exchange vector for in-frame deletion of cya 
(VC0122) 
This study 
pCVD442::∆cpdA Allelic exchange vector for in-frame deletion of cpdA This study 
pCVD442::∆vpsT Allelic exchange vector for in-frame deletion of vpsT This study 
pCVD442::∆vpsR Allelic exchange vector for in-frame deletion of vpsR (47) 
pCVD442::∆flrA Allelic exchange vector for in-frame deletion of flrA This study 
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Table 3.3. Primers used in this study. 
Primer 
Name Oligonucleotide sequence (5’ to 3’) * Reference 
pCVDseqF CTGTTGCATGGGCATAAAGTTGCC This study 
pCVDseqR ACACAGGAACACTTAACGGCTGAC This study 
Vc1F1 CCTCTAGATACTCGTCAGGTCTTTGG This study 
Vc1R1 TTGCATGCTTGCCAAAGTGTGACCGAGAG This study 
Vc1F2 TTGCATGCCAGCTAACAAAGAAGAGTCTGTG This study 
Vc1R2 AAGAGCTCCGAGTGTACACGGTATCG This study 
gbpAF1 TTGCATGCTACTCGTCAGGTCTTTGG This study 
gbpAR1 TTGGTACCCATCACAGACTCTTCTTTG This study 
gbpAF2 TTGGTACCTAAGTTATCCTCCCTCTTAC This study 
gbpAR2 TTGAGCTCTTTCTCTGGATGGGAGTC This study 
gbpAF0 GCAAACGGTAGCAAGAAG This study 
nagCF1 GAGCATGCCTGACGATACGATGATTGATAC This study 
nagCR1 GACCATGGCATTATCAATTCTGCTCGTATTGTC This study 
nagCF2 GACCATGGGAAGACTGAGCTTTTTAGTTAAGC This study 
nagCR2 GAGAGCTCGAGCATCATCCCTAAGATCAG This study 
nagCF0 CGATACCATGCACAAAGC This study 
crpF1 CCTCTAGATTTATGAAGGCTTACACGGC This study 
crpR1 CCGCATGCCATAATAATCTCACTTCCTCTGCAG This study 
crpF2 CCGCATGCTAAGTGCCCCGATAACCC This study 
crpR2 CCGAGCTCTTGAACATCCCGATCCTTTG This study 
crpF0 CCCTACTTACTGGCGATGAT This study 
cyaF1 CCGAGCTCCATTGACGGCGTAAACTG This study 
cyaR1 CCGAATTCCAAGTTTGCTTCCCTGATATG This study 
cyaF2 CCGAATTCTAACTCGTTGACGTCTCAG This study 
cyaR2 CCTCTAGACATAAAGCGGTGTACCGTAC This study 
cyaF0 CAAGCTTACTTAGGCGAGTC This study 
cpdAF1 CCTCTAGAGCTGACTGTAGGCAGAATTG This study 
cpdAR1 GGGCATGCCAAAATCGGTAAACCTAACTCTG This study 
cpdAF2 GGGCATGCTGATATGACTGCTCGTCCTG This study 
cpdAR2 AAGAGCTCGTCTAAGGGCAACATAGTCTG This study 
cpdAF0 GTCGAGCGGGAAATGTTTG This study 
vpsTF1 CCGCATGCGCGAAGTTTCACGTACTCG This study 
vpsTR1 CCGGTACCCATTTCACCCCTCCTAACAC This study 
vpsTF2 CCGGTACCTAATTCGTTGTGTAATGTCTCTTCG This study 
vpsTR2 CCGAGCTCCATCCCACACATACCAACC This study 
vpsTF0 CGATGATATCTTGGCTCAACTC This study 
vpsTF1 TGCATGCCTACAACCCAAATCACGC This study 
vpsTR1 AATCAGCAAAACTTACATGAACCTATATTCCTT This study 
vpsTF2 GAATATAGGTTCATGTAAGTTTTGCTGATTTAC This study 
vpsTR2 TTTCTAGAGGTAAACTCAAGCCGATT This study 
vpsTF0 CTCTGTGGCGTTAGAAG This study 
FLRAF1 CCGCATGCCAACTTGTGGAACAGATGCAG This study 
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FLRAR1 CCGGTACCCTGCATAGGTGAGATTATTTGCC This study 
FLRAF2 CCGGTACCAACATGCAACGCTAGGG This study 
FLRAR2 CCGAGCTCTCGACCATAGGCATAAATTCG This study 
flrAF0 GTTAGGCTATTTGGCCGAG This study 
RPB2F CTGTCTCAAGCCGGTTACAA (51) 
RPB2R TTTCTACCAGTGCAGAGATGC (51) 
gyrAqF AATGTGCTGGGCAACGACTG This study 
gyrAqR GAGCCAAAGTTACCTTGGCC This study 
gbpAqF CAGTGGATTAGCGTATGGACAC This study 
gbpAqR GTATTGAATCGCGCCACAGT This study 
crpqF GGTGAGAAAGCGGAAACGCTGTACTA This study 
crpqR CTTCAAACAAGCCAAGCTCACCGA This study 
VC1046qF GCCTTGATCGAGCGGATTAT This study 
VC1046qR TCACAGGCGATGATGTTGAG This study 
VC2013qF CTATCGTCGGTTACGGCATTAT This study 
VC2013qR ACCCAGATATTCAGGCAGTTG This study 
VC2544qF TTCGCTTGGCACCTTCTATC This study 
VC2544qR GTCCCTCTTCTGGCACATTT This study 
CRPeF ccGAATTCGCAGAGGAAGTGAGATTATTATGG This study 
CRPeH6R ccGTCGACTTAATGGTGATGGTGATGGTGGCGAGTGCCGTAAACCA This study 
 
* The underlined sequences represent restriction enzyme recognition sites. Italicized sequences 
encode a 6-histidine tag.  
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CHAPTER 4: DISCUSSION 
SUMMARY OF RESULTS 
Each year, the facultative human pathogen V. cholerae causes millions of cases 
of severe cholera diarrheal disease, resulting in substantial morbidity and mortality. 
During outbreaks, in the absence of treatment, mortality rates can exceed 20% (1-3). 
Despite being primarily an aquatic organism, V. cholerae is adept at colonizing and 
flourishing in the human small intestine. V. cholerae has acquired the distinct ability to 
persist and transition between disparate environments by controlling the production of 
colonization, metabolic and virulence factors (3). Therefore, V. cholerae naturally 
inhabiting aquatic environments can serve as a continuous source of V. cholerae for 
ingestion and subsequent contamination of humans. In this thesis, we describe the 
regulation of gbpA by the combined contribution of two nucleotide second messengers, 
c-di-GMP and cAMP. GbpA is a colonization factor that is important for both persistence 
of V. cholerae in the aquatic environment and for colonizing the host intestinal 
epithelium (4). We first examine posttranscriptional regulation of gbpA by c-di-GMP 
through Vc1, a putative c- di-GMP riboswitch in V. cholerae (5). Vc1 is located in the 5’ 
untranslated region of gbpA, and we provide evidence that in response c-di-GMP 
sensing, it positively regulates GbpA production. Furthermore, we provide evidence that 
cAMP promotes gbpA transcription via cAMP-CRP binding to the gbpA promoter, 
however c-di-GMP has a negative effect on cAMP-CRP activation of gbpA (Figure 4.1). 
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Collectively, these data suggest that distinct extracellular cues that signal to intracellular 
c-di-GMP and cAMP-CRP pathways, help modulate GbpA production in multiple 
environments encountered by V. cholerae.   
The bacterial second messenger c-di-GMP relays iinformation about the 
extracellular environment to intracellular effectors. Although various types of c-di-GMP 
effectors have been indentified, many remain poorly defined, particularly the c-di-GMP 
riboswitch.  We examine the function of the putative c-di-GMP riboswtich Vc1, and 
provide strong evidence that Vc1 responds to c-di-GMP in vivo. Specifically, we find that 
introducing the Vc1 sequence into a translational reporter construct (PlacUV5-Vc1UTR-
lacZ), by fusing it to a reporter gene (lacZ) and placing the fusion under the 
transcriptional control of a heterologous, constitutive promoter, renders reporter activity 
regulatable by c-di-GMP. Whereas depletion of c-di-GMP through the ectopic 
expression of a c-di-GMP PDE gene reduces reporter activity, expression of a DGC 
gene augments reporter activity. These regulatory effects are attributable specifically to 
altered c-di-GMP, as expression of a mutant PDE gene incapable of c-di-GMP 
hydrolysis does not affect expression. Moreover, mutating a single residue in the Vc1 
sequence, the G12 nucleotide predicted to be involved in c-di-GMP binding, eliminates 
regulation of downstream expression by c-di-GMP. These findings support our results 
showing that the same mutation at the native gbpA locus similarly inhibits downstream 
gene expression. SHAPE and equilibrium dialysis studies using Vc1 RNA corroborate a 
direct interaction between Vc1 and c-di-GMP. SHAPE analysis indicates that the 
reactivity of Vc1 changes in the presence of c-di-GMP, specifically in regions predicted 
to be contact points between c-di-GMP and Vc1. Moreover, the G12 mutation that 
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reduces downstream gene expression similarly diminishes the Vc1-c-di-GMP interaction 
observed through SHAPE analysis. Furthermore, in vivo experiments using the 
PlacUV5-Vc1UTR-lacZ reporter reveal that induction of a c-di-GMP PDE using a broad 
range of inducer concentrations, that reflect a range of intracellular c-di-GMP levels, 
promotes downstream gene expression in a dose-dependent manner. The ability of Vc1 
to respond to a range of c-di-GMP levels is consistent with the predicted functions of a 
riboswitch. Together these results support a role for the Vc1 element in regulation of 
gbpA expression in response to c-di-GMP, and point to Vc1 functioning as an “on” 
switch in response to c-di-GMP. 
Despite strong evidence that Vc1 functions as a c-di-GMP responsive element, 
some of our results suggest that Vc1 differs from Vc2, the canonical c-di-GMP 
riboswitch. For example, despite conservation of key residues in Vc1, we suspect the 
interaction of c-di-GMP with Vc1 RNA is much weaker than that with Vc2 RNA. We 
attempted to use equilibrium dialysis to determine the affinity of c-di-GMP for Vc1, but 
found that the maximum amount of binding observed, even with high concentrations of 
RNA, is ~70%. This severely limits the range of c-di-GMP concentrations we can work 
with, making it impossible to determine an accurate affinity measurement. Another 
reason for apparent weak binding may be the improper folding of Vc1. Indeed, when 
folded Vc1 RNA is run on a native gel, we observe several bands indicating multiple 
species of folded Vc1 RNA. In addition, the equilibrium dialysis data suggest that the 
rate of dissociation of c-di-GMP from Vc1 and Vc2 differs. The addition of excess, non-
radiolabelled competitor c-di-GMP to the equilibrium chambers leads to displacement of 
labeled c-di-GMP from Vc1, but not from Vc2. These results suggest that binding of c-
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di-GMP by Vc1 is reversible, which may allow for more rapid adaptation and modulation 
of GbpA production. Furthermore, previous analyses of Vc2 show that mutating G20 
(equivalent to G12 in Vc1) reduces binding of c-di-GMP by 30,000-fold, essentially 
abolishing the interaction of Vc2 with c-di-GMP (23). However, using equilibrium 
dialysis, we show that the Vc1 G12 mutation reduces, but does not eliminate, the 
interaction with c-di-GMP in vitro. We confirm the interaction of Vc1 with c-di-GMP using 
SHAPE analysis, and find that regions in Vc1 adjacent to G12 and A39 have 
significantly altered reactivity in the presence of c-di-GMP, suggesting that those 
residues participate in c-di-GMP sensing. However, C104, which is equivalent to C92 in 
Vc2 and an essential residue for binding c-di-GMP, does not show a change in SHAPE 
reactivity, suggesting it is not essential for c-di-GMP binding to Vc1.  
In addition to positive regulation of GbpA production by c-di-GMP through the 
Vc1 riboswitch, we also find that gbpA transcription is repressed by c-di-GMP. 
Specifically, we find that lowering intracellular c-di-GMP significantly increases gbpA 
transcription and GbpA production. We sought to determine the c-di-GMP responsive 
regulator that acts on the gbpA promoter, and in the process, identified CRP as a 
positive regulator gbpA transcription. The CRP protein binds the gbpA promoter in a 
cAMP-dependent manner in vitro, and a crp mutant has somewhat decreased 
production of GbpA. Moreover, in the crp mutant, depletion of c-di-GMP does not result 
in increased gbpA expression. The same effect is apparent in a cya mutant, which lacks 
the adenylate cyclase responsible for cAMP synthesis (eliminating the CRP activating 
signal). Interestingly, a cAMP phosphodiesterase (cpdA) mutant, with constitutively 
activated CRP, does not show elevated GbpA production and has the same increase in 
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GbpA upon c-di-GMP depletion as the parental strain. This observation indicates that 
when active, cAMP-CRP is poised to promote gbpA transcription, but it is only 
maximally active on the gbpA promoter when c-di-GMP levels are low. Consistent with 
the contribution of cAMP-CRP, c-di-GMP inhibition of gbpA expression is observed 
during growth on carbon sources that do not rely on PTS for uptake (glucose, maltose 
and casamino acids)- conditions in which cAMP is produced and CRP is active (6). In 
contrast, growth in media with the PTS-dependent sugars sucrose and fructose, whose 
uptake does not stimulate cAMP production and CRP activation, does not reveal an 
effect of c-di-GMP (6). Thus, c-di-GMP inhibition of gbpA transcription is observable 
when cAMP-CRP levels are high.  
In order to determine effect of c-di-GMP on CRP activation of gbpA expression, 
we tested the possibility that c-di-GMP influences CRP levels or CRP activity in vivo. 
We find that c-di-GMP does not impact CRP gene transcription and protein abundance. 
Furthermore, c-di-GMP does not affect CRP regulatory activity in vivo, since 
manipulating intracellular c-di-GMP does not impact the expression of other CRP-
regulated genes. Lastly, we show that CRP does bind the gbpA promoter in a cAMP-
dependent manner, and c-di-GMP does not affect cAMP-CRP binding in vivo. Together 
these findings indicate that c-di-GMP does not directly regulate CRP. We hypothesize 
that c-di-GMP controls the levels or activity of another effector, which along with cAMP-
CRP co-regulates gbpA expression. We directly evaluated three previously defined 
transcription factors known to bind c-di-GMP in V. cholerae, VpsT, VpsR and FlrA, as 
potential mediators of gbpA inhibition by c-di-GMP (7-9). However, none of these 
factors regulate gbpA expression in c-di-GMP dependent manner. To our knowledge, 
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our findings provide the first link of the regulatory effects of both cAMP and c-di-GMP at 
a single promoter. We speculate that direct interplay between cAMP-CRP and a c-di-
GMP regulated factor may impact gbpA transcription such that maximal CRP-
dependent activation of gbpA is apparent under conditions in which cAMP is abundant 
and c-di-GMP is low. The effector that senses c-di-GMP and impinges on gbpA 
activation remains unidentified, but may reveal a larger regulon shared by c-di-GMP and 
cAMP pathways. Alternatively, the two regulatory events may be independent, and the 
effect of c-di-GMP is only observable when cAMP-CRP is present. Additional studies 
are needed to determine how nutrient availability, cAMP-CRP and c-di-GMP interact to 
control gbpA expression, and perhaps expression of other genes. 
 
BIOLOGICAL IMPACT OF gbpA REGULATION 
 In this thesis, we propose a complex model of gbpA regulation by c-di-GMP. We 
determine that c-di-GMP augments GbpA production via Vc1, a putative c-di-GMP 
riboswitch, which lies in the gbpA 5’ untranslated region. Positive regulation of c-di-GMP 
through Vc1 appears to oppose the inhibitory effect of c-di-GMP at the gbpA promoter. 
Based on these findings, we expect that in environmental conditions when c-di-GMP 
levels are low, gbpA expression is maximally activated by cAMP-CRP, however the 
proportion of gbpA transcripts bound to c-di-GMP via Vc1 are relatively few. Conversely, 
conditions where c-di-GMP levels are high prevents maximal activation of gbpA 
transcription by cAMP-CRP, but a higher proportion of gbpA transcripts are bound by c-
di-GMP. Thus, under high and low c-di-GMP, GbpA production is promoted via 
posttranscriptional and transcriptional mechanisms, respectively. As such, the net 
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accumulation of GbpA relies heavily the levels of intracellular c-di-GMP, and the 
threshold amount that mediates inhibition of gbpA transcription initiation and promotes 
GbpA production through interactions with Vc1. 
 Several lines of evidence suggest that c-di-GMP levels change in V. cholerae 
during transitions between its native aquatic environment and the host intestine. For 
example, V. cholerae forms biofilms on surfaces in the environment, such as chitin, and 
numerous studies have shown that biofilm formation is positively regulated by c-di-GMP 
(7, 10, 11). Furthermore, increased intracellular c-di-GMP enhances the binding of V. 
cholerae to chitin in vitro in a process dependent on the hemagglutinin FrhA (12). 
Conversely, reduction of c-di-GMP is required to promote bacterial motility and increase 
expression of virulence factors in the intestinal tract (7, 10, 11). Genetic evidence 
suggests that c-di-GMP levels again increase during later stages of infection (13). In the 
context of V. cholerae biology, the effect of Vc1 sensing of c-di-GMP to augment GbpA 
production may contribute to colonization of environmental (chitin) surfaces, when c-di-
GMP levels may be elevated. Conversely, the effect of low c-di-GMP on increasing 
gbpA transcription may contribute to attachment of host (small intestine) surfaces when 
c-di-GMP levels may be low. 
Defining the role of c-di-GMP in controlling GbpA production was further 
complicated by the finding that gbpA transcription is positively regulated by cAMP-CRP. 
Previous studies have suggested a link between the cAMP-CRP pathway and GbpA in 
V. cholerae. Specifically, it was observed that reducing or eliminating cAMP-CRP 
activity, diminished the ability of V. cholerae to interact with chitin, degrade chitin and 
participate in chitin-induced competence (14). As GbpA also plays a role in colonization 
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of chitin, it is tempting to speculate that cAMP-CRP links gbpA expression with 
expression of genes encoding chitin utilization and chitin-induced competence 
components (4, 15). In addition, in a germ-free mouse model, V. cholerae requires 
functional cAMP-CRP to persist in the intestine, presumably by influencing expression 
of virulence factors important for nutrient utilization and colonization (16-19). Therefore, 
positive regulation of gbpA by cAMP-CRP may also contribute to intestinal colonization 
during infection. Interestingly, cAMP-CRP also controls the expression of ten genes 
predicted to encoded enzymes with DGC and PDE activity, suggesting that cAMP-CRP 
signaling can influence intracellular c-di-GMP turnover (20). Deletion of one of the 
predicted DGCs, cdgA, eliminated the elevated biofilm production observed in a crp 
mutant (20). Furthermore, cholera toxin and flagella, which are negatively regulated by 
c-di-GMP, are positively regulated by cAMP-CRP in V. cholerae (16, 17, 21, 22). 
Therefore, it appears that in V. cholerae, some pathways normally repressed by c-di-
GMP signaling, are positively regulated by cAMP-CRP. These opposing modes of 
regulation employed by cAMP-CRP and c-di-GMP are reflected in our findings 
presented in this thesis.  
 
CAVEATS AND FUTURE DIRECTIONS 
 We came across several caveats when characterizing the function of Vc1 in V. 
cholerae. First, analysis of the interaction between Vc1 and c-di-GMP using equilibrium 
dialysis showed that Vc1 RNA binds c-di-GMP to a lesser degree than Vc2 RNA. These 
results may reflect a lower binding affinity of Vc1 for c-di-GMP compared to the affinity 
of Vc2, which is extremely high (10 pM) (23). The equilibrium dialysis assay lacks the 
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sensitivity necessary to determine the KD of Vc1 and c-di-GMP. However, unlike Vc2, 
the affinity of Vc1 for c-di-GMP may fall closer within the biological range of intracellular 
c-di-GMP concentrations, or Vc1 may not directly sense c-di-GMP. Using a more 
sensitive binding assay would better allow us to assess the affinity of c-di-GMP for Vc1. 
 Another caveat to consider with the Vc1 studies is that we were unable to 
determine the mode of regulation by c-di-GMP. We hypothesize that Vc1 binding 
stabilizes gbpA transcript, thus promoting gene expression. Unlike the c-di-GMP 
riboswitches described to date, the sequence immediately 3’ of the predicted Vc1 
aptamer does not indicate a likely mechanism of gene regulation. There are no obvious 
Rho-independent transcription terminator or anti-Shine Delgarno sequences. The same 
is true for the region 3’ of the Vc1 aptamer. Quantitative reverse transcriptase PCR 
analysis of the entire gbpA transcript, which involved probing for the aptamer as well as 
four additional regions along the length of the mRNA, showed that the G12 mutation in 
Vc1 results in significantly reduced transcript abundance uniformly across the gbpA 
mRNA (data not shown). Additional work is needed to determine whether this occurs as 
a result of Vc1 controlling transcriptional read-through or transcript stability, or as an 
indirect effect on transcript stability in the absence of translation elongation. The 
mechanism by which the canonical GEMM riboswitch Vc2 regulates VC1722 expression 
also remains unknown. 
 Lastly, determining the role of Vc1 in controlling chitin binding or host colonization 
would thus require testing Vc1 mutants for altered phenotypes. Unfortunately, despite 
using the same V. cholerae strain and numerous approaches, we were unable to 
reproduce the effects of an in-frame deletion of gbpA on V. cholerae binding to chitin or 
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host colonization, so we could not assess the role of Vc1 specifically in these 
processes. Future work will define the roles of Vc1 and Vc2 in modulating c-di-GMP-
regulated processes in response to extracellular cues in V. cholerae. 
Our findings looking at the regulation of gbpA transcription initiation cAMP-CRP 
also presented with some caveats. Specifically, we could not unequivocally rule out the 
possibility that c-di-GMP impacts gbpA regulation by affecting cAMP-CRP activity. The 
effect of c-di-GMP on cAMP levels were not directly tested, therefore a negative impact 
of c-di-GMP on cAMP production could serve as an explanation of our findings. 
However, we considered this to be unlikely given the data we obtained in the cpdA 
background, which has elevated cAMP, but shows similar regulation of gbpA by c-di-
GMP as the parent strain. 
In the future, we plan to determine the role of non-conserved residues in Vc1 in c-
di-GMP binding, and what role alternate contacts play in downstream gene expression. 
Furthermore, we plan to compare in vivo kinetics of Vc1 and Vc2 by comparing 
PlacUV5-Vc1UTR-lacZ reporter to the PlacUV5-Vc2UTR-lacZ reporter. Relating to the 
cAMP-CRP studies, it is possible that growth on different carbon source influences c-di-
GMP levels in V. cholerae. Earlier findings showed cross-talk between cAMP and c-di-
GMP signaling pathways in V. cholerae (20). Therefore, we plan to measure 
intracellular c-di-GMP concentrations in V. cholerae strains grown in PTS and non-PTS 
nutrient sources. We also hope to indentify the c-di-GMP responsive regulator important 
for cAMP-CRP activation of gbpA. 
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Figure 4.1. GbpA regulation by c-di-GMP and cAMP. Extracellular cues and nutrient 
availability can regulation intracellular levels of c-di-GMP (red circle) and cAMP (green 
diamond), respectively. Under low intracellular c-di-GMP conditions, cAMP-CRP 
promotes gbpA transcription, resulting in increased levels of GbpA at the cell surface. In 
contrast, under conditions of high intracellular c-di-GMP, gbpA levels are 
posttranscriptionally regulated through binding of c-di-GMP to the Vc1 riboswitch. 
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1APPENDIX: A SYSTEMATIC ANALYSIS OF THE IN VITRO AND IN VIVO 
FUNCTIONS OF THE HD-GYP DOMAIN PROTEINS OF VIBRIO CHOLERAE 
 
Summary 
Background: The second messenger cyclic diguanylate (c-di-GMP) plays a 
central role in bacterial adaptation to extracellular stimuli, controlling processes such as 
motility, biofilm development, cell development and, in some pathogens, virulence. The 
intracellular level of c-di-GMP is controlled by the complementary activities of 
diguanylate cyclases containing a GGDEF domain and two classes of c-di-GMP 
phosphodiesterases containing an EAL or HD-GYP hydrolytic domain. Compared to the 
GGDEF and EAL domains, the functions of HD-GYP domain family proteins are poorly 
characterized. The human diarrheal pathogen Vibrio cholerae encodes nine putative 
HD-GYP domain proteins. To determine the contributions of HD-GYP domain proteins 
to c-di-GMP signaling in V. cholerae, we systematically analyzed the enzymatic 
functionality of each protein and their involvement in processes known to be regulated 
by c-di-GMP: motility, biofilm development and virulence.  
Results: Complementary in vitro and in vivo experiments showed that four HD-
GYP domain proteins are active c-di-GMP phosphodiesterases: VC1295, VC1348, 
VCA0210 and VCA0681. Mutation of individual HD-GYP domain genes, as well as 
combinatorial mutations of multiple HD-GYP domain genes, had no effect on motility or 
                                            
1 Contributing authors: Robert W. McKee, Benjamin Mudrak and Courtney Whitaker 
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biofilm formation of V. cholerae under the conditions tested. Furthermore, no single HD-
GYP domain gene affected intestinal colonization by V. cholerae in an infant mouse 
model. However, inactivation of multiple HD-GYP domain genes, including the four 
encoding functional phosphodiesterases, significantly attenuated colonization.  
Conclusions: These results indicate that the HD-GYP family of c-di-GMP 
phosphodiesterases impacts signaling by this second messenger during infection. 
Altogether, this work greatly furthers the understanding of this important family of c-di-
GMP metabolic enzymes and demonstrates a role for HD-GYP domain proteins in the 
virulence of V. cholerae. 
 
Introduction 
Cyclic diguanylate (c-di-GMP) is a bacterial second messenger first identified as 
an activator of cellulose synthesis in Gluconacetobacter xylinus [1]. Since its discovery, 
the number of processes known to be regulated by c-di-GMP in bacteria has expanded. 
c-di-GMP signaling has been shown to regulate numerous processes including, but not 
limited to, motility and biofilm production in numerous bacterial species (reviewed in [2-
4]). In certain pathogens, c-di-GMP also influences virulence properties [5-17].   
 The concentration of c-di-GMP is controlled by the competing actions of two 
classes of enzymes: diguanylate cyclases, which are responsible for the synthesis of c-
di-GMP from two molecules of GTP, and phosphodiesterases, which hydrolyze c-di-
GMP forming two molecules of GMP. Diguanylate cyclase activity has been 
demonstrated in proteins containing GGDEF domains, and c-di-GMP 
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phosphodiesterase activity has been observed in two unrelated protein domains, the 
EAL and HD-GYP domains [18-24]. EAL domain phosphodiesterases were the first to 
be described and have been more extensively studied in terms of structure and 
biochemical and biological function. Comparatively little is known about the functions of 
HD-GYP domain proteins.  
 The first protein containing an HD-GYP domain shown to act as a c-di-GMP 
phosphodiesterase was RpfG from plant pathogenic Xanthomonas spp. [21]. RpfG is a 
response regulator containing a phosphoreceiver (REC) domain and an HD-GYP 
domain. Along with the sensor histidine kinase RpfC, RpfG responds to extracellular 
diffusible signal factor (DSF), a cell-to-cell signaling factor. Evidence suggests that, in 
response to DSF, RpfC phosphorylates the REC domain of RpfG, triggering the 
phosphodiesterase activity of the HD-GYP domain [25, 26]. The consequent decrease 
in intracellular c-di-GMP leads to derepression of Clp, a transcription factor inhibited by 
binding of c-di-GMP, activating transcription of genes necessary for virulence factor 
production [27-30]. Deletion of rpfG or amino acid substitutions in conserved residues of 
the HD-GYP domain, both of which abrogate c-di-GMP hydrolysis, resulted in 
decreased virulence factor secretion, and virulence factor secretion was restored in 
bacteria complemented with an EAL domain phosphodiesterase, indicating that c-di-
GMP hydrolysis by RpfG is responsible for this phenotype [21, 25, 31, 32].  
 In Pseudomonas aeruginosa, two genes encoding HD-GYP domains, PA4108 
and PA4781, are necessary for full virulence in the Greater wax moth Galleria 
mellonella and for optimal swarming motility [33-35]. The HD-GYP phosphodiesterase 
PdeB of Borrelia burgdorferi plays a role in motility and contributes to survival of the 
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bacterium in the tick vector Ixodes scapularis and to transmission of the bacterium to 
mice [13, 36].  
 The human diarrheal pathogen Vibrio cholerae genome contains numerous 
genes encoding confirmed or putative c-di-GMP metabolic enzymes: 31 genes 
encoding GGDEF domains, 12 genes encoding EAL domains, 10 genes encoding 
tandem GGDEF-EAL genes, and 9 genes encoding HD-GYP domains [37, 38]. A 
handful of diguanylate cyclases and EAL domain phosphodiesterase enzymes have 
been shown to impact motility, biofilm formation and virulence in animal models [14, 15, 
39-46]. HD-GYP domain phosphodiesterases similarly have the potential to impact 
motility, biofilm formation and virulence of V. cholerae through modulation of c-di-GMP. 
However, relatively little is known about the function(s) of HD-GYP domain proteins in 
V. cholerae. The expression of four of these genes (VC2340, VCA0210, VCA0681, 
VCA0895) was upregulated in the presence of the quorum sensing autoinducers [47]. 
Ectopic over-expression of VCA0681 resulted in a reduced intracellular c-di-GMP 
concentration, indicating that VCA0681 possesses c-di-GMP phosphodiesterase activity 
[47]. Mutation of either VCA0681 or VCA0895 had no effect on biofilm formation in that 
study. Recently, bile acids, an extracellular signal encountered by V. cholerae in the 
intestine, were shown to activate and repress expression of the HD-GYP domain genes 
VC2497 and VC1295, respectively [48]. Furthermore, a VC1295 mutant has somewhat 
increased c-di-GMP and biofilm formation in the presence of bile acids, consistent with 
PDE function [48]. Beyond these experiments, not much is known about the function of 
HD-GYP containing proteins in V. cholerae or whether these proteins have 
phosphodiesterase activity.  
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Herein, we systematically analyze the biochemical and biological functions of the 
putative HD-GYP phosphodiesterases encoded by V. cholerae. We present in vitro and 
in vivo evidence that a subset of the HD-GYP domain proteins are enzymatically active 
and assess the roles of each HD-GYP domain gene in motility, biofilm formation and 
virulence of V. cholerae. This work greatly furthers the understanding of this important 
family of c-di-GMP metabolic enzymes and demonstrates a role for HD-GYP domain 
proteins in the virulence of V. cholerae. 
 
Methods 
Bacterial strains and growth conditions. V. cholerae C6706 and isogenic mutant 
strains (Table 1) were cultured in Luria-Bertani (LB) broth containing 100 µg/ml 
streptomycin (Sm) at 37 °C with aeration. Escherichia coli strains were grown in LB 
broth. When needed to select for plasmids, 50 µg/ml ampicillin (Amp) was added to the 
V. cholerae and E. coli cultures.  
 
DNA manipulations and strain construction. Primers used in the construction of 
in-frame deletions of genes encoding putative HD-GYP domain proteins are listed in 
Table 3. Primers for deletion constructs are labeled with the locus tag of the target gene 
followed by F1, R1, F2 or R2 (e.g. VC1087F1 and VC2340R2). Deletions were made 
using standard allelic exchange methods [49]. Briefly, regions of homology upstream 
and downstream of the gene of interest were PCR amplified from V. cholerae C6706 
genomic DNA using the geneF1+ geneR1 primers for the upstream fragment and 
geneF2 + geneR2 primers for the downstream fragment. The primers introduced 
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restriction sites (Table 3, underlined) that allowed cloning of the two PCR products to 
each other and into the suicide vector pCVD442. Ligation reaction products were 
transformed into DH5α λpir by electroporation, which were then selected by growth on 
LB-Amp agar. The desired clones were identified by screening by PCR with geneF1 + 
geneR2 primers and CVDseqF + CVDseqR primers that flank the multiple cloning site. 
Plasmids were purified from confirmed clones and transformed into Sm10λpir cells by 
electroporation. Sm10λpir strains containing the pCVD442 deletion constructs and V. 
cholerae recipient strains were grown on LB agar with Amp or Sm, respectively, then 
mated on LB agar lacking antibiotics for 6 hours at 37 °C. Growth was collected from 
the agar plate and streaked onto LB-Sm-Amp agar to select for V. cholerae 
transconjugants. Single colonies were grown in 1 mL LB broth lacking antibiotics for 8 
hours. Dilutions were plated onto LB-Sm agar containing 10% sucrose and incubated 
for 16 hours at 30 °C. Sucrose-resistant, Amp-sensitive colonies were screened for 
deletion of the target gene by PCR using geneF0 and geneR2 primers.    
 We were unable to inactivate VC2497 by allelic exchange, so VC2497 was 
instead mutated by plasmid disruption with pGP704. An internal portion of VC2497 was 
amplified by PCR from V. cholerae C6706 genomic DNA using primers 2497koF and 
2497koR. The product was digested with BglII and EcoRI and ligated into similarly 
digested pGP704. Ligation reaction products were transformed into DH5αλpir cells by 
electroporation, followed by selection on LB-Amp agar. Insert-positive clones were 
identified by PCR using 2497koF + 2497koR. The resulting pGP704::’VC2497’ plasmid 
was introduced into V. cholerae C6706 by a triparental mating with this recipient strain, 
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DH5αλpir (pGP704::’VC2497’), and E. coli (pRK2013::Tn9). The integration of pGP704 
into the VC2497 locus was confirmed by PCR using 2497koF + CVDseqR.  
 For the “DHDGYP7” strain, the following genes were sequentially inactivated as 
above, in order: VCA0681, VCA0210, VC2340, VC1348, VCA0895, VC1295, and 
VCA0931. 
  
Construction of strains for overexpression. The genes encoding the 9 putative 
HD-GYP-domain containing proteins were amplified by PCR from V. cholerae C6706 
using the geneF and geneHR primers listed in Table 2 (e.g. VC1087F and VC1087HR 
primers were used to amplify VC1087). The exception is VC1295, which was amplified 
from V. cholerae N16961, because VC1295 from strain C6706 contains a mutation 
encoding a premature stop codon. The geneHR primers introduce a sequence encoding 
six histidine residues at the C-terminus of the translated protein product. The PCR 
products for each gene were digested with the restriction enzymes indicated in the table 
and ligated into pMMB67EH. The ligations were transformed into E. coli DH5α, with 
subsequent selection on LB-Amp agar. Clones were screened using primers geneF + 
geneHR and primers 67EHF and 67EHR, which flank the multiple cloning site of 
pMMB67EH. The correct plasmids were introduced into E. coli BL21 via electroporation.  
To generate a construct for expressing an inactive allele of VC1348, we replaced 
the codons for the HD motif (amino acids 217 and 218) with two codons for alanine. 
Using C6706 genomic DNA as a template, regions upstream and downstream of (and 
including) the targeted sequence were amplified with primers VC1348F + VC1348R1-
AA and VC1348F2-AA + VC1348HR, respectively. The two fragments, which overlap by 
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21 nucleotides including HD to AA mutation, were spliced together and the full product 
was amplified by PCR with primers VC1348F + VC1348HR. The resulting product was 
digested with SacI and XbaI, ligated into similarly digested pMMB67EH, and 
transformed into E. coli DH5a. Correct clones were identified by PCR and sequencing, 
yielding pMMB67EH::VC1348AA-His6. 
All expression plasmids were introduced into V. cholerae by conjugation. 
 
In vitro c-di-GMP phosphodiesterase assays.  Purified His6-WspR protein from 
Pseudomonas aeruginosa, which contains a catalytically active GGDEF domain, was 
used to synthesize the radiolabelled c-di-GMP substrate for the phosphodiesterase 
enzymatic assays [50]. Purified His6 –WspR (10 µL) was incubated overnight at 37 °C 
with 5 µL of [α-32P]GTP (3000 Ci/mmol; PerkinElmer Life Sciences) and 5 µL of 100 mM 
GTP buffer containing 75 mM Tris, pH 8, 250 mM NaCl, 25 mM KCl, and 10 mM MgCl2. 
Subsequent steps were carried out as described [24]. 
E. coli BL21 containing either HD-GYP overexpression plasmid or vector were 
grown in LB-Amp broth overnight at 37 °C with aeration, then diluted 1:100 in 12 mL of 
LB-Amp containing 1 mM IPTG. Cultures were grown at 30 °C until an OD600 of 0.6-0.7 
was reached. Cells were collected by centrifugation at 5000 x g for 10 minutes at 4 °C. 
The cells were suspended in 1 mL of phosphodiesterase buffer containing 75 mM Tris, 
pH 8, 25 mM KCl, 25 mM MnCl2, and 10% glycerol. The cells were lysed by three 
rounds of freeze-thaw followed by sonication.  Samples were centrifuged at 5,000 × g 
for 10 minutes at 4 °C. Supernatants (soluble material) were removed and stored at –20 
°C prior to use in phosphodiesterase enzymatic assays. Reaction products were 
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identified based on previously determined migration in KH2PO4 buffer [51]. 
 
Assay for in vitro phosphodiesterase activity. Soluble fractions from E. coli BL21 
overexpressing HD-GYP genes were tested for phosphodiesterase activity by 
incubating 18 µL of cell lysates with 2 µL of [32P]c-di-GMP for 0 min to 30 min at room 
temperature as previously described [14]. As negative controls, cell lysates from 
similarly treated E. coli with empty vector and a buffer-only control were tested. The 
reactions were stopped by spotting 0.5 µL of the reactions on PEI-cellulose and allowing 
the spots to air-dry. Nucleotides were separated by thin layer chromatography in 1.5 M 
KH2PO4, pH 3.65.  PEI-cellulose plates were air-dried. Reaction products were 
visualized by phosphorimagery using a Storm Phosphorimager (GE Healthcare). 
 
Phenotype assays. Biofilm production was assayed by crystal violet staining as 
described previously [52, 53]. Briefly, biofilms of V. cholerae were grown statically in LB 
broth in 13 mm diameter glass culture tubes at room temperature (~23 °C) for 24 hours. 
Where indicated, 1 mM IPTG was added to induce phosphodiesterase gene expression. 
Unattached cells were removed, and the remaining biofilms were rinsed and stained 
with 0.1% crystal violet. The stained biofilms were washed with water, and then the 
stain was solubilized with 2 ml of 50% v/v ethanol. The biofilm material was dispersed 
using a sonicating water bath. Biofilm formation (sugar, water and of course purple) was 
determined by measuring the absorbance at 540 nm. At least 3 independent samples 
were assayed.  
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Motility was measured using soft agar assays as described [54]. Strains were 
grown overnight at 37 °C on LB + 1.5% agar. Single colonies were inoculated into 
motility plates (1% tryptone, 0.5% NaCl, 0.3% agar). Where indicated, 1 mM IPTG was 
added the plates to induce phosphodiesterase gene expression. Motility plates were 
incubated for 16 hours at 30 °C, and colony swarm diameters were measured. Three 
independent experiments of at least 4 replicates of each strain were performed. 
 
Western blots. BL21 and V. cholerae strains containing HD-GYP expression 
vectors were grown in LB-Amp broth overnight at 37 °C with aeration, then diluted 1:100 
in LB-Amp containing 1 mM IPTG. Cultures were grown at 30 °C with aeration to an 
OD600 of ~0.7. Cells were collected by centrifugation at 12,000 x g and suspended in 
100 µL of 2x Laemmli sample buffer [55]. Samples were separated by electrophoresis 
on a 12% polyacrylamide SDS gel then transferred to a nitrocellulose membrane. 
Western blots were carried out according to standard procedures. Primary mouse His-6 
antibody (ThermoScientific) was used at a 1:1000 dilution.  Dylight 800 goat α-mouse 
secondary antibody (ThermoScientific) was used at a 1:15000 dilution. Blots were 
imaged using an Odyssey imager (LI-COR Biosciences). 
 
In vivo competition: The animal experiments were done in accordance with 
protocol 12-239 approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. Mouse in vivo competition experiments were 
carried out in 5 day old CD-1 mice as described previously [56]. Briefly, HD-GYP mutant 
strains were mixed 1:1 with WT ∆lacZ mice in 0.85% NaCl. To determine the ratio of 
 160 
mutant to WT in the inocula, these mixtures were plated on LB-Sm agar containing 40 
µg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), which allows 
differentiation of mutant and ∆lacZ bacteria (blue versus white colonies, respectively). 
Mice were inoculated intragastrically with ~105 total bacteria. Animals were sacrificed 21 
hours post-inoculation. Small intestines were harvested and homogenized, then 
dilutions were plated on LB-Sm agar containing X-Gal. The competition index was 
determined by dividing the ratio of mutant / ∆lacZ bacteria in the homogenates (output) 
by the ratio of mutant / ∆lacZ bacteria in the inocula. In parallel, the mixtures used to 
inoculate mice for in vivo competition experiments were also diluted 1:1,000 into 2 ml of 
fresh LB broth and incubated overnight to determine the in vitro competition index. At 
least 5 mice were used for each competition. Data were analyzed by the Wilcoxon 
signed-rank test, with values compared to a hypothetical value of 1.  
 
Results 
A subset of the 9 genes of V. cholerae is predicted to encode enzymatically 
active HD-GYP domains. V. cholerae N16961 encodes 9 putative HD-GYP domain c-di-
GMP phosphodiesterases with variable lengths, domain architectures and predicted 
cellular localizations. Most of the proteins are estimated to be approximately 400-500 
amino acids in length, though VCA0895 is considerably larger, with 981 amino acids. 
Two HD-GYP domain proteins, VC1295 and VCA0895, have predicted transmembrane 
domains and are predicted to be localized in the inner membrane. As is common of c-di-
GMP metabolic enzymes, all 9 HD-GYP domain proteins contain additional domains 
potentially involved in regulating protein function. Three HD-GYP domain proteins, 
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VC1087, VC1348 and VCA0210, possess a phosphoreceiver (REC) domain, 
suggesting that they may be modulated by phosphorylation. Two of the proteins, 
VC1295 and VCA0895, contain a domain present in Histidine kinases, Adenylate 
cyclases, Methyl-accepting proteins and Phosphatases (HAMP), which is a linker 
domain suggested to function in intramolecular signal transduction [57-59]. Three 
contain additional domains of unknown function: VC2497, DUF3391; VCA0210, 
DUF3369; and VCA0931, DUF3392. Interestingly, VCA0681 contains tandem HD and 
HD-GYP domains. Together, these 9 putative c-di-GMP phosphodiesterases have the 
potential to respond to myriad signals to modulate intracellular c-di-GMP. 
Previous studies have used genetic and biochemical approaches to identify the 
residues of HD-GYP domain proteins that are important for catalytic activity [21, 60-62]. 
Mutational analysis of PmGH, an HY-GYP domain phosphodiesterase from 
Persephonella marina for which the c-di-GMP cocrystal structure has been solved, 
identified at least 11 amino acids required for full phosphodiesterase activity [60]. Based 
on conservation of residues deemed critical for activity of the HD-GYP domain 
phosphodiesterase PmGH, four of the 9 putative HD-GYP domain proteins encoded by 
V. cholerae are predicted to be enzymatically active: VC1295, VC1348, VCA0210 and 
VCA0931 (Figure 1B). VC2497, VC2340 and VCA0681 (predicted to have tandem HD 
and HD-GYP domains, labeled “a” and “b” in Figure 1, respectively) contain one non-
conserved residue required for activity of PmGH. Two, VC1087 and VCA0895, lack an 
intact HD motif and are expected to be enzymatically inactive.  
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Four HD-GYP domain proteins of V. cholerae are enzymatically active in vivo. To 
assess the enzymatic activity of each putative HD-GYP domain phosphodiesterase, we 
used motility and biofilm formation, processes well-known to be inhibited and activated 
by c-di-GMP in V. cholerae, respectively, as phenotypic indicators of in vivo enzymatic 
activity [14, 40, 43, 63]. Each HD-GYP domain-encoding gene was ectopically 
expressed in V. cholerae under the regulation of an inducible promoter. We used alleles 
containing a C-terminal sequence encoding a 6-histidine tag, allowing us to confirm 
expression by western blot. Each strain produced a His6-tagged protein of 
approximately the anticipated molecular weight, though the abundance of the proteins 
varied (Figure 2A, left). Expression of VCA0895-His6 was relatively poor; visualization 
required loading twice the amount of sample and a longer exposure of the membrane 
(Figure 2A, right).  
The strains were then assayed for altered motility and biofilm formation 
compared to the parental strain carrying vector only, each with and without IPTG to 
induce gene expression. V. cholerae expressing the characterized EAL domain 
phosphodiesterase VC1592 was included as a positive control for both experiments 
[46]. Expression of VC1592, VC1295, VC1348, VCA0210, and VCA0681 significantly 
increased motility of V. cholerae through 0.3% agar medium, as evinced by expanded 
diameters of motility (Figure 2B). Expression of the same genes significantly decreased 
biofilm formation in rich medium on glass (Figure 2C). These results are consistent with 
reduced intracellular c-di-GMP upon expression of c-di-GMP phosphodiesterases and 
suggest that VC1295, VC1348, VCA0210 and VCA0681 encode active HD-GYP 
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domain c-di-GMP phosphodiesterases. As expected, VC1087 and VCA0895, which lack 
an intact HD motif, had no effects on motility or biofilm formation. 
 
A subset of HD-GYP domain proteins of V. cholerae are enzymatically active in 
vitro. Because the HD-GYP domain proteins could affect biofilm formation and 
swimming motility independently of c-di-GMP hydrolytic activity, we also assayed their 
enzymatic activity in vitro. The same plasmids used for expression in V. cholerae were 
transformed into E. coli BL21. These strains were grown in the presence of IPTG to 
induce gene expression; E. coli BL21 with vector only was included as a negative 
control. Production of His6-tagged HD-GYP domain proteins was confirmed by western 
blot (Figure 3A, left). As in V. cholerae, E. coli expressing VCA0895 produced less 
protein, and loading 2-fold more sample was needed to detect VCA0895-His6 (Figure 
3A, right). Culture lysates were tested for the ability to hydrolyze c-di-GMP by incubating 
them with radiolabeled c-di-GMP. The reaction products were separated by TLC and 
visualized by phosphorimagery. In vitro, VC1295, VCA0210 and VCA0681 reproducibly 
hydrolyzed c-di-GMP (Rf ~ 0.3) at levels above that of the vector-only negative control. 
Notably, in these reactions, both linearized pGpG (Rf ~ 0.55) and GMP (Rf ~ 0.65) were 
apparent. VC1348, which showed activity in vivo, failed to hydrolyze c-di-GMP above 
background levels. VC1087 and VCA0895, as expected, were inactive.  
 
The effect of VC1348 expression on swimming motility require(s) c-di-GMP 
phosphodiesterase activity. For eight of the nine HD-GYP domain proteins, the in vivo 
over-expression and in vitro enzymatic assays were in agreement, indicating that 
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VC1295, VCA0210 and VCA0681 are functional c-di-GMP phosphodiesterases. 
Expression of the remaining HD-GYP domain protein, VC1348, increased motility and 
decreased biofilm formation of V. cholerae, consistent with reduced c-di-GMP in this 
strain. However, no c-di-GMP phosphodiesterase activity could be detected in vitro. To 
determine if the phenotypic changes upon VC1348 expression in V. cholerae were due 
to phosphodiesterase activity, the effect of expressing a mutant allele of VC1348 on V. 
cholerae motility was assessed as described above. The resulting mutant protein, 
herein named VC0398AA, contains alanine substitutions in the HD motif (amino acids 
217 and 218), which has been shown to be required for c-di-GMP phosphodiesterase 
activity [21]. Expression of the positive control gene VC1592 and wild type VC1348 
significantly increased motility of V. cholerae through 0.3% agar, while expression of 
VC1348AA did not (Figure 4). These results indicate that the HD motif of VC1348, and 
therefore c-di-GMP hydrolysis by this protein, is required for function in vivo. 
 
Expression of the HD-GYP domain genes in V. cholerae during planktonic and 
biofilm growth. We postulated that the expression of the HD-GYP domain-encoding 
genes may be differentially expressed during growth of V. cholerae in a biofilm 
compared to in planktonic culture. For instance, one or more of the genes might be 
down-regulated, leading to increased intracellular c-di-GMP and enhanced biofilm 
formation. To get a picture of the transcriptional profiles of the HD-GYP domain genes, 
we used qRT-PCR to determine the relative expression of each HD-GYP domain gene 
in biofilm and planktonic culture. The vpsT gene, previously determined to be 
upregulated in a biofilm, was included as a positive control [64]. Several transcripts, 
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VC1348, VCA0210, VCA0681, and VCA0895, were significantly more abundant in 
biofilm cells than in planktonic cells (Figure 5). Only one, VC2497, was significantly 
reduced in biofilms. These data suggest that c-di-GMP phosphodiesterases can be 
upregulated in biofilms, for example to counter the activities of diguanylate cyclases 
during biofilm development. 
 
Analysis of the roles of HD-GYP domain phosphodiesterases in motility, biofilm 
and virulence of V. cholerae. To assess the functions of the HD-GYP domain 
phosphodiesterases in V. cholerae, in-frame deletions were made in each gene, and the 
mutants were tested for altered biofilm formation and motility. None of the mutants 
showed phenotypes different from the WT parental strain (Figure 6A and 6C). To 
address the possibility that two or more of the HD-GYP proteins have redundant 
functions, additional mutants were made in which multiple HD-GYP encoding genes 
were deleted. None of these mutants, including strain DHDGYP7 (∆VCA0681 
∆VCA0210 ∆VC2340 ∆VC1348 ∆VCA0895 ∆VC1295 and ∆VCA0931), which contains 
mutations in all HD-GYP genes encoding functional enzymes, were phenotypically 
different from the WT parent (Figures 6B and 6D). 
Previous work with the infant mouse model has shown that c-di-GMP inhibits the 
ability of V. cholerae to effectively colonize the intestine. Mutation of the EAL domain 
phosphodiesterase VieA reduced fitness of V. cholerae O395 in the infant mouse [15]. 
We thus tested each of the HD-GYP mutants for colonization of the infant mouse small 
intestine using a competition assay. In this study, equivalent numbers of differentially 
labeled WT (lacZ+) and mutant (∆lacZ) bacteria were co-inoculated into infant mice. 
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After 21 hours, the small intestines were harvested, homogenized and plated on media 
containing X-gal to enumerate the WT and mutant bacteria. Competition indices were 
determined by dividing the ratio of mutant: WT bacteria in the tissues to the ratio of 
mutant: WT bacteria in the input mixtures. None of the individual HD-GYP gene 
mutations affected the ability of V. cholerae to colonize the infant mouse small intestine 
(Figure 7). Interestingly, the additive mutation of 7 HD-GYP domain genes (DHD-
GYP7), including all those that are enzymatically active PDEs, led to a significant 
decrease in bacterial burden in the small intestine (mean CI = 0.135, P < 0.001). This 
may be attributable in part to overall reduced fitness of the mutant, as the DHD-GYP7 
strain was slightly attenuated for growth in LB compared to the ∆lacZ control (mean CI = 
0.639, P < 0.05). These results indicate that two or more HD-GYP genes in combination 
are important for virulence of V. cholerae. Alternatively, the cumulative effects of 
multiple PDE on intracellular c-di-GMP levels during infection may impair host 
colonization. 
  
Discussion 
The c-di-GMP signaling system of V. cholerae is complex, including a large 
number of c-di-GMP synthases, hydrolases, effectors and regulatory targets. This work 
presents a methodical analysis of the functions of all 9 HD-GYP domain proteins 
encoded by V. cholerae.  
Using in vitro and in vivo approaches, we found that a subset of the HD-GYP 
domain proteins possesses c-di-GMP phosphodiesterase activity. Activity correlates 
well with conservation of residues previously determined to be required for activity and 
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with the overall consensus sequence of the HD-GYP domain [61, 65]. We expected that 
VC1295, VC1348, VCA0210 and VCA0931 would be enzymatically active proteins; 
each contains conserved residues previously shown to be required for activity of PmGH 
[61].  In addition, each contains conserved residues in the GYP motif region and other 
residues involved in recognition of c-di-GMP [61, 66]. We consistently observed in vivo 
and in vitro activity for VC1295 and VCA0210. VC1348 caused increased motility and 
reduced biofilm formation when expressed in V. cholerae, suggesting that it is able to 
hydrolyze c-di-GMP in vivo, but we did not detect enzymatic activity in vitro. Mutating 
the HD residues required for phosphodiesterase activity of HD-GYP domain proteins 
ablated the effect of VC1348 expression on motility of V. cholerae. These results 
indicate that VC1348 is indeed a functional c-di-GMP phosphodiesterase in V. cholerae. 
We suspect that expression of VC1348 in V. cholerae allows VC1348 to be post-
translationally activated, likely though its REC domain, but that the activating partner is 
absent in E. coli BL21. The adjacent, divergently transcribed gene VC1349 encodes a 
putative sensor kinase/response regulator and may regulate VC1348 in V. cholerae. 
VCA0931 failed to demonstrate c-di-GMP hydrolysis, neither affecting biofilm formation 
or motility of V. cholerae nor hydrolyzing c-di-GMP in vitro. VCA0931 possesses an N-
terminal domain of unknown function, which may post-translationally regulate the HD-
GYP domain in response to specific cues lacking in our assays, or mask activity of the 
HD-GYP domain [33].  
As we anticipated, VC1087 and VCA0895, which lack the HD dyad characteristic 
of HD metal-dependent phosphohydrolases, showed no evidence of c-di-GMP 
hydrolytic activity in vivo and in vitro. The activities of a subset of the HD-GYP domain 
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proteins could not be easily predicted due to lack of conservation of one or more 
residues expected to be required for activity: VC2497, VC2340 and VCA0681 [21, 61]. 
While VC2497 and VC2340 were inactive in all assays used, VCA0681 consistently 
showed phosphodiesterase activity. VCA0681 is one of the few HD-GYP proteins 
studied to date. Its enzymatic activity was previously demonstrated and its crystal 
structure was solved [47, 60]. The differences between the inactive VC2497 and 
VC2340 and the active HD-GYP domain proteins that determine enzymatic functionality 
are not readily apparent. Indeed, VCA0681 is a functional PDE despite lacking an 
aspartic acid required for activity of PmGH (D308 in PmGH, Q373 in VCA0681). The 
substitution of an aspartic acid with an asparagine in VCA0681 may preserve enzymatic 
activity, or the requirements of PmGH may not be universal to all HD-GYP domain 
PDEs. Further characterization of structure-function relationships of HD-GYP domain 
phosphodiesterases from a variety of organisms will be necessary to define the features 
required for activity.  
Analysis of the expression of the HD-GYP domain genes in V. cholerae showed 
that VC1348, VCA0210, VCA0681 and VCA0895 transcripts are significantly higher in 
biofilm-derived V. cholerae than in planktonic cells. Interestingly, three of these genes, 
VCA0210, VCA0681 and VCA0895 were among the four HD-GYP domain genes 
regulated by quorum sensing [47]. Thus, high cell density in the V. cholerae biofilm may 
be the signal controlling expression of these genes.  
 We found that mutation of individual HD-GYP domain genes did not affect c-di-
GMP regulated phenotypes of V. cholerae under the conditions tested. Even removal of 
all active (and many inactive) HD-GYP domain proteins in a single strain had no effect 
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on motility or biofilm production. There are several possible reasons for the lack of 
phenotypic differences from the parent strain. First, it remains possible that HD-GYP 
domain phosphodiesterases, individually or as a class, impact c-di-GMP regulated 
processes other than those investigated here. Second, not all HD-GYP domain proteins 
are likely to be produced or enzymatically active under the conditions tested, so 
eliminating them may not have an observable effect. Our qRT-PCR studies of HD-GYP 
gene expression in planktonic and biofilm cultures support this possibility—expression 
of each HD-GYP domain gene is variable within those conditions. The observation that 
a VC1295 mutant produces somewhat more biofilm in the presence of bile acids further 
indicate that specific extracellular cues may be necessary to stimulate HD-GYP 
production and/or activity [48].  
There may also be strain-dependent differences in the panel of c-di-GMP 
metabolic enzymes used, and different results might be obtained using a different V. 
cholerae strain. For example, mutation of the EAL domain phosphodiesterase VieA in 
the classical biotype of V. cholerae (strain O395) causes marked effects on motility, 
biofilm formation and virulence gene expression [15, 40]; the same mutation in the El 
Tor strain C6709 has no effect on these processes [14, 47].  
HD-GYP domain proteins can also perform their regulatory function via physical 
interactions with other proteins, independently of c-di-GMP phosphodiesterase activity. 
In Xanthomonas spp., for example, the HD-GYP phosphodiesterase RpfG interacts with 
two diguanylate cyclases to regulate motility [21, 66, 67]. The HD-GYP domain protein 
ECA3548 from Pectobacterium atrosepticum lacks apparent c-di-GMP 
phosphodiesterase activity (and lacks the conserved HD motif), yet still impacts c-di-
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GMP regulated processes, possibly via direct interactions with other proteins [68]. The 
HD-GYP domain proteins of V. cholerae may also rely on protein-protein interactions to 
mediate their effects, and the necessary interactions may not have been achieved 
through over-expression or mutagenesis.  
Finally, there is potential for phenotypic redundancy among the HD-GYP domain 
phosphodiesterases, as well as with EAL domain phosphodiesterases. Upon mutation 
of each of the GGDEF and EAL domain genes in V. cholerae, and only some mutants 
showed altered motility and/or biofilm development [41, 45]. Therefore the chance of 
observing an effect of mutating the HD-GYP subset of c-di-GMP phosphodiesterases 
may be low. This is supported by our finding that individually, mutation of HD-GYP 
genes had no effect on the ability of V. cholerae to colonize the infant mouse small 
intestine, but a combination of mutations (DHDGYP7) significantly impaired 
colonization. It is possible that a combination of two or more HD-GYP domain proteins, 
or that the additive effects of multiple c-di-GMP PDEs, influence virulence of V. 
cholerae. These findings suggest that HD-GYP domain proteins as a family influence c-
di-GMP levels during infection, which has previously been shown to impact V. cholerae 
virulence by regulating the virulence gene regulator ToxT [14, 15].  
In the context of an infection, discrete extracellular signals may trigger the 
production or activity of a specific c-di-GMP phosphodiesterase (or diguanylate 
cyclase), with cumulative but targeted effects on virulence gene expression. Strictly 
speaking, the c-di-GMP phosphodiesterases involved would not be mechanistically 
redundant (for example, having different interacting partners or subcellular localization), 
but work together toward the same phenotypic output. Such a regulatory system may 
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allow V. cholerae to induce virulence gene expression in the host despite the absence 
or mitigation of one specific extracellular signal. A different set of c-di-GMP metabolic 
enzymes could modulate biofilm or motility in response to a distinct set of signals.    
 
Conclusions 
Compared to GGDEF domain diguanylate cyclases and EAL domain 
phosphodiesterases, the HD-GYP domain phosphodiesterases have been 
understudied. This may be partly due to the fact that genes encoding HD-GYP domains 
are less widespread in bacterial genomes than those encoding GGDEF and EAL 
domains [38, 65]. In V. cholerae, only a subset of the HD-GYP domain genes encoded 
are functional c-di-GMP PDEs. The individual HD-GYP domain genes are dispensable 
for motility and biofilm formation under the conditions tested, but collectively two or 
more of the genes are important for virulence of V. cholerae. Additional studies of HD-
GYP domain proteins from other bacteria are needed to gain a full understanding their 
roles in c-di-GMP signaling. 
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Figures 
 
 
Figure 1. Domain architectures and sequence conservation of putative HD-GYP 
domain proteins of V. cholerae. (A) Predicted domains of the nine HD-GYP domain 
proteins encoded by V. cholerae. Shown are HD-GYP domains (blue), phosphoreceiver 
domains (red), HAMP domains (green), domains of unknown function (white) and 
putative transmembrane domains (black). The lengths of the proteins (number of amino 
acids) are indicated. (B) Alignment of V. cholerae HD-GYP domains. The HD-GYP 
domain amino acid sequences from V. cholerae, including the two tandem domains in 
VCA0681, were aligned to the HD-GYP domains of RpfG from X. campestris and 
PmGH from Persephonella marina using Clustal Omega software. Highlighted are the 
HD and GYP motifs (yellow), identical amino acid residues (orange) and conserved 
amino acid residues (green). Asterisks indicate residues previously shown to be 
required for enzymatic activity of PmGH [61]. 
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Figure 2. Ectopic over-expression of HD-GYP genes in V. cholerae. Each gene 
encoding a putative HD-GYP domain protein, tagged with a 6-histidine sequence at the 
3’ end, was expressed ectopically in V. cholerae using an IPTG-inducible promoter. (A) 
Production of each protein in V. cholerae after ~3 hours growth in the presence of 1 mM 
IPTG was assessed by western blot using anti-His6 antibodies. The predicted molecular 
weights of each protein, in kDa, are indicated at the bottom. Right: Expression of the 
large, predicted membrane protein VCA0895 was relatively poor; detection of the 
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recombinant protein required loading more sample. (B) Motility of V. cholerae 
expressing each of the HD-GYP domain genes was assayed in soft agar medium as an 
indication of c-di-GMP hydrolysis, which augments flagellar motility of V. cholerae. Each 
strain was inoculated into motility medium with (grey bars) or without (white bars) 0.5 
mM IPTG. The diameter of each motility swarm was measured after 20 hours incubation 
at room temperature. Shown are means and standard deviations for three biological 
replicates. (C) Biofilm formation by V. cholerae expressing each of the HD-GYP domain 
encoding genes was assessed as an indication of c-di-GMP hydrolysis, which 
decreases biofilm formation by V. cholerae. Each strain was grown in LB broth with 
(grey bars) or without (white bars) 0.5 mM IPTG to induce gene expression. Biofilm was 
assayed using standard crystal violet methods. Shown are means and standard 
deviations for three biological replicates. * P < 0.05 by two-way ANOVA with 
Bonferroni’s post-test. 
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Figure 3. Heterologous expression of HD-GYP genes in E. coli. Each gene encoding a 
putative HD-GYP domain protein, tagged with a 6-histidine sequence at the 3’ end, was 
expressed ectopically in E. coli BL21. (A) Production of each protein after ~3 hours 
growth in the presence of 1 mM IPTG was assessed by western blot using anti-His6 
antibodies. The predicted molecular weights of each protein, in kDa, are indicated at the 
bottom. Right: Expression of the large, predicted membrane protein VCA0895 was 
relatively poor; detection of the recombinant protein required loading more sample. (B) 
Lysates of E. coli BL21 expressing each of the HD-GYP domain-encoding genes were 
tested for the ability to hydrolyze c-di-GMP as described in the Materials and Methods. 
Buffer only (“B”) and lysates from E. coli BL21 with vector only were included as 
negative controls. The radiolabeled c-di-GMP substrate has a relative mobility (Rf) of 
~0.3 and appears for all samples at t = 0, when the reaction was initiated by addition of 
[32P]-c-di-GMP. The GMP reaction product appears at Rf ~ 0.65. 
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Figure 4. The HD residues of VC1348 are required for in vivo function. The genes 
encoding wild type VC1348 and VC1348 with alanine substitutions in the HD motif 
(VC1348AA) were expressed ectopically in V. cholerae using an IPTG-inducible 
promoter. The EAL domain PDE VC1592 was included as a positive control. The 
motility of V. cholerae bearing expression plasmids or vector control was assayed in soft 
agar medium as an indication of c-di-GMP hydrolysis, which augments flagellar motility 
of V. cholerae. Each strain was inoculated into motility medium with (grey bars) or 
without (white bars) 0.5 mM IPTG. The diameter of each motility swarm was measured 
after 20 hours incubation at room temperature. Shown are the means and standard 
deviations for six biological replicates. *** P < 0.001 by two-way ANOVA with 
Bonferroni’s post-test. 
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Figure 5. Abundance of mRNA encoding HD-GYP domain proteins in V. cholerae 
biofilms. qRT-PCR was used to measure the transcript abundance for each HD-GYP 
mRNA, the reference housekeeping gene rpoB, and the biofilm-induced control gene 
vpsT. The relative differences in transcript abundance between biofilm and planktonic V. 
cholerae cells were determined as described in the Materials and Methods. * P < 0.05 
by unpaired t-test comparing biofilm to planktonic values, indicating a significant change 
in transcript abundance in biofilm relative to planktonic cells. 
 178 
 
 
Figure 6. Biofilm and motility phenotypes of V. cholerae strains containing mutations in 
one or more HD-GYP domain encoding genes. V. cholerae containing mutations in 
single (A) or multiple (B) HD-GYP genes were assayed for biofilm formation after 48 
hours static growth in rich medium using crystal violet staining. A vpsR mutant was 
included as a negative control. Shown are the means and standard deviations for three 
biological replicates. V. cholerae containing mutations in single (C) or multiple (D) HD-
GYP genes were assayed for motility in soft agar medium. A flaA mutant was included 
as a negative control. Swarm diameters were measured after 20 hours growth at room 
temperature. Shown are the means and standard deviations for three biological 
replicates.  
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Figure 7. Assessment of virulence phenotypes V. cholerae HD-GYP gene mutants 
using the infant mouse model. Competition experiments were performed using the 
infant mouse model. Each mutant was co- inoculated in equal numbers with V. cholerae 
∆lacZ (1:1 ratio) into 5-day-old CD1 mice. The bacteria present in the small intestine 
after 21 hours were enumerated on LB agar plates containing X-gal to differentiate 
mutant bacteria (blue colonies) from ∆lacZ bacteria (white colonies). The competition 
index (CI) was calculated as [(mutant CFU / ∆lacZ CFU)output] / [(mutant CFU / ∆lacZ 
CFU)input]. Each circle represents the CI from an individual animal, and the bars 
indicate the median. At least 4 mice were used per competition. *** P < 0.001, one 
sample t-test comparing values to a hypothetical value of 1 (i.e., no difference between 
mutant and wild-type) and by one-way ANOVA. 
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